Investigation on Cyclodipeptide Formation and Metabolism in Actinomycetes and Application of Fungal Prenyltransferases in the Chemoenzymatic Synthesis

Untersuchungen zur Entstehung und Metabolismus von zyklischen Dipeptiden in Aktinomyzeten sowie Anwendungen von pilzlichen Prenyltransferazen in der chemoenzymatischen Synthese

> Dissertation zur Erlangung des Doktorgrades der Naturwissenschaften (Dr. rer. nat.)

> dem Fachbereich Pharmazie der Philipps-Universität Marburg

> > vorgelegt von

## Huili Yu

aus Tai'an, China

Marburg an der Lahn, 2018

Erstgutachter: Prof. Dr. Shu-Ming Li

Zweitgutachter: Prof. Dr. Michael Keusgen

Eingereicht am 16. August 2018

Tag der mündlichen Prüfung: 02. Oktober 2018

Hochschulkennziffer: 1180

Dedicated to my family

(献给我的家人)

# **Table of Contents**

Table of ContentsI
List of publicationsIll
Share of author contributionsIV
Academic activitiesV
AbbreviationsVI
Summary1
Zusammenfassung 3
1 Introduction
1.1 Actinobacteria 5
1.2 Cyclodipeptides 6
1.2.1 CDPs from NRPS pathways6
1.2.2 CDPs from CDPS pathways
1.2.3 CDP tailoring enzymes10
1.3 Cytochromes P45014
1.3.1 Catalytic mechanism of P450s14
1.3.2 Aryl–aryl coupling catalyzed by P450s in natural product biosynthesis16
1.3.3 P450s involved in the CDPS pathways20
1.4 Prenylated aromatic compounds in nature21
1.4.1 Prenylated tyrosine derivatives21
1.4.2 Chemoenzymatic synthesis of prenylated aromatic compounds with DMAPP22
1.4.3 Chemoenzymatic synthesis of prenylated aromatic compounds with unnatural prenyl analogs
2 Aims of this thesis25
3 Results and discussion
3.1 Identification of nine tryptophan-containing cyclcodipeptide synthases from <i>Streptomyces</i> strains

3.2 Coupling of <i>cyclo</i> -L-Trp-L-Trp and guanine by a P450 homologue from <i>Streptomyces</i>
3.3 Tyrosine O-prenyltransferases TyrPT and SirD displaying similar behavior toward unnatural alkyl or benzyl diphosphate as their natural prenyl donor dimethylallyl diphosphate
4 Publications40
4.1 Expanding tryptophan-containing cyclodipeptide synthase spectrum by identification of nine members from <i>Streptomyces</i> strains40
4.2 Coupling of guanine with <i>cyclo</i> -L-Trp-L-Trp mediated by a cytochrome P450 homologue from <i>Streptomyces purpureus</i> 72
4.3 Tyrosine O-prenyltransferases TyrPT and SirD displaying similar behavior toward unnatural alkyl or benzyl diphosphate as their natural prenyl donor dimethylallyl diphosphate.
5 Conclusions and future prospects119
6 References121
Statutory Declaration132
Acknowledgements133
Curriculum Vitae

## List of publications

 Liu, J.\*, <u>Yu, H.</u>\*, & Li, S.-M. (2018). Expanding tryptophan-containing cyclodipeptide synthase spectrum by identification of nine members from *Streptomyces* strains. *Appl. Microbiol. Biotechnol.*, *102* (10), 4435-4444. [\*equal contribution]

Liu, J\*., <u>Yu, H\*.</u>, & Li, S.-M. (2018). Correction to: Expanding tryptophancontaining cyclodipeptide synthase spectrum by identification of nine members from *Streptomyces* strains. *Appl. Microbiol. Biotechnol.*, *102*, 5787-5789. [\*equal contribution]

- Yu, H., Xie, X., & Li, S.-M. (2018). Coupling of guanine with *cyclo*-L-Trp-L-Trp mediated by a cytochrome P450 homologue from *Streptomyces purpureus*. *Org. Lett.*, *20* (16), 4921-4925.
- Yu, H., Liebhold, M., Xie, X., & Li, S.-M. (2015). Tyrosine O-prenyltransferases TyrPT and SirD displaying similar behavior toward unnatural alkyl or benzyl diphosphate as their natural prenyl donor dimethylallyl diphosphate. *Appl. Microbiol. Biotechnol.*, 99 (17), 7115-7124.

# Share of author contributions

Publications	Authors	Estimated equity ratio [%]	Status
Tyrosine O-prenyltransferases TyrPT and SirD	Yu, H.; Liebhold,	60	published
displaying similar behavior toward unnatural	M.; Xie, X. and Li,		
alkyl or benzyl diphosphate as their natural	SM.		
prenyl donor dimethylallyl diphosphate. (Appl.			
Microbiol. Biotechnol.)			
Expanding tryptophan-containing	Liu, J.*; <u>Yu, H.*</u>	40	published
cyclodipeptide synthase spectrum by	and Li, SM.		
identification of nine members from			
Streptomyces strains. (Appl. Microbiol.			
Biotechnol.)			
Coupling of guanine with cyclo-L-Trp-L-Trp	<u>Yu, H.;</u> Xie, X.	65	published
mediated by a cytochrome P450 homologue	and Li, SM.		
from Streptomyces purpureus. (Org. Lett.)			

\*: These authors contributed equally to this work.

Doctoral candidate:

Supervisor:

# Academic activities

Yu, H., Liebhold, M., Xie, X., & Li, S. M.

Enzymatic *N*- and *O*-alkylation/benzylation of tyrosine and derivatives

**Poster presentation**, Annual Conference of the Association for General and Applied Microbiology (VAAM), 01–03. March 2015, Marburg

# Abbreviations

The international system of units and units derived thereof have been used.

CDP	cyclodipeptide
CDPS	cyclodipeptide synthase
NRP	nonribosomal peptide
NRPS	nonribosomal peptide synthetase
DKP	diketopiperazine
E. coli	Escherichia coli
HPLC	high performance liquid chromatography
LC-MS	liquid chromatography-mass spectrometry
HR-EIMS	high-resolution electron ionization mass spectrometry
NMR	nuclear magnetic resonance spectroscopy
cWX	tryptophan-containing cyclodipeptide
cWW	<i>cyclo</i> -∟-Trp-∟-Trp
cWA	<i>cyclo</i> -L-Trp-L-Ala
cWL	<i>cyclo</i> -L-Trp-L-Leu
cWP	<i>cyclo</i> -∟-Trp-∟-Pro
cWY	<i>cyclo</i> -L-Trp-L-Tyr
DMATS	dimethylallyltryptophan synthase
DMAPP	dimethylallyl diphosphate
GPP	geranyl diphosphate
FPP	farnesyl diphosphate
MAPP	methylallyl diphosphate
2-pen-PP	2-pentenyl diphosphate
benzyl-PP	benzyl diphosphate

GC-content	guanine-cytosine content
A domain	adenylation domain
T domain	thiolation domain
C domain	condensation domain
TE domain	thioesterase domain
aa-tRNA	aminoacyl-tRNA
ncAA	non-canonical amino acid
α-KGD	$\alpha$ -ketoglutarate/Fe <sup>II</sup> -dependent dioxygenase
CDO	cyclic dipeptide oxidase
cWF	<i>cyclo</i> -L-Trp-L-Phe
cWH	<i>cyclo</i> -∟-Trp-∟-His
cFS	<i>cyclo</i> -L-Phe-L-Ser
cFL	<i>cyclo</i> -L-Phe-L-Leu
cLL	<i>cyclo</i> -L-Leu-L-Leu
cYY	<i>cyclo</i> -L-Tyr-L-Tyr
cFY	<i>cyclo</i> -L-Phe-L-Tyr
cFF	<i>cyclo</i> -L-Phe-L-Phe
cIL	<i>cyclo</i> -L-IIe-L-Leu
cFH	<i>cyclo</i> -L-Phe-L-His
P450	cytochrome P450
P450cam	cytochrome P450 metabolizing camphor in Pseudomonas
	putida
PDB	protein data bank
NADH	reduced nicotinamide adenine dinucleotide
NADPH	reduced nicotinamide adenine dinucleotide phosphate

Cpd 0	compound 0
Cpd I	compound I
Cpd II	compound II
S. coelicolor	Streptomyces coelicolor
PT	prenyltransferase
m/z	mass-to-charge ratio
Ni-NTA	nickel-nitrilotriacetic acid
kDa	kilo Dalton
Км	Michaelis-Menten constant
K <sub>cat</sub>	turnover number
UV-Vis	ultraviolet-visible
SDS-PAGE	sodium dodecyl sulfate polyacrylamide gel electrophoresis
OD600	optical density at 600 nm
ТВ	Terrific-Broth
DNA	deoxyribonucleic acid
gDNA	genomic DNA
PCR	polymerase chain reaction
PPi	inorganic pyrophosphate
ppm	parts per million
J	coupling constant
$\delta_{C}$	chemical shift of <sup>13</sup> C
$\delta_{H}$	chemical shift of <sup>1</sup> H
MHz	mega hertz
S	singlet
d	doublet

t	triplet
q	quartet
m	multiplet
APT	attached proton test
COSY	correlation spectroscopy
DQF-COSY	double-quantum filtered COSY
HSQC	heteronuclear single quantum coherence
HMBC	heteronuclear multiple bond correlation
D <sub>2</sub> O	deuterium oxide
CDCI <sub>3</sub>	deuterated chloroform
CD <sub>3</sub> OD	deuterated methanol
DMSO-d6	deuterated dimethyl sulfoxid

#### Summary

Secondary metabolites originated from plants, bacteria and fungi constitute a large group of compounds, which are not directly related to the growth, development and reproduction of the organism. However, the producer can benefit from these metabolites to defend itself against natural enemies, competitors or environmental pressure. Furthermore, they often exhibit useful and interesting biological and pharmaceutical activities, which provide benefits to human health and life. For example, cyclodipeptides (CDPs) and their derivatives have gained increasing attention for their interesting and diverse pharmaceutical activities. Natural CDPs are mainly formed by nonribosomal peptide synthetases (NRPSs) or cyclodipeptide synthases (CDPSs). The CDP cores resulted from the NRPS or CDPS pathways are often further modified by varieties of tailoring enzymes leading to the formation of sophisticated natural products. The small size of CDPSs (200–300 residues) makes them genetically easily manipulated in synthetic biology.

In the first project of this thesis, a cooperation project with Jing Liu, nine new CDPS genes from eight *Streptomyces* strains were functionally characterized after cloning into pET28a vector and expressing in *E. coli*. The products were analyzed on LC-MS and then isolated for NMR analysis. The products were identified as tryptophan-containing cyclodipeptides (cWXs) that are the most common precursors of diketopiperazines (DKPs) with pharmaceutical interest, due to the various modification possibilities on the indole ring. The nine identified CDPSs include six specific CDP synthases consisting of one cWL synthase, two cWP synthases and three new cWW synthases as well as three unspecific CDPSs producing several products with cWA or cWY as the major cyclodipeptide. Total product yields of CDPs were calculated based on HPLC analysis to be 46 to 211 mg/L *E. coli* culture. Our findings represent rare examples of cWXs derived from CDPS pathways in actinobacteria. This study also provides a valid experimental basis for further combination of CDPSs with other tailoring enzymes in biosynthesis of interesting compounds.

The three identified cWW synthases from *Streptomyces purpureus* NRRL B-5737, *Streptomyces lavendulae* NRRL B-2774, and *Streptomyces xanthophaeus* NRRL B-5414 are genetically associated with a putative cytochrome P450. The three P450 homologues share sequence identities of more than 75% with each other on the amino acid level, indicating same or very similar function. As a representative, the function of P450<sub>NB5737</sub> from *S. purpureus* was identified by heterologous expression in *Streptomyces coelicolor* and *in vitro* assays with the recombinant protein produced in *E. coli.* Isolation and structure elucidation confirmed that P450<sub>NB5737</sub> catalyzes the transfer of a guanine moiety onto the indole ring of cWW *via* a C–N bond, leading to unprecedented adducts of cyclodipeptide with a nucleobase. This represents one additional example of rare P450 enzymes catalyzing the coupling of two different substrates.

Besides CDPs, prenylated aromatic products often possess various biological and pharmacological activities, in comparison to their non-prenylated precursors. The prenyltransferases of the DMATS superfamily show broad flexibility toward aromatic substrates, but relatively strict prenyl donor tolerance. They usually accept only DMAPP, but not GPP or other prenyl donors with a longer chain length. To broaden the prenyl donor spectra, the acceptance of tyrosine *O*-prenyltransferases TyrPT and SirD towards unnatural DMAPP analogs such as MAPP, 2-pen-PP, and benzyl-PP was tested in the presence of tyrosine and its derivatives. The results revealed that TyrPT and SirD also use the unnatural donors and exhibit similar behavior as their natural prenyl donor DMAPP. Alkylated or benzylated products at the same positions of that with DMAPP have therefore been identified. This study increased significantly the diversity of prenylated products by chemoenzymatic synthesis.

The results presented in this thesis contributed significantly to the formation and metabolism of tryptophan-containing CDPs in nature and expanded the potential application of prenyltransferases. They provide a solid basis for applications in the synthetic biology in the future.

## Zusammenfassung

Sekundärmetabolite aus Pflanzen, Bakterien und Pilzen stellen eine große Substanzklasse dar, die nicht direkt mit Wachstum, Entwicklung und Reproduktion des Organismus zusammenhängen. Jedoch kann der Produzent sich diese Metaboliten zu Nutze machen, um sich vor natürlichen Feinden, Konkurrenten oder Umwelteinflüssen zu schützen. Darüber hinaus weisen sie oft nützliche und interessante biologische und pharmazeutische Aktivitäten auf, wovon die menschliche Gesundheit und das Leben profitieren können. Zum Beispiel haben zyklische Dipeptide (CDPs) und ihre Derivate an zunehmender Aufmerksamkeit in Bezug auf ihre interessanten und vielfältigen pharmazeutischen Aktivitäten gewonnen. Natürlich vorkommende CDPs werden in der Regel von nichtribosomalen Peptidsynthetasen (NRPSs) oder Cyclodipeptidsynthasen (CDPSs) gebildet. Die von der NRPS- oder CDPS-Synthesewege gebildeten CDP-Grundstrukturen werden häufig mithilfe von verschiedenen "Tailoring enyzmes" weiter modifiziert, sodass komplexere Naturstoffe entstehen. Wegen ihrer geringen Größe (200–300 Aminosäuren) können CDPSs gentechnisch leicht manipuliert werden.

In dem ersten Projekt dieser Arbeit, einem Kooperationsprojekt mit Jing Liu, wurden neun neue CDPS-Gene aus acht *Streptomyceten*-Stämmen jeweils in einen pET28a Vektor kloniert und in *E. coli* exprimiert. Die Produkte wurden mittels LC-MS analysiert und anschließend für die Strukturaufklärung isoliert. Die Produkte wurden als zyklische Dipeptide mit einer Tryptophaneinheit (cWXs) identifiziert. Diese sind pharmazeutisch besonders interessant, da sie vielseitig am Indolring modifiziert werden können. Sechs der neun identifizierten CDPSs sind spezifische CDP-Synthasen, davon eine cWL Synthase, zwei cWP Synthasen und drei neuen cWW Synthasen, sowie drei unspezifische CDPSs, die cWA oder cWY als Hauptprodukt, bilden.

Die Gesamtmenge an produzierten CDPs von 46 bis 211 mg/L in *E. coli* Kultur wurde mittels HPLC berechnet. Unsere Ergebnisse repräsentieren seltene Beispiele an cWXs, die aus den CDPS-Synthesewegen von Actinobakterien hervorgehen. Diese Arbeit liefert auch eine valide experimentelle Grundlage für weitere Kombinationen von CDPSs mit anderen modifizierende Enzymen in der synthetischen Biologie.

Die drei identifizierten cWW-Synthasen aus Streptomyces purpureus NRRL B-5737, Streptomyces lavendulae NRRL B-2774 und Streptomyce xanthophaeus NRRL B-5414 sind genetisch mit putativen Cytochrom P450 Enzymen assoziiert. Die drei P450 Homologe weisen untereinander eine Identität der Aminosäuresequenz von mehr als 75% auf, was auf die gleiche oder eine sehr ähnliche Funktion hindeutet.

Als repräsentativer Vertreter der drei P450s wurde die Funktion von P450<sub>NB5737</sub> aus *S. purpureus* durch heterologe Expression in *Streptomyces coelicolor*, sowie mithilfe von *in vitro* Assays mit dem rekombinanten Protein untersucht. Die Übertragung einer Guanineinheit auf den Indolring von cWW mit Ausbildung einer C–N-Bindung durch P450<sub>NB5737</sub> wurde nach Isolierung und anschließender Strukturaufklärung bestätigt. Diese Verknüpfung stellt die Katalyse eines noch nie nachgewesenen Addukts zwischen einem zyklisches Dipeptid mit einer Nukleinbase dar. Dies ist ein weiteres Beispiel von seltenen P450 Enzymen, welche die Verknüpfungen zwei unterschiedlicher Substrate katalysierten.

Im Vergleich zu ihren nicht prenylierten Vorläufern, zeigen prenylierte aromatische Produkte oft diverse biologische und pharmazeutische Aktivitäten. Die Prenyltransferasen der DMATS-Superfamilie sind ihren aromatischen Substraten gegenüber sehr flexibel, allerdings weisen sie ihrem Prenyldonor gegenüber nur eine geringe Toleranz auf. In der Regel akzeptieren sie nur DMAPP, jedoch nicht GPP oder andere Prenyldonoren mit einer noch längeren Kettenlänge. Um das Spektrum des Prenyldonors wurde die Akzeptanz zu erweitern, von zwei Tyrosin-O-Prenyltransferasen TyrPT und SirD gegenüber unnatürlichen DMAPP Analoga wie MAPP, 2-pen-PP und Benzyl-PP in Anwesenheit von Tyrosin und Derivaten getestet. Die Ergebnisse zeigten, dass TyrPT und SirD auch die Übertragung der unnatürlichen Donoren katalysieren und dabei ein ähnliches Verhalten wie mit dem natürlichen Prenyldonor DMAPP beibehalten. Produkte, die die Alkyl- bzw. Benzylgruppe an denselben Positionen wie mit DMAPP tragen, wurden daher identifiziert. Diese Arbeit trägt erheblich zur Vielfalt von prenylierten Produkten durch chemoenzymatische Synthese bei.

Die Ergebnisse dieser Dissertation tragen maßgeblich zur Bildung und zum Metabolismus von tryptophanhaltigen CDPs in der Natur bei, sowie die Erweiterung potenzieller Anwendungen von Prenyltransferasen. Darüber hinaus bilden sie eine solide Grundlage für zukünftige Anwendungen in der synthetischen Biologie.

## **1** Introduction

#### 1.1 Actinobacteria

Actinobacteria is one of the largest phyla of Domain Bacteria. It contains gram-positive bacteria with high guanine-cytosine (GC) content from 51% to over 70% in their DNA. with some exceptions of less than 50% G+C<sup>1,2</sup>. They are widely distributed in both terrestrial and aquatic habitats<sup>3</sup>. Containing most members of economic or medical significance, the order of Actinomycetales often grows extensive mycelia and can be reproduced by spores or hyphae. Behaving like fungi as decomposer in soil, they exhibit economic importance for agriculture and forests. Actinomycetes also play important roles in drug discovery and contribute to 61% of all microorganism-derived bioactive compounds so far discovered<sup>4</sup>. Two-thirds of known antibiotics in current use are originated from actinomycetes, with Streptomyces as the main source<sup>4,5</sup>. Since the discovery of streptomycin from Streptomyces griseus in 1943, numerous antibiotics and their derivatives within different chemical classes such as β-lactams, tetracyclines, aminoglycosides. macrolides. and glycopeptides have been discovered in actinomycetes and used clinically in modern medicine for treatment of different diseases<sup>6</sup>. However, the increasing occurrence of antibiotic-resistant pathogenic organisms<sup>7</sup> and the remarkable decline in discovery of novel antimicrobial agents<sup>8</sup> make the public heath confront with great challenges. To solve the antibiotic-resistance problem and identify more bioactive compounds, intensive researches on novel approaches for natural product discovery have been performed in recent decades. One strategy is to activate silent or cryptic gene clusters of secondary metabolites by the induction *in vivo* or heterologous expression in engineered *Streptomyces* host with clear background<sup>9</sup>. Other efforts include exploiting rare actinomycetes in extreme habitats, metagenomics analysis of uncultured environmental samples, improvement of analytical methods<sup>10</sup>, and elicitation of secondary metabolite with biological, chemical and molecular strategies<sup>11</sup>.

### **1.2 Cyclodipeptides**

Cyclodipeptides (CDPs) and their derivatives constitute a large class of secondary metabolites with potential biological and pharmacological activities<sup>12,13</sup>. For instance, *cyclo*-L-His-L-Tyr (**1**) and *cyclo*-L-His-L-Phe (**2**) could be employed as antiarrhythmic agents<sup>14</sup>. Compound **2** and its derivative phenylahistin (**3**) show significant antitumor activity<sup>14,15</sup>. *cyclo*-L-Phe-L-Pro (**4**) and *cyclo*(L-Phe-*trans*-4-OH-L-Pro) (**5**) act as antifungal agents<sup>16</sup>. *cyclo*-L-Leu-L-Pro (**6**) and echinulin (**7**) inhibit mycobacteria<sup>17,18</sup>. *cyclo*-L-His-L-Pro (**8**) and *cyclo*(dehydroala-L-Leu) (**9**) represent antihyperglycaemic agents<sup>19,20</sup> and **8** also exerts anti-inflammatory effects (Figure 1)<sup>21</sup>. The main structure of CDPs are generated by the condensation of two  $\alpha$ -amino acids, which can be achieved through total chemical synthesis or biosynthesis catalyzed by two groups of enzymes, non-ribosomal peptide synthetases (NRPSs) and cyclodipeptide synthases (CDPSs), in nature<sup>13</sup>.




Figure 1. Selected examples of cyclodipeptides and derivatives with pharmacological activities.

#### 1.2.1 CDPs from NRPS pathways

Non-ribosomal peptide synthetases (NRPSs) are large multimodular enzymes that assemble complex peptides with diverse structures and biological activities in microorganisms such as bacteria and fungi<sup>22</sup>. In the single polypeptide chain of NRPS lies an array of large, repetitive modules and each module comprises several catalytic domains. As shown in Figure 2, one elongation module contains at least three domains, adenylation (A), thiolation (T), and condensation (C) domain. The initiation module has no C domain and the termination module has an additional thioesterase (TE) domain. The non-ribosomal peptides (NRPs) assembly initiates with the activation of the amino acid substrate resulting in an aminoacyl-AMP intermediate under the catalysis of A domain. The first activated intermediate is then transferred to the thiol group tethered of T domain and condensed with the second intermediate bound to the adjacent T domain to form the peptide bond, which is catalyzed by C domain. After condensation with the last amino acid, the final product is released by hydrolysis or cyclization catalyzed by TE domain<sup>23</sup>. Different to the normal ribosomal-dependent synthesis




Figure 2. Model of NRPs biosynthesis. (Modified from review <sup>23</sup>)

machinery that incorporates only the proteinogenic amino acids, NRPSs can catalyze additionally the assembly of hundreds of other building blocks like D- and  $\beta$ -amino acids,  $\alpha$ -keto- and  $\alpha$ -hydroxy acids and even heterocycles and fatty acids<sup>24</sup>, which increases significantly the structural diversity of natural products. The biosynthetic origins of many CDP-containing natural products in fungi and some bacteria are catalyzed by NRPSs, through dedicated biosynthetic pathways (bimodular NRPS) or through premature release of dipeptidyl intermediates as side CDP products during the biosynthesis of a larger peptide by NRPSs<sup>25-27</sup>. Several bioactive compounds such as thaxtomin (10)<sup>25,28,29</sup>, roquefortine C (11)/meleagrin (12)<sup>30</sup>, gliotoxin (13)<sup>31</sup>, fumitremorgin (14)<sup>32</sup>, acetylaszonalenin (15)<sup>33</sup>, and ditryptophenalaine (16)<sup>34</sup> (Figure 3) are products of NRPS pathways, and the core CDPs are catalyzed by bimodular NRPSs.




Figure 3. Selected examples of CDP-containing bioactive compounds generated by NRPS pathways.

#### 1.2.2 CDPs from CDPS pathways

In addition to NRPSs, the characterization of AlbC in 2002, an NRPS-unrelated enzyme able to specifically form CDPs by hijacking aminoacyl-tRNAs (aa-tRNA) as substrates in the albonoursin pathway in *Streptomyces noursei*, revealed a new enzyme family

named cyclodipeptide synthases (CDPSs), which started a new era in the investigation on biosynthesis of cyclodipeptides<sup>35,36</sup>. Subsequently, several CDPSs from different organisms were identified to form varieties of CDPs<sup>37</sup>. Benefiting from the steadily increasing number of complete or partial genome sequences available since 2005<sup>38</sup>, more than one hundred CDPSs have been experimentally characterized so far, incorporating 18 of the 20 proteinogenic amino acids into cyclodipeptides, with the exception for Asp and Lys<sup>37,39-42</sup>. In contrast to the large NRPSs, CDPSs are small peptide bond–forming enzymes with typical polypeptides of 200–300 amino acid residues<sup>39</sup>. They were found to be mostly distributed in the Actinobacteria, Proteobacteria and Firmicutes, with only a few were identified in eukaryotes<sup>37,39,43</sup>.

To investigate the catalytic mechanism of CDPSs, crystal structures of three CDPSs, AlbC from *S. noursei*, Rv2275 from *Mycobacterium tuberculosis* and YvmC from *Bacillus licheniformis*, have been solved<sup>44-47</sup>. It was proposed that CDPSs used a pingpong mechanism to catalyze the formation of CDPs by hijacking aa-tRNAs from primary metabolism as substrates (Figure 4)<sup>37</sup>. The reaction begins with binding of the first aa-tRNA, followed by the transfer of its aminoacyl moiety onto the conserved S37 (AlbC numbering) of the enzyme pocket. The resulted aminoacyl enzyme intermediate subsequently reacts with the aminoacyl moiety of the second aa-tRNA leading to formation of the dipeptidyl enzyme intermediate. Then the second peptide bond is formed by intramolecular cyclization thus generating the final CDP<sup>37</sup>.

During the formation of CDP, the catalytic residues S37, N40, Y178, E182, Y202 and H203 play important roles in catalysis *via* hydrogen bond formation or deprotonation of ammonium group for nucleophilic attack<sup>47</sup>. Based on the distinguished conserved residues at position 40 and 203 and the highly conserved Y202 within the active sites, CDPSs are classified into three subfamilies, NYH, SYQ and XYP subfamiliy<sup>39</sup>. CDPSs can also incorporate non-canonical amino acids (ncAAs) into CDPs by loading the ncAAs to tRNAs using the promiscuity of aminoacyl-tRNA synthetases, which breaks the limitation of potential precursors to the 20 proteinogenic amino acids and diversifies CDPS products significantly<sup>48</sup>. Until now, several bioactive compounds derived from the CDPS pathways have been described, for instance, albonoursin (**17**)<sup>35,36</sup>, cWW-Me<sub>2</sub>

(18)<sup>49</sup>, pulcherriminic acid (19)<sup>45,50</sup>, mycocyclosin (20)<sup>51,52</sup>, nocazine E (21)/neihumicin (22)<sup>53</sup>, bicyclomycin (23)<sup>54,55</sup>, and dehydrophenylahistin (24)<sup>56</sup> (Figure 5).




Figure 4. Proposed mechanism for cyclodipeptide biosynthesis by CDPS<sup>37</sup>.





Figure 5. Selected examples of CDP-containing bioactive compounds generated by CDPS pathways.

#### 1.2.3 CDP tailoring enzymes

In the CDP-containing natural product biosynthesis, the initially assembled CDPs by CDPSs or NRPSs are usually further modified by the associated tailoring enzymes (Scheme 1). In the CDPS pathways, a variety of putative enzyme classes can be found genetically associated with respective CDPS gene. These include numerous oxidative enzymes of different types of cytochromes P450, α-ketoglutarate/Fe<sup>II</sup>-dependent dioxygenases (α-KGDs) and flavin-containing monooxygenases. A large number of different *O*-, *N*-, and *C*-methyltransferases, α/β-hydrolases, peptide ligases, and acyl-CoA transferases also belong to the CDP tailoring enzymes<sup>57</sup>. Among the modifying enzymes, cyclic dipeptide oxidases (CDOs), a family of novel flavin-dependent amino acyl α,β-dehydrogenases, are widely distributed in the CDPS pathways and show extensive substrate specificity<sup>35,36,53</sup>. NRPS-dependent pathways contain similar types of modification enzymes, with the distinguishing feature of wide presence of a range of prenyltransferases catalyzing regular or reverse prenylation at different positions of the CDP scaffold<sup>58,59</sup>. The tailoring enzymes involved in the biosynthesis of selected CDP-containing natural products from NRPS and CDPS pathways are summarized in Table 1 and Table 2, respectively.

By using synthetic biology, combinatorial expression of tailoring enzymes originating from unrelated biosynthetic pathways provides the possibility to produce newly modified CDPs with diverse structures. For example, dehydrophenylahistin (**24**) is transformed by CDO-containing cell-free extract of *Streptomyces albulus* KO-23 from the fungal metabolite phenylahistin (**3**), resulting in more than 1000 times higher cytotoxicity than phenylahistin<sup>56</sup>. Among the CDP modifying enzymes, cytochromes P450 play important roles in natural product biosynthesis *via* diverse oxidative reactions.



Scheme 1. Different kinds of modifications of CDP generated by CDPS or NRPS.

Table 1. Overview of different tailoring enzymes associated within gene clusters of the NRPS pathways.

Compounds	CDP Core	Tailoring Enzymes (Function)
(Producer)		
thaxtomin A (10)	cWF	cytochrome P450 (hydroxylation)
(Streptomyces scabies)		
roquefortine C(11)/	cWH	prenyltransferase (C3-reverse prenylation)
meleagrin (12)		methyltransferase (O-methylation)
(Penicillium chrysogenum)		cytochrome P450 (oxidative cyclization)
		N-hydroxylase ( <i>N</i> -hydroxylation)
		oxidoreductase ( $\alpha$ , $\beta$ -dehydrogenatioin)
gliotoxin ( <b>13</b> )	cFS	two cytochromes P450 (oxidation)
(Aspergillus fumigatus)		glutathione S-transferase (sulfurization)
		aminocyclopropane carboxylic acid synthase
		(cyclopropane-formation)
		two methyltransferase (O- /N-methylation)
fumitremorgin B (14)	cWP	two prenyltransferases (N- /C2-prenylation)
(Aspergillus fumigatus,		three cytochrome P450 (oxidative
Neosartorya fischeri)		cyclization, hydroxylation)
		methyltransferase (O-methylation)
acetylaszonalenin (15)	cWF	prenyltransferase (C3-reverse prenylation)
(Neosartorya fischeri)		acetyltransferase (N-acetylation)
ditryptophenalaine (16)	cWF	cytochrome P450 (dimerization)
(Aspergillus fumigatus)		

Table 2. Overview of different tailoring enzymes associated within gene clusters of the CDPS pathways.

Compounds	CDP Core	Tailoring Enzymes (Function)
albonoursin (17)	cFL	CDO (α,β-dehydrogenation)
(Streptomyces noursei)		
cWW-Me <sub>2</sub> (18)	cWW	methyltransferase ( <i>N</i> -methylation)
(Actinosynnema mirum)		
pulcherriminic acid (19)	cLL	cytochrome P450 ( <i>N</i> -oxide formation and
(Bacillus subtilis)		aromatization of the DKP-ring)
mycocyclosin (20)	cYY	cytochrome P450 (intramolecular C-C
(Mycobacterium		coupling)
tuberculosis)		
nocazine E (21)/	cFY	CDO (α,β-dehydrogenation)
neihumicin ( <b>22</b> )	cFF	methyltransferase (O-methylation)
(Nocardiopsis dassonvillei)		
bicyclomycin (23)	cIL	α-KGD (epoxidation)
(Streptomyces		three α-KGDs (hydroxylation)
sapporonensis)		α-KGD (dehydrogenation)
		cytochrome P450 (hydroxylation)
dehydrophenylahistin (24)	cFH	CDO (α,β-dehydrogenation)

#### 1.3 Cytochromes P450

Cytochromes P450 (P450s) constitute a large superfamily of heme-containing monooxygenases distributed in all life kingdoms. They catalyze diverse oxidative reactions with a wide range of substrates<sup>60</sup>. The terminology P450 is based on their typically maximum absorbance at 450 nm in reduced form when bound to carbon monoxide<sup>61</sup>. P450s are the most versatile biological catalysts in nature for their contribution to biosynthesis of steroids, fatty acids, fat-soluble vitamins and bile acids. They are also involved in biotransfomation of xenobiotics, metabolism of drugs, as well as conversion of alkanes, terpenes and aromatic compounds<sup>62</sup>. With extraordinarily broad substrate spectra and regio- and stereoselectivity, they play important roles in the biosynthesis of natural products<sup>63,64</sup>.

#### 1.3.1 Catalytic mechanism of P450s

Since the determination of the first crystal structure of P450<sub>cam</sub>, a monooxygenase metabolizing camphor in *Pseudomonas putida*, in the mid-1980s<sup>65,66</sup>, more than 800 entries with "P450" can be found in the Protein Data Bank (PDB) to date. Many of them are involved in natural product biosynthesis<sup>67</sup>. In all members of P450 family, the only absolutely conserved and catalytically most important residue is cysteine (Cys), which is situated at the N-terminus of the L-helix and acts as the fifth axial ligand of the heme iron coordinating to the Fe atom via a thiolate bond<sup>63</sup>. The vast majority of P450s catalyze the chemical reactions depending on the transfer of electrons to the heme iron via an electron transport chain. Based on the components of redox partners, different classes of electron transfer chains were described by Hannemann et al.<sup>62</sup> Most bacterial P450s belong to class I redox system consisting of three separate and soluble proteins, *i.e.* ferredoxin, ferredoxin reductase and P450<sup>62</sup>. Usually, bacterial P450s, especially those from Streptomyces, also accept electrons from heterologous redox partners<sup>64</sup>. In the P450 catalytic cycle, the electrons are transferred from NAD(P)H to iron of the P450, resulting in the incorporation of one oxygen atom into the substrate via complex multiple steps (Figure 6). The catalytic cycle begins with the binding of substrate to displace the iron coordinated water. The ferric heme iron is reduced by the first electron. Molecular oxygen binding is followed by the second reduction with electron and two successive

protonations of the distal oxygen, leading to the formation of the intermediate Compound 0 (Cpd 0, Fe<sup>III</sup>-OOH) and reactive ferryl-oxo intermediate Compound I (Cpd I, Fe<sup>IV</sup>=O, porphyrin  $\pi$ -cation radical). The substrate radical is formed through abstraction of one hydrogen atom by Cpd I, and followed by the recombination with hydroxyl radical from ferryl-hydroxo Compound II (Cpd II) to give the hydroxylated product. Finally, the hydroxylated product is released from the active site and water rebinds to restore the enzyme to its resting state.





Figure 6. P450 catalytic cycle with hydroxylation of the substrate RH to ROH as an example.

#### 1.3.2 Aryl-aryl coupling catalyzed by P450s in natural product biosynthesis

As ubiquitous catalysts in nature, P450s catalyze diverse reactions in natural product biosynthesis. Among them, hydroxylation of C-H or N-H bond and epoxidation of C=C bond are regarded as common P450 reactions, leading to only slight changes in the substrate skeleton<sup>68</sup>. These typical P450s often exhibit multifunction and catalyze consecutive hydroxylation/epoxidation during the biosynthesis of interesting molecules, such as the MycG involved in the formation of macrolide mycinamicin I, II, V from *Micromonospora griseorubida*<sup>69,70</sup> and Taml from *Streptomyces* sp. 307-9 catalyzing the production of diverse tirandamycins<sup>71,72</sup>. In addition to the common P450 reactions, unusual reactions, such as aromatic/phenolic coupling, bond cleavage or migration and ring opening or rearrangement, have gained more and more attention in recent years. One well-known example is the P450 TxtE in the biosynthesis of phytotoxin thaxtomin A (10), which catalyzes the unusual nitration of L-tryptophan (25) resulting in the formation of L-4-nitrotryptophanthen (26). The P450 enzyme TxtC performs the typical phenylalanyl hydroxylation after the CDP assembly (27)<sup>25,28,29</sup> (Scheme 2.). Additionally, intra-/intermolecular aryl-aryl coupling reactions have been found in many natural product biosynthesis, as illustrated in Scheme 3 and Scheme 4, respectively. For example, the CDP tailoring P450 CYP121 from *Mycobacterium tuberculosis* catalyzes the intermolecular C-C coupling of the tyrosine side chain of cyclo-L-Tyr-L-Tyr (28) to form mycocyclosin (20), which acts as a causative agent of tuberculosis<sup>52</sup>. In the biosynthesis of staurosporine (30) in Streptomyces sp. TP-A0274, two intermediates are formed by P450-catalyzed intramolecular C–C and C–N coupling. The indolocarbazole skeleton K252c (31) is formed by intramolecular C-C bond connection of chromopyrrolic acid (32) by StaP<sup>73</sup>. StaN catalyzes the C–N bond (C5'-N12) formation of the intermediate (33) from holyrine A (34)<sup>74</sup>. A similar aromatic coupling reaction also occurs during the biosynthesis of magnoflorine (35) in the plant Coptis japonica. The transformation of (S)-reticuline (36) to (S)-corytuberine (37) is catalyzed by CYP80G2<sup>75</sup>.




Scheme 3. Examples of intramolecular aryl-aryl coupling reactions catalyzed by P450s.

The dimeric compounds often show useful and interesting biological activities. One such example are the pigments dimeric flaviolins (**38** and **39**) formed *via* intermolecular C–C

coupling of flaviolin (40) by two P450s (CYP158A1 and CYP158A2) in S. coelicolor A3 (2). These pigments are thought to protect microbes from UV radiation<sup>76,77</sup>. Similarly, intermolecular dimerization of 1,3,6,8-tetrahydroxynaphthalene (41) to generate 1,4,6,7,9,12-hexahydroxyperylene-3,10-quinone (42) via intermediate (43) was achieved by P-450mel in Streptomyces griseus<sup>78</sup>. In marine bacteria Pseudoalteromonas luteoviolacea 2ta16 and P. phenolica O-BC30, the P450 Bmp7 was found to catalyze the formation of polybrominated aromatic compounds (44-46) via homo or heterodimerization of their monomers (47, 48)<sup>79</sup>. In addition to bacteria, P450s from fungi also catalyze intermolecular aryl-aryl coupling. Two homologous fungal P450 enzymes, KtnC from A. niger and DesC from Emericella desertorum, were identified to mediate aryl-aryl coupling of 7-demethylsiderin (49) at different positions to form regioisomers *P*-orlandin (50) and *M*-desertorin A (51), respectively<sup>80</sup>. In the biosynthesis of communesins in *Penicillium expansum*, the P450 enzyme CnsC is responsible for heterodimeric coupling of two different indole moieties, tryptamine (52) and aurantioclavine (53), resulting in the formation of heterodimer (54), a precursor of communesin scaffold (55)<sup>81</sup>. The CDP tailoring P450 in the NRPS pathway from A. flavus, DtpC, catalyzes the homodimerization of N-methyltryptophenaline (56) to form ditryptophenaline (57)<sup>34</sup>. The enzymes Bmp7 and CnsC represent rare examples of P450s that are able to perform aryl-aryl coupling of two different substrates.


#### INTRODUCTION



Scheme 4. Examples of intermolecular aryl–aryl coupling reactions catalyzed by P450s.

#### 1.3.3 P450s involved in the CDPS pathways

Although several gene clusters of natural products derived from CDPS pathways have been identified (Table 2), only three associated P450s were functionally characterized: i) the CYP121 from *M. tuberculosis*<sup>52</sup> described in Scheme 3; ii) CYP134A1 from *B. subtilis* catalyzing double N-oxide formation and aromatization of the DKP-ring of *cyclo*-L-Leu-L-Leu (**59**) leading to the formation of pulcherriminic acid (**19**). Further transformation to pulcherrimin pigment (**60**) happens *via* a non-enzymatic reaction<sup>50</sup>; iii) P450 BcmD, performing the hydroxylation of intermediate **62** in late modification step during the biosynthesis of bicyclomycin (**23**) in *Streptomyces sapporonensis*, leading to the formation of intermediate (**63**), which is further modified by  $\alpha$ -KGD BcmF<sup>55</sup>. The reactions catalyzed by the latter two P450s are illustrated in Scheme 5.



Scheme 5. P450s involved in the CDPS pathways.

#### 1.4 Prenylated aromatic compounds in nature

As mentioned under **1.2.3**, prenyltransferases (PTs) participate in many prenylated secondary metabolite biosynthesis and catalyze regular (**67**) or reverse prenylation (**68**) at different positions of the CDP scaffold derived from the NRPS pathway. Besides the CDP core, PTs also catalyze the attachment of one or more prenyl moieties (**69**) to other aromatic cores in natural product biosynthesis, such as indole (**70**), tyrosine (**71**), xanthone (**72**), flavone (**73**), and hydroxynaphthalene (**74**)<sup>82-85</sup> (Figure 7). PTs are found in many living organisms including plants, bacteria, and fungi and can be classified in different subgroups based on their amino acid sequences structures, and biochemical properties<sup>86-88</sup>. The resulted prenylated preducts often show biological and pharmacological activities distinct from their non-prenylated precursors, which makes these enzymes to be attractive biocatalysts for structure modifications<sup>58,89</sup>.




Figure 7. Regular and reverse prenyl pattern, different lengths of prenyl moieties and aromatic scalfolds as PT acceptors.

#### 1.4.1 Prenylated tyrosine derivatives

Tyrosine is one of the 20 proteinogenic amino acids that are used by cells to synthesize proteins in nature. It is produced *via* shikimate pathway in plants and most microorganisms and from the essential amino acid phenylalanine (derived from food) in mammals<sup>90</sup>. Benefiting from the *para*-hydroxyl group, tyrosine is readily to take chemical reactions and signal transductions as well as the post-translational modifications such as phosphorylation, sulfation, nitration, oxidation, halogenation,

glycosylation, AMPylation or cross-linking<sup>90</sup>. Several simple prenylated tyrosine derivatives were found to be *O*- or *C3*-prenylated, such as the 5-HT receptor ligand (**75**) isolated from *Pithomyces Ellis*<sup>91</sup>, stachyline A (**76**) found in *Stachylidium* sp. harboring a unique terminal oxime group<sup>92</sup> and a *C3*-prenylated tyrosine (**77**) isolated from *Streptomyces* sp. IFM 10937<sup>93</sup>. Until now, two tyrosine PTs have been identified and characterized biochemically. The first one, SirD, catalyzes the *O*-prenylation of L-tyrosine (**78**) resulting in **79**, which is the precursor of the phytotoxin sirodesmin PL (**80**) in *Leptosphaeria maculans*<sup>94,95</sup>. Another tyrosine PT, TyrPT, from an unknown biosynthetic pathway in *A. niger* shows similar biochemical features as SirD (Figure 8)<sup>96</sup>.




Figure 8. Examples of simple prenylated tyrosine derivatives and the function of the two identified tyrosine PTs.

#### 1.4.2 Chemoenzymatic synthesis of prenylated aromatic compounds with DMAPP

As described previously, many prenylated secondary metabolites exhibit different and efficient activities comparing to their non-prenylated precursors<sup>58,97</sup>. Therefore, the diversity of prenylated compounds has gained increasing attention in pharmaceutical study. With the advantage of broad aromatic substrate spectra, high regio- and stereoselectivity of the reactions and mild reaction conditions in comparison to the chemical synthesis, chemoenzymatic synthesis of unnatural prenylated compounds is of interest for current research. Such compounds can be obtained by using aromatic PTs

#### INTRODUCTION

with diverse substrates. For example, the regiospecific regular C4-, C5- and C7prenylated simple indole derivatives (**81–86** in Figure 9) were generated *via* chemoenzymatic synthesis by the respective L-tryptophan PTs FgaPT2, 5-DMATS and 7-DMATS in the presence of DMAPP<sup>59,98,99</sup>. In addition to tryptophan derivatives, the indole PTs also use other aromatic substrates with distinct structures such as hydroxynaphthalenes, flavonoids, or xanthones<sup>100-102</sup>. FgaPT2 and 7-DMATS have been demonstrated to accept tyrosine and its derivatives as substrates besides the simple indole derivatives<sup>96,103</sup>. Similarly, the tyrosine PTs SirD and TyrPT catalyze both the *O*- or *N*-prenylation of a variety of tyrosine derivatives and the prenylation of tryptophan and derivatives<sup>95,96,104,105</sup>.




Figure 9. Examples of prenylated indole derivatives.

# 1.4.3 Chemoenzymatic synthesis of prenylated aromatic compounds with unnatural prenyl analogs

As mentioned above, the PTs of DMATS superfamily utilize a large number of aromatic substrates. In contrast to their flexible aromatic substrate spectra, most of the DMATS members show a restricted specificity toward their prenyl donors, accepting usually DMAPP as prenyl donor<sup>88</sup>, with a few exceptions that use GPP, or both DMAPP and GPP, or DMAPP, GPP, and FPP as prenyl donors<sup>102,106-108</sup>. To broaden their specificity

for alkyl donors, two tryptophan PTs FgaPT2 and 5-DMATS and five cyclic dipeptide prenyltransferases BrePT, FtmPT1, AnaPT, CdpNPT, and CdpC3PT have been demonstrated prior to this study to accept the unnatural prenyl analogs methylallyl diphosphate (MAPP) (87), 2-pentenyl diphosphate (2-pen-PP) (88), and benzyl diphosphate (benzyl-PP) (89), with partial or complete shifts of alkylation or benzylation positions (90-92) comparing to the natural prenyl donor (Figure 10)<sup>109-111</sup>.




Figure 10. Examples of unnatural prenyl analogs and alkylated or benzylated Ltryptophan derivatives.

# 2 Aims of this thesis

The following issues have been addressed in this thesis:

# 1) <u>Identification of CDPSs that catalyze the formation of tryptophan-</u> containing cyclodipeptides from *Streptomyces*

CDPSs catalyze the formation of CDPs by using the loaded tRNAs as substrates. Tryptophan-containing CDPs have received an increasing interest in recent years due to their promising scaffolds for structural modification. Although over ten specific cWW synthases have been functionally characterized, only one CDPS originating from the sea anemone *Nematostella vectensis* was demonstrated to produce several cWXs prior to this study. The product yields are however very low with only 0.8–1.0 mg/L in *E. coli*. The aim of this project is to find new CDPSs for the formation of CDPs comprising tryptophan and another amino acid. The following experiments were carried out:

- Search for CDPS homologues in database by blast with the CDPSs that form cWW
- > Phylogenetic analysis of the CDPS candidates with the known CDPSs
- > Cloning of the CDPS genes into pET28a vector and expression in *E. coli*
- > LC-MS analysis of the *E. coli* cultures harboring the CDPS expressing constructs
- Isolation and structure elucidation of CDPS products by HR-EIMS and NMR analyses
- Determination of the CDPS product yields on HPLC

# 2) <u>Functional proof of a cytochrome P450 homologue from</u> <u>Streptomyces purpureus NRRL B-5737</u>

In nature, the CDP cores synthesized by NRPSs or CDPSs are usually further modified by diverse tailoring enzymes to form sophisticated compounds. In the first project, several CDPSs that catalyze the formation of cWXs have been identified in different *Streptomyces* strains, including cWW synthases from *S. pupureus*, *S. lavendulae*, and *S. xanthophaeus.* In these three strains, the cWW-forming CDPS coding gene is genetically associated with a gene encoding putative cytochrome P450 in the downstream with the same orientation. The three P450 homologues share sequence identities of more than 75% on the amino acid level with each other. Therefore it could be speculated that these three clusters might synthesize similar CDP derivatives. The aim of this project is to identify the function of the three tailoring P450 homologues by taking P450<sub>NB5737</sub> as a representative. The following experiments were carried out:

- Phylogenetic analysis of the three P450 homologues with structurally defined natural product P450s from bacteria
- Phylogenetic analysis of P450s from this study and functionally characterized P450s from bacteria
- Cloning of CDPS<sub>NB5737</sub> alone or together with P450<sub>NB5737</sub> into integrative plasmid pSET152 or replicative vector pPWW50 and expression in S. coelicolor M1146
- Confirmation of the cWW metabolism by P450<sub>NB5737</sub> via biotransformation experiment
- Isolation of the P450<sub>NB5737</sub> product and structure elucidation by HR-EIMS and NMR analyses
- Production of the recombinant P450<sub>NB5737</sub> in *E. coli* and performing *in vitro* assays of P450<sub>NB5737</sub>
- Postulation of the catalytic mechanism of P450<sub>NB5737</sub>

# 3) <u>Biochemical investigations on the acceptance of unnatural DMAPP</u> analogs by tyrosine O-prenyltransferases TyrPT and SirD

Prenyltransferases of the DMATS superfamily show broad substrate spectra, but strict prenyl donor specificity. The aim of this thesis was to elucidate the behavior of *O*-prenyltransferases TyrPT and SirD towards chemically synthesized DMAPP analogs, MAPP, 2-pen-PP and benzyl-PP. The following experiments were carried out:

> Overproduction of TyrPT and SirD in *E. coli* and subsequent purification

- Incubation of assays containing L-tyrosine and derivatives and the DMAPP analogs in the presence of TyrPT and SirD, respectivey
- > Analysis of the enzyme activities on HPLC and isolation of the enzyme products
- > Structure elucidation of the products by HR-EIMS and NMR analyses
- > Determination of the kinetic parameters of the corresponding reactions

# **3 Results and discussion**

# 3.1 Identification of nine tryptophan-containing cyclcodipeptide synthases from *Streptomyces* strains

Prior to this study, dozens of CDPSs that are responsible for cyclodipeptide formation have been identified<sup>37,39-42</sup>. Overview the CDPS products, 17 of 20 proteinogenic amino acids have been incorporated into cyclodipeptides<sup>39</sup>. Although over ten specific cWW synthases have been characterized<sup>39,49,112</sup>, CDPSs synthesizing other tryptophan-containing cyclodipeptides have not been reported for microorganisms.

The working flow of this project is illustrated in Figure 11. Firstly, to get the CDPSs for tryptophan-containing cyclodipeptides, a BlastP search was carried out using sequences of known cWW-forming CDPSs. To this end, thirteen candidate CDPSs from eleven *Streptomyces* strains were selected as investigation objectives.




Figure 11. Working flow of identification of cWX-forming CDPSs

For functional proof, the coding genes of CDPSs were amplified by PCR with their respective gDNA as templates. Subsequently, genes encoding CDPSswere ligated into pET28a vector via pGEM T easy constructs and transformed in E. coli SoluBL21. The production of CDP was induced with appropriate concentration of IPTG when an absorption of OD<sub>600</sub> at 0.6 was reached. The expression system was tested with two known cWW-forming CDPSs WP\_014141671 and WP\_014140974 from Streptomyces cattleya DSM 46488. The expected product cWW was confirmed by LC-MS and NMR analyses. The expression constructs of other eleven CDPSs were also expressed in E. coli SoluBL21. The optimized expression condition for each CDPS was tested with different IPTG concentrations (0.2 mM and 0.5 mM) and incubation temperatures (20 °C, 30 °C and 37 °C). The cultures of E. coli transformant harboring each CDPS expression construct were analyzed on LC-MS, with the empty vector pET28a as negative control. Then CDPSs products were isolated and sent for NMR analysis. Structure elucidation revealed nine cWX-forming CDPSs including one cWL, two cWP, and three cWW synthases as well as three unspecific CDPSs producing several products with cWA or cWY as the major cyclodipeptide (Figure 12). The other two CDPSs WP 031028810 from Streptomyces sp. NRRL F-5639 and BAU83478 from Streptomyces laurentii DSM 41684 were proven to catalyze the formation of cFL.

Total product yields of CDPs were calculated based on HPLC analysis to be 46 to 211 mg/L *E. coli* culture after cultivation for 36 h under their optimized conditions. Phylogenetic analysis of these CDPS homologues with the known CDPSs from actinomycetes revealed that tryptophan-containing cyclodipeptide synthases from actinobacteria are located in two clades: clade I comprising only cWX synthases with the exception for cLL and clade II including not only cWX synthases but also cFX and cYX synthases.

The results presented in this project expanded significantly the spectrum of tryptophancontaining cyclodipeptide (**93-100**) synthases (Scheme 6). And the high product yields of cWXs provided a solid basis for further combination of these CDPS genes with other modification genes in synthetic biology.





Figure 12. HPLC analysis of recombinant *E. coli* strains with empty vector (a) or with CDPS genes (b–l)<sup>40</sup>.



(96) X= V, R1=H, R2= -CH(CH<sub>3</sub>)<sub>2</sub>
(97) X= A, R1= H, R2= -CH<sub>3</sub>
(98) X= P, R1-R2= -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>(99) X= M, R1= H, R2= -CH<sub>2</sub>CH<sub>2</sub>SCH<sub>3</sub>
(100) X=Y, R1=H, R2= 4OH phenyl

Scheme 6. The CDPSs catalyzing the formation of cWX in this study.

This project was cooperated with Jing Liu. The expression constructs of CDPSs with names "pHY××" (Figure 12 B-G, I, J) were prepared by the author of this thesis.


#### For details on this work, please see the publication (section 4.1)

Liu, J.\*, <u>Yu, H.\*</u>, & Li, S.-M. (2018). Expanding tryptophan-containing cyclodipeptide synthase spectrum by identification of nine members from *Streptomyces* strains. *Appl. Microbiol. Biotechnol.*, *102* (10), 4435-4444. [\*equal contribution]

Liu, J\*., <u>Yu, H\*.</u>, & Li, S.-M. (2018). Correction to: Expanding tryptophan-containing cyclodipeptide synthase spectrum by identification of nine members from *Streptomyces* strains. *Appl. Microbiol. Biotechnol.*, *102*, 5787-5789. [\*equal contribution]

# 3.2 Coupling of *cyclo*-L-Trp-L-Trp and guanine by a P450 homologue from *Streptomyces purpureus*

Cytochrome P450s are common CDP tailoring enzymes that participate in the modification of CDP cores to form sophisticated natural products. However, only three P450s involved in CDPS pathways have been identified prior to this study. They are CYP121 in the biosynthesis of mycocyclosin from *M. tuberculosis*<sup>52</sup>, CYP134A1 in the pulcherrimin pathway from *B. subtilis*<sup>50</sup>, and the P450 BcmD in the bicyclomycin pathway<sup>55</sup>. Inspection of the CDPS genes identified in the first project revealed that the cWW-forming CDPS genes from *S. pupureus*, *S. lavendulae*, and *S. xanthophaeus* are respectively associated with a downstream putative cytochrome P450 gene with the same orientation (Figure 13).



## Figure 13. CDPS- and P450-containing gene clusters from three Streptomyces strains.

As is shown in Figure 14, to characterize the three CDP tailoring P450s from *S. pupureus*, *S. lavendulae*, and *S. xanthophaeus*, the bioinformatic analysis was made firstly. The gene and amino acid sequences of the three P450 homologues were downloaded from the NCBI database. Alignments of the three P450 genes with the structurally defined P450s from bacteria revealed three featured motifs that are conserved in the bacterial P450s: (i) the highly conserved A/G<sup>241</sup>G<sup>242</sup>XXT<sup>245</sup> motif with Thr as a critical residue for the H-bonding network (this residue is replaced by a Ser in

the CDP tailoring P450s; EryF numbering); (ii) E<sup>280</sup>XXR<sup>283</sup> motif found in the K helix; (iii) G<sup>347</sup>XXXC<sup>351</sup> motif in the heme-binding loop harboring the invariant and catalytically most important Cys. Phylogenetic analysis of the CDP tailoring P450s with functionally characterized P450s from bacteria indicated that the CDP tailoring P450s of interest are closely related to CYP121 as well as P-450mel, CYP158A1 and CYP158A2, which catalyze the intramolecular C–C coupling of cYY and dimerization of hydroxynaphthalenes/-naphthoquinones *via* aryl–aryl coupling in *Streptomyces*<sup>76-78</sup>.





Figure 14. Working flow of identification of a cWW tailoring P450.

Due to the high identity of over 75% on the amino acid sequence level among the three P450 homologues, the P450<sub>NB5737</sub> was investigated as a representative. *CDPS*<sub>NB5737</sub> alone or together with *P450*<sub>NB5737</sub> were cloned into the integrative plasmid pSET152 or replicative vector pPWW50 and expressed in *S. coelicolor* M1146. LC-MS analysis of cultures of M1146 transformants carrying the coexpression constructs of *CDPS*<sub>NB5737</sub> with *P450*<sub>NB5737</sub> revealed the additional product with [M +H]<sup>+</sup> ions at *m/z* 522.1997 comparing to the *CDPS*<sub>NB5737</sub> transformant. The cWW metabolism by P450<sub>NB5737</sub> was

confirmed by feeding 80  $\mu$ M cWW to two days old culture of *CDPS*<sub>NB5737</sub> transformant. For structure elucidation, 13 mg of P450<sub>NB5737</sub> product was isolated from 4 L GYM cultures of M1146 transformant carrying the expression construct of *CDPS*<sub>NB5737</sub> and *P450*<sub>NB5737</sub> and sent to <sup>1</sup>H, <sup>13</sup>C APT, DQF-COSY, HSQC, and HMBC NMR analyses. The structure elucidation indicated that the P450<sub>NB5737</sub> catalyze the transfer of a guanine moiety to the indole ring of the cWW (**102**) *via* a C–N bond, leading to formation of **103** (Scheme 7).



Scheme 7. Biosynthesis and metabolism of cWW in *S. purpureus* NRRL B-5737 (modified from publication<sup>113</sup>)

To investigate the activity of P450<sub>NB5737</sub> in vitro, the P450<sub>NB5737</sub> gene was cloned into pET28a vector and expressed in *E. coli* Rosetta (DE3). P450<sub>NB5737</sub> production was induced with 0.5 mM IPTG at 18 °C for 20 h in TB media. Approximate 3.5 mg/L culture P450<sub>NB5737</sub> was obtained after purification with Ni-NTA agarose. SDS-PAGE analysis revealed a dominant band at approximate 44.0 kDa (Figure 15). The enzyme assays were carried out by using spinach ferredoxin and ferredoxin-NADP+ reductase for electron transport. Incubation of the purified P450<sub>NB5737</sub> with cWW and guanine in the presence of electron transport composition and NADPH resulted in the formation of same product as from the CDPS<sub>NB5737</sub> and P450<sub>NB5737</sub> transformant. No product was detected in negative controls with heat-inactivated protein, without cWW or guanine. Unfortunately, the conversion yield was extremely low, with only around 1% was observed from in vitro assays. Increasing the concentration of ferredoxin, ferredoxin reductase, or both to 5-fold did not change the conversion yield. UV-Vis spectra analysis of ferrous CO complex of P450<sub>NB5737</sub> after reduction with sodium dithionite revealed strong absorption at 415 nm of an inactive form and only a very weak shoulder peak around 446 nm of the active form. This could be caused by the inappropriate

folding or non-incorporation of heme group into P450<sub>NB5737</sub> produced in *E. coli*. The incorrect state of the protein could also explain the low activity *in vitro*.




Figure 15. SDS-PAGE analysis of the recombinant P450<sub>NB5737</sub>.

Finally, the catalytic mechanism of P450<sub>NB5737</sub> was proposed (Figure 16). In this hypothesis, two radicals (compound II) are formed parallel *via* oxidation of FeII *via* FeIII and ferryl-oxo intermediate (Fe<sup>IV</sup>=O, compound I). Coupling of the two radicals leads to the formation of cWW adducts with guanine.

In conclusion, we identified in this study a P450 enzyme from *Streptomyces* that catalyzes an unusual coupling reaction of a cyclodipeptide with a nucleobase, leading to unprecedented adducts of cyclodipeptide with guanine. This represents one additional rare atypical P450 example catalyzing the coupling of two different substrates. Coupling of guanine with cWW significantly increases the CDP diversity and opens new prospective pathways in natural product discovery. To better understand the catalytic mechanism of this P450, the crystal structure is necessary to be solved in the future.




Figure 16. The proposed catalytic mechanism of P450<sub>NB5737</sub>.

#### For details on this work, please see the publication (section 4.2)

<u>Yu, H.</u>, Xie, X., & Li, S. M. (2018). Coupling of guanine with *cyclo*-L-Trp-L-Trp mediated by a cytochrome P450 homologue from *Streptomyces purpureus*. *Org. Lett. 20* (16), 4921-4925.

# 3.3 Tyrosine *O*-prenyltransferases TyrPT and SirD displaying similar behavior toward unnatural alkyl or benzyl diphosphate as their natural prenyl donor dimethylallyl diphosphate

As described previously, prenyltransferases of the DMATS superfamily are versatile enzymes accepting a large number of aromatic substrates with relatively strict prenyl donor spectra<sup>88</sup>. To broaden the prenyl donor spectra, the acceptance of the unnatural prenyl analogs such as MAPP, 2-pen-PP, and benzyl-PP have been tested in the presence of two tryptophan prenyltransferases FgaPT2 and 5-DMATS and five cyclic dipeptide prenyltransferases, BrePT, FtmPT1, AnaPT, CdpNPT, and CdpC3PT in our laboratory prior to this study<sup>109-111</sup>. The results indicated that the unnatural DMAPP analogs were successfully utilized by these PTs. The structure elucidation of the products revealed partial or complete shifts of alkylation or benzylation positions comparing to the natural prenyl donor DMAPP<sup>109-111</sup>. This inspired us to test these DMAPP analogues towards tyrosine *O*-prenyltransferases TyrPT and SirD. The working flow was described in Figure 17.





Figure 17. Working flow of investigation on the acceptance of TyrPT and SirD toward unnatural DMAPP analogs.

The enzyme assays towards the unnatural substrates often require relatively high amount of proteins in comparison to their natural substrates. Therefore the expression vector of SirD was changed from pQE70 (pAK2) to pET28a (pHY07). With the help of the strong T7 promoter and nutrient-rich TB media, the protein yield was improved from 2 to 4 mg/L *E. coli* SoluBL21 culture. TyrPT (pHC 16) with yield of 4–6 mg/L was obtained in *E. coli* SoluBL21.

At first, the DMAPP analogs MAPP, 2-pen-PP and benzyl-PP were incubated in the presence of TyrPT or SirD together with tyrosine and 12 derivatives. The conversion yields were measured on HPLC. Nineteen of the enzyme assays showed product yields of more than 10%. Only one substrate, 4-amino-L-phenylalanine (**106**), accepted all three DMAPP analogs with high conversions (34%–67%) for both TyrPT and SirD.

For structure elucidation, nine of the products were isolated on HPLC using reverse phase C18 column and subjected to NMR and MS analyses. It was shown that both TyrPT and SirD catalyzed the *O*-/*N*-alkylation/benzylation of tyrosine and derivatives (**104-117**) at the same position as in the presence of their natural prenyl donor DMAPP (Scheme 8).



**106** X=NH; R<sub>1</sub>=H; R<sub>2</sub>=····H **117** 

Scheme 8. The reactions of tyrosine and derivatives and unnatural DMAPP analogs catalyzed by TyrPT and SirD, respectively.

Finally, Michaelis-Menten constants ( $K_M$ ) values and turnover number ( $k_{cat}$ ) of TyrPT and SirD were calculated for unnatural alkyl or benzyl donors in the presence of Ltyrosine or 4-amino- L-phenylalanine. The results indicated that MAPP was accepted by both enzymes with lower  $K_M$  values than those of 2-pen-PP, benzyl-PP, and DMAPP. All three unnatural donors showed much lower  $k_{cat}$  values than those of DMAPP.

In conclusion, tyrosine *O*-prenyltransferases TyrPT and SirD were demonstrated to accept MAPP, 2-pen-PP and benzyl-PP in the presence of tyrosine and derivatives by exhibiting similar behavior as their natural prenyl donor DMAPP. This study expanded the prenyl donor spectra of TyrPT and SirD and increased significantly the diversity of prenylated products by chemoenzymatic synthesis.

### For details on this work, please see the publication (section 4.3)

<u>Yu, H.</u>, Liebhold, M., Xie, X., & Li, S. M. (2015). Tyrosine *O*-prenyltransferases TyrPT and SirD displaying similar behavior toward unnatural alkyl or benzyl diphosphate as their natural prenyl donor dimethylallyl diphosphate. *Appl. Microbiol. Biotechnol.*, *99* (17), 7115-7124.

# **4** Publications

4.1 Expanding tryptophan-containing cyclodipeptide synthase spectrum by identification of nine members from *Streptomyces* strains.

**BIOTECHNOLOGICALLY RELEVANT ENZYMES AND PROTEINS** 



# Expanding tryptophan-containing cyclodipeptide synthase spectrum by identification of nine members from *Streptomyces* strains

Jing Liu<sup>1</sup> • Huili Yu<sup>1</sup> • Shu-Ming Li<sup>1</sup>

Received: 17 January 2018 / Accepted: 28 February 2018 / Published online: 24 March 2018 © Springer-Verlag GmbH Germany, part of Springer Nature 2018

#### Abstract

Cyclodipeptide synthases (CDPSs) comprise normally 200–300 amino acid residues and are mainly found in bacteria. They hijack aminoacyl-tRNAs from the ribosomal machinery for cyclodipeptide formation. In this study, nine new CDPS genes from eight *Streptomyces* strains were cloned into pET28a vector and expressed in *Escherichia coli*. Structural elucidation of the isolated products led to the identification of one *cyclo*-L-Trp-L-Leu, two *cyclo*-L-Trp-L-Pro, and three *cyclo*-L-Trp-L-Trp synthases. Other three CDPSs produce *cyclo*-L-Trp-L-Ala or *cyclo*-L-Trp-L-Tyr as the major cyclodipeptide. Total product yields of 46 to 211 mg/L *E. coli* culture were obtained. Our findings represent rare examples of CDPS family derived from actinobacteria that form various tryptophan-containing cyclodipeptides. Furthermore, this study highlights the potential of the microbial machinery for tryptophan-containing cyclodipeptide biosynthesis and provides valid experimental basis for further combination of these CDPS genes with other modification genes in synthetic biology.

Keywords Aminoacyl t-RNA  $\cdot$  Diketopiperazine  $\cdot$  Cyclodipeptide synthase  $\cdot$  Streptomyces  $\cdot$  Tryptophan-containing cyclodipeptide

#### Introduction

Cyclodipeptides (CDPs) with a 2,5-diketopiperazine (DKP) skeleton are chemically condensation products of two amino acids and represent a class of secondary metabolites with simple scaffold, but different modification possibilities (Borthwick 2012). A large number of DKP derivatives show a broad range of biological and pharmacological activities such as antibacterial, antifungal, antiviral, and immunosuppressive activities (Borthwick 2012; Giessen et al. 2013), which make them attractive molecules for drug discovery and development. So far, DKP derivatives are mainly isolated from microorganism including bacteria and fungi. The DKP scaffold in fungi is usually assembled by bimodular

Jing Liu and Huili Yu contributed equally to this work.

**Electronic supplementary material** The online version of this article (https://doi.org/10.1007/s00253-018-8908-6) contains supplementary material, which is available to authorized users.

Shu-Ming Li shuming.li@staff.uni-marburg.de nonribosomal peptide synthetases (NRPSs) with a typical polypeptide chain length of 2300 amino acids (Maiya et al. 2006; Walsh 2016; Xu et al. 2014), whereas in bacteria mainly by tRNA-dependent cyclodipeptide synthases (CDPSs) comprising normally 200–300 amino acid residues (Giessen and Marahiel 2014; Gondry et al. 2009; James et al. 2015; Moutiez et al. 2017). NRPSs can use both proteinogenic and non-proteinogenic free amino acids as substrates, while CDPSs directly hijack the activated aminoacyl-tRNAs (aa-tRNAs) from the ribosomal machinery for cyclodipeptide formation (Huang et al. 2010).

The DKP scaffold is frequently modified by methylation, hydroxylation, prenylation, dimerization, and further cyclization (Borthwick 2012; Giessen et al. 2013; Li 2010; Xu et al. 2014). Among the DKPs, tryptophan-containing CDPs have received an increasing interest in recent years due to their promising scaffolds for structural modification (Li 2010; Xu et al. 2014). The electron-rich indole ring in tryptophanyl moiety can undergo different enzymatic and spontaneous modifications and rearrangement like prenylation, oxidation, methylation, and dehydrogenation to generate increased chemical complexity (Alkhalaf and Ryan 2015; Walsh 2014).

Since 2005, we have intensively studied prenyltranferases (PTs) involved in the biosynthesis of indole alkaloids in microorganisms, especially those for the prenylation of

<sup>&</sup>lt;sup>1</sup> Institut für Pharmazeutische Biologie und Biotechnologie, Philipps-Universität Marburg, Robert-Koch-Straße 4, 35037 Marburg, Germany

tryptophan and tryptophan-containing CDPs (Winkelblech et al. 2015). The tryptophan-containing CDP PTs catalyzed regio- and stereospecific prenylations at the indole ring. PTs for specific prenylation at nearly all the positions of the indole ring have been characterized (Winkelblech et al. 2015; Wohlgemuth et al. 2017). Most of these PTs are from ascomycetous fungi and are involved in the modification of CDPs assembled by NRPSs. In the view of synthetic biology, it would be of essential importance to combine such PT genes with the small CDPS genes forming tryptophan-containing CDPs, especially those for cyclo-L-Trp-L-Pro (cWP), cyclo-L-Trp-L-Ala (cWA), cyclo-L-Trp-L-Leu (cWL), and cyclo-L-Trp-L-Trp (cWW). All these CDPs serve as precursors in the biosynthesis of diverse pharmacologically active compounds and are very well accepted by microbial PTs (Fan et al. 2015; Li 2010; Winkelblech et al. 2015).

By the end of July 2016, about 450 putative CDPS genes were identified by sequence homology search and their number is increasing steadily (Moutiez et al. 2017). Sixty-five of these genes have been proven to be responsible for the formation of different DKPs and about 30 are from actinomycetes (Brockmeyer and Li 2017; Jacques et al. 2015; James et al. 2015; Moutiez et al. 2017). At least ten of the identified CDPSs from eight actinomycetes catalyze the formation of cWW as the sole product (Fig. S1). These include Amir 4627 from Actinosynnema mirum, NozA, and NcdA from Nocardiopsis sp. CMB-M0232, whose products had been isolated and identified (Giessen et al. 2013; James et al. 2015). The products of other known cWW synthases were identified by LC-MS analysis (Jacques et al. 2015). CDPSs synthesizing other tryptophan-containing cyclodipeptides have not been reported in microorganisms. Until now, only one CDPS originating from the sea anemone Nematostella vectensis was demonstrated to produce a number of tryptophan-containing cyclodipeptides like cWL, cWA, cyclo-L-Trp-L-Phe (cWF), cyclo-L-Trp-L-Met (cWM), and cyclo-L-Trp-Gly (cWG) with very low product yields of 0.8-1.0 mg/L in Escherichia coli (Seguin et al. 2011). It is therefore absolutely essential to find new CDPSs for the formation of DKPs comprising tryptophan and another amino acid.

#### Materials and methods

#### **Computer-assisted sequence analysis**

Protein sequences listed in Figs. 1 and S1 were taken from the NCBI database (http://www.ncbi.nlm.nih.gov/protein) and compared with each other by using BLAST programs (http:// blast.ncbi.nlm.nih.gov/). Multiple sequence alignments were carried out by using the program ClustalW and visualized with ESPript 3.0 (http://espript.ibcp.fr/ESPript/cgi-bin/ESPript.cgi) to identify strictly conserved amino acid residues.

The phylogenetic trees in Figs. 1 and S1 were created by MEGA version 5.0 (http://www.megasoftware.net).

#### Bacterial strains, plasmids, and culture conditions

pGEM-T Easy used for cloning and pET28a (+) for expression experiments were obtained from Promega (Mannheim, Germany) and Novagen (Darmstadt, Germany), respectively. *E. coli* DH5 $\alpha$  (Invitrogen) was used as host for cloning and SoluBL21 (Genlantis) for expression experiments. They were grown at 37 °C in liquid Luria-Bertani (LB) medium (10 g/L tryptone, 5 g/L yeast extract, and 5 g/L NaCl)) or on solid LB medium with 1.5% agar (*w*/*v*). For selection of recombinant *E. coli* strains, 100 µg/mL of ampicillin or 50 µg/mL of kanamycin were supplied in the media.

Streptomyces strains listed in Table S1 were kindly provided by ARS Culture Collection (NRRL) or purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ). They were maintained at 28 °C in GYM (4.0 g/L glucose, 4.0 g/L yeast extract, 10.0 g/L malt extract, 15.0 g/L agar, and pH 7.2) or ISP4 medium (10.0 g/L soluble starch, 1.0 g/L K<sub>2</sub>HPO<sub>4</sub>, 1.0 g/L MgSO<sub>4</sub> 7H<sub>2</sub>O, 1.0 g/L NaCl, 2.0 g/L (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 1.0 g/L CaCO<sub>3</sub>, 1.0 mL/L trace element solution, 15.0 g/L agar, and pH 7.2).

#### Plasmid construction and gene expression in E. coli

Genetic manipulation in *E. coli* was carried out according to the protocol by Sambrook and Russell (2001). Isolation of genomic DNA from *Streptomyces* was performed as described previously (Kieser et al. 2000). The genes encoding CDPSs were amplified by PCR from genomic DNA by using primers listed in Table 1 with Phusion® High-Fidelity DNA Polymerase from New England Biolabs (NEB). The generated PCR fragments were cloned into pGEM-T Easy vector and sequenced by SEQLAB (Göttingen, Germany) to confirm sequence integrity. After sequencing, the fragments were released with the appropriate restriction endonucleases from pGEM-T Easy vector and ligated into pET28a (+) vector, which was digested with the same enzymes previously. The generated plasmids (Table 1) were transformed into *E. coli* SoluBL21 for gene expression.

For CDPS overproduction, 0.5 mL of 16-h cultures of different expression constructs was used to inoculate 50 mL LB medium containing 50  $\mu$ g/mL kanamycin. The cultures were maintained at 230 rpm and 37 °C to an absorption at 600 nm of about 0.6. Isopropyl  $\beta$ -D-thiogalactopyranoside (IPTG) was then added to the cultures to a final concentration of 0.2 or 0.5 mM. The induction was kept at 20, 30, or 37 °C for 20 h for condition optimization (Table S2) or for 36 h for quantification. One milliliter of culture was extracted with one volume of ethyl acetate for three times. The organic phases were combined and evaporated, and the residues were afterward




Fig. 1 Phylogenetic analysis of CDPSs from actinobacteria. The main CDPS products are given in parenthesis. Enzymes investigated in this study are highlighted in red

dissolved in 40  $\mu$ L of methanol. Five microliters of such samples were taken for LC-MS analysis.

#### **HPLC and LC-MS analyses**

The ethyl acetate extracts were analyzed on an Agilent HPLC 1260 series equipped with a photo diode array detector and a Bruker microTOF QIII mass spectrometer by using the Agilent Eclipse XDB C18 column (5  $\mu$ m, 4.6 × 150 mm). A linear gradient of 5–100% acetonitrile in water, both containing 0.1% formic acid, in 40 min and a flow rate at 0.25 mL/ min were used. The column was then washed with 100%

acetonitrile containing 0.1% formic acid for 5 min and equilibrated with 5% acetonitrile in water for 5 min. The parameters of the spectrometer were set as following: electrospray positive ion mode for ionization, capillary voltage with 4.5 kV, collision energy with 8.0 eV.

For quantification, an Agilent HPLC 1200 series equipped with a photo diode array detector and an identical column were used. A linear gradient of 10 to 100% acetonitrile in water without acid in 40 min was followed by 100% acetonitrile for 5 min and 10% acetonitrile in water for 5 min. The flow rate was 0.5 mL/min. The absorption at 280 nm was used for quantification.

 Table 1
 Information on CDPSs identified in this study

CDPS	Accession number	Protein length (aa)	Primer sequences (5'-3')	Cloning constructs in pGEM-T easy	Cloning sites in pET28a	Expression constructs
CWWS1 <sub>D46488</sub>	WP_014141671	278	AACATATGCACGACAACGGTCATCGGCCC TTGGATCCTTACGTCACCGGCT	pHY02	NdeI BamHI	pHY34
CWWS2 <sub>D46488</sub>	WP_014140974	234	GC <u>CATATG</u> CTGCATCGAACGTCCTT TAGGATCCTCACGGCTCGGCGGGCAGTT	pHY01	NdeI BamHI	pHY11
CWWS1 <sub>NB2774</sub>	WP_078950527	265	CATATGACGATCACAGCTGACGCATCATTC GGATCCTCAAGCTGCTCGACGCTCAT	pHY72	NdeI BamHI	pHY82
CWWS1 <sub>NB5737</sub>	WP_019889609	239	GCCATATGACTCTCATCGAAGACAC GGATCCTCAAGCGGCTCGACGGTCAT	pHY08	NdeI BamHI	pHY09
CWWS1 <sub>NB5414</sub>	WP_063768158	273	CATATGAGGGCGATCACACAGGTGAC GGATCCTCAAGCTGCTCGACGCTCAT	pHY77	NdeI BamHI	pHY83
CWPS1 <sub>NS1868</sub>	WP_078873129	241	CATATGAACACTTCCCTCGCTGC GAATTCTCAGCGTTCGGCCGCCCGGTC	pHY103	NdeI EcoRI	pHY107
CWLS1 <sub>NF5053</sub>	WP_051847149	243	CATATG CATATG TGCGAGGGGCGCCGATGTGC GGATCCTCAGGATTCGTCCACCGG	pJL03	NdeI BamHI	pJL26 <sup>a</sup>
CWPS1 <sub>NF5123</sub>	WP_052397358	263	CATATGACCAGCAGGACCGAAAC GAATTCTCACGGAAGCAGCCGGGGG	pHY100	NdeI EcoRI	pHY105
CWXS1 <sub>NS1868</sub>	WP_078872750	267	CATATGGCCACACACGCCTCCGC GAATTCTCACTGCTGCGTCACGTGGTC	pHY101	NdeI EcoRI	pHY106
CWXS1 <sub>NB3589</sub>	KOG90878	255	CATATG GGGGGGCCCCGCAGCCC GGATCCTCACGTCAAGTCCCTTTCTCC	pJL02	NdeI BamHI	pJL25
CWXS1 <sub>NB24309</sub>	WP_078624487	282	GCGCATATGAGTGCATCGCAGGCTGCTG GGATCCTCACGTCACG	pJL01	NdeI BamHI	pJL24 <sup>b</sup>
CPYS1 <sub>NF5639</sub>	WP_031028810	278	CATATGAACCGCCGCTGTTCCTTCG GGATCCTCATGCTCCTGGGGCACTG	pJL04	NdeI BamHI	pJL29
CPYS1 <sub>D41684</sub>	BAU83478	224	CGCATATGAACCAGTTCGACGTGCTGCC GGATCCCCGGACCACGAGGAAGCC	pJL05	NdeI BamHI	pJL30 <sup>c</sup>

Restriction sites for cloning are underlined in primer sequences

<sup>a</sup> The 12 base pairs at the 5'-end of the sequence coding for WP\_051847149 were not included in the expression construct pJL26

<sup>b</sup> The 96 base pairs at the 5'-end of the sequence coding for WP\_078624487 were not included in the expression construct pJL24

<sup>c</sup> According to the annotation in database, BAU83478 comprises 484 amino acids and consists of CDPS sequence at its N-terminus and that for a putative methyltransferase at its C-terminus. The sequence coding for amino acids 1-224 of BAU83478 was cloned into pET28a generating pJL30

#### Isolation and structural elucidation of generated cyclodipeptides


For structural elucidation of the accumulated CDPs, E. coli SoluBL21 cultures carrying the respective expression constructs were prepared under the best tested conditions (Table S2) and extracted with ethyl acetate. The CDPs were then isolated on an Agilent HPLC 1260 series equipped with a photo diode array detector by using a semi-preparative Multospher 120 RP-18 column ( $10 \times 250$  mm, 5 µm) with the same solvents and gradient as for quantification. The flow rate was set to 2.5 mL/min. The obtained products were purified on the same column with slightly improved gradients, if necessary. In this study, 5, 3, and 4 mg of cWW were isolated as white powders from 300 mL E. coli cultures with pHY34, pHY11, and pHY09, respectively. Thirty milligrams of cWP and 12 mg of cWL were isolated as white powders from 1000 mL E. coli/pHY107 and E. coli/pJL26, respectively. From 2000 mL E. coli culture with pJL25, 1.5 mg of cWA, 10 mg of cyclo-L-Trp-L-Tyr (cWY), 5 mg of cWM, 2.5 mg of cyclo-L-Trp-L-Val (cWV), and 2.5 mg of cWF were obtained as white powders.

The isolated compounds were subjected to NMR and MS analyses. <sup>1</sup>H NMR spectra (Figs. S2–S9) were recorded at room temperature on an ECX-500 spectrometer (JEOL, Tokyo, Japan). All spectra were processed with MestReNova 5.2.2 (Metrelab Research, S5 Santiago de Compostella, Spain). MS and NMR data of the cyclodipeptides are provided as Tables S3 and S4. Interpretation of the NMR and MS data of the isolated products and comparison with those of known compounds led to the undoubted identification of the cyclodipeptides.

#### Results

#### **Phylogenetic analysis of CDPSs**

Phylogenetic analysis of known CDPSs from actinomycetes (Fig. S1) revealed that the known cWW synthases are located close together, with the exception for WP\_016576960 from *Streptomyces albulus*. CDPSs for DKPs consisting of aliphatic amino acids like *cyclo*-L-Cys-L-Cys (cCC) and *cyclo*-L-Glu-L-Ala (cEA) and those **Fig. 2** LC-MS analysis of recombinant *E. coli* strains with empty vector (**a**) or with CDPSs (**b–l**). The ethyl acetate extracts were analyzed on an Agilent HPLC series 1260 with UV and mass detections. Absorptions at 280 nm are illustrated in this figure. The products are predicted by inspection of their exact [M + H]<sup>+</sup> ions and proven by NMR analysis after isolation



comprising aromatic amino acids such as *cyclo*-L-Tyr-L-Tyr (cYY) and *cyclo*-L-Tyr-L-X (cYX) build their own groups. To get CDPSs for other tryptophan-containing DKPs rather than cWW, we searched in databases for homologs of the actinobacterial cWW synthases and integrated them into Fig. S1 generating Fig. 1. Thirteen candidate CDPSs close to cWW and cYY synthases from 11 *Streptomyces* strains (highlighted in red in Fig. 1) were selected as investigation objectives.

# Overproduction of CDPSs in *E. coli* and identification of the products

For functional proof, we established our expression system in *E. coli* SoluBL21 by using the two known CDPSs WP\_014141671 and WP\_014140974 from *Streptomyces cattleya* DSM 46488, termed CWWS1<sub>D46488</sub> (cWW synthase

1 from strain DSM 46488) and CWWS2<sub>D46488</sub> in this study, respectively (Fig. 1). After optimization of expression conditions (Table S2), the 20-h-old cultures after induction at 30 °C with 0.5 mM IPTG for CWWS1<sub>D46488</sub> and 0.2 mM for CWWS2<sub>D46488</sub> were extracted with ethyl acetate and then analyzed on LC-MS. In comparison to the culture of *E. coli* harboring the empty vector (Fig. 2a), one additional predominant peak each with the expected  $[M + H]^+$  ion at m/z 373.1636 for cWW was detected in *E. coli* transformants (Fig. 2b, c). Isolation and structure elucidation of both peaks with the help of NMR confirmed their integrity as cWW (Tables S3 and S4, Fig. S2).

In analogy, the other nine candidate genes were individually cloned into pET28a (+) (Table 1) and expressed in *E. coli* SoluBL21 under different optimized conditions (Table S2). The ethyl acetate extracts of the 20-h cultures were analyzed on LC-MS. In comparison to that of negative control (Fig. 2a),






Fig. 3 Formation of tryptophan-containing cyclodipeptides by CDPSs

the chromatograms of five CDPS transformants showed one predominant product peak each (Fig. 2d–h). These include WP\_078950527 from *Streptomyces lavendulae* NRRL B-2774 (Fig. 2d), WP\_019889609 from *Streptomyces purpureus* NRRL B-5737 (Fig. 2e), WP\_063768158 from *Streptomyces xanthophaeus* NRRL B-5414 (Fig. 2f), WP\_078873129 from *Streptomyces* sp. NRRL S-1868 (Fig. 2g), and WP\_051847149 from *Streptomyces* sp. NRRL F-5053 (Fig. 2h). The products of the first three transformants (Fig. 2d–f) share the same retention time and  $[M + H]^+$  ion with those of the two known CWWS1<sub>D46488</sub> and CWWS2<sub>D46488</sub> (Fig. 2b, c), indicating the presence of cWW. Interpretation of the NMR and MS data of the isolated peak from the culture with pHY09 (Tables S3 and S4, Fig. S2) confirmed these products to be cWW (Giessen et al. 2013; Lu et al. 2017). Therefore, these three enzymes were termed CWWS1<sub>NB2774</sub>, CWWS1<sub>NB5737</sub>, and CWWS1<sub>NB5414</sub>, respectively (Fig. 3).

For structure elucidation, the products of WP\_078873129 (Fig. 2g) and WP\_051847149 (Fig. 2h) were isolated from the bacterial cultures and subjected to NMR and MS analyses (Tables S3 and S4; Figs. S3 and S4), which proved unequivocally cWP (Grundmann and Li 2005; He et al. 2013; Kumar et al. 2014) as the sole product of WP\_078873129, termed hereafter CWPS1<sub>NS1868</sub> (Fig. 3). The two products of WP\_051847149 with a ratio of 120:1 were identified as cWL (Kumar et al. 2014) and cWF (Chu et al. 2011),



**Fig. 4** Product yields of CDPSs. The data were obtained from three independent 36-h old cultures



respectively. Due to the significant dominance of cWL, this enzyme was named as  $CWLS1_{NF5053}$  (Fig. 3).

Two product peaks each were detected in the transformants with WP\_052397358 from *Streptomyces* sp. NRRL F-5123 (Fig. 2i) and another CDPS WP\_078872750 from *Streptomyces* sp. NRRL S-1868 (Fig. 2j). One of them was found in both extracts and identified as cWP by comparison of its retention time and  $[M + H]^+$  ion with those of CWPS1<sub>NS1868</sub> product (Fig. 2g). cWP in the transformant with WP\_052397358 contributes about 94% to the total CDPs, and this enzyme was therefore termed CWPS1<sub>NF5123</sub>. The minor product of CWPS1<sub>NF5123</sub> showed a  $[M + H]^+$  of cWL. Another main product in *E. coli* with pHY106 (Fig. 2j) had a  $[M + H]^+$  of cWA, which was identified by comparison with the product from KOG90878 of *Streptomyces varsoviensis* NRRL B-3589 (Fig. 2k). WP\_078872750 was therefore termed CWXS1<sub>NS1868</sub>.

The transformant with KOG90878 had a similar and complex product spectrum as WP\_078624487 from *Streptomyces monomycini* NRRL B-24309 (Fig. 21). Two predominant and at least four minor peaks were detected for both cultures at 280 nm. They differ slightly from each other in the product yields and ratios, especially those of the two dominant peaks. Product isolation from the culture with KOG90878 and structural elucidation proved the main peak at 15.4 min to be cWY and the second major peak as a mixture of cWF and cWW. The four minor peaks were identified as cWA, cWV, and cWL, respectively (Tables S3 and S4; Figs. S5–S9).

KOG90878 and WP\_078624487 are therefore responsible for the formation of at least seven tryptophancontaining cyclodipeptides and termed CWXS1<sub>NB3589</sub> and CWXS1<sub>NB24309</sub>, respectively (Fig. 3).

#### **Product yields of CDPs**

Generally, high product yield is a prerequisite for potential application in the biotechnology. The product yields of cWW from E. coli culture at 29 and 42 mg/L were reported for the known cWW synthases Amir 4627 and NozA after codon optimization, respectively (Giessen et al. 2013; James et al. 2015). To prove the productivity of the recombinant strains, we determined the CDP contents of 36-h-old cultures by HPLC analysis using the isolated products as standards. As shown in Fig. 4, the product yields achieved in this study for several enzymes are much higher than those mentioned above. The product vields of the five cWW synthases were detected between  $46 \pm 10$  and  $104 \pm 10$  mg/L with the best one for CWWS1<sub>NB2774</sub>. The highest product yield of  $211 \pm$ 12 mg cWP per liter culture was observed for the culture with CWPS1<sub>NS1868</sub>, followed by  $120 \pm 5$  mg cWL in the culture with CWLS1<sub>NF5053</sub>. Total product yields between 100 and 140 mg/L were calculated for other four CDPSs. These data provide a solid basis for further combination of these CDPS genes with other modification genes in synthetic biology.

			eids ee ocket		ıting						ls cons ket P2		g			Reported product	Predicted product*	Identified in this study
AlbC Amir_4627					L <sub>119</sub> M <sub>119</sub>											cFL, cFF, cFY cWW (Giessen et al. 2013)		
NozA	L <sub>32</sub>	G <sub>34</sub>	V <sub>64</sub>	A <sub>66</sub>	L <sub>118</sub>	F <sub>183</sub>	F <sub>184</sub>	S <sub>198</sub>	M <sub>151</sub>	A <sub>154</sub>	V <sub>155</sub>	S <sub>158</sub>	M <sub>202</sub>	L <sub>204</sub>	P <sub>205</sub>	cWW (James et al. 2015)		
NcdA	V <sub>36</sub>	G <sub>38</sub>	V <sub>58</sub>	P <sub>60</sub>	M <sub>112</sub>	F <sub>177</sub>	F <sub>178</sub>	N <sub>192</sub>	M <sub>145</sub>	D <sub>148</sub>	V <sub>149</sub>	A <sub>152</sub>	R <sub>196</sub>	L <sub>198</sub>	P <sub>199</sub>	cWW (James et al. 2015)		
WP_016576960	L <sub>53</sub>	G55	I <sub>85</sub>	P <sub>87</sub>	L <sub>139</sub>	L <sub>204</sub>	C <sub>205</sub>	H <sub>219</sub>	A <sub>17</sub>	K <sub>175</sub>	A <sub>176</sub>	S <sub>179</sub>	Q <sub>223</sub>	I <sub>225</sub>	P <sub>226</sub>	cWW (Jacques et al. 2015)		
WP_009073312	V <sub>26</sub>	G <sub>28</sub>	I <sub>58</sub>	P <sub>60</sub>	M <sub>112</sub>	F <sub>177</sub>	F <sub>178</sub>	N <sub>192</sub>	M <sub>145</sub>	E <sub>148</sub>	V <sub>149</sub>	A <sub>152</sub>	Q <sub>196</sub>	L <sub>198</sub>	P <sub>197</sub>	cWW (Jacques et al. 2015)		
EPD89497	V <sub>29</sub>	G <sub>31</sub>	I <sub>61</sub>	P <sub>63</sub>	M <sub>115</sub>	F <sub>180</sub>	F <sub>181</sub>	C <sub>195</sub>	A <sub>148</sub>	T <sub>151</sub>	V <sub>152</sub>	A <sub>155</sub>	R <sub>199</sub>	L <sub>201</sub>	P <sub>198</sub>	cWW (Jacques et al. 2015)		
WP_027751606	V <sub>25</sub>	G <sub>27</sub>	I <sub>57</sub>	P <sub>59</sub>	M <sub>111</sub>	F <sub>176</sub>	F <sub>177</sub>	N <sub>191</sub>	M <sub>144</sub>	D <sub>147</sub>	V <sub>148</sub>	A <sub>151</sub>	Q <sub>195</sub>	L <sub>197</sub>	P <sub>208</sub>	cWW (Jacques et al. 2015)		
WP_017537615	V <sub>35</sub>	G <sub>37</sub>	I <sub>67</sub>	P <sub>69</sub>	M <sub>121</sub>	F <sub>186</sub>	F <sub>187</sub>	N <sub>201</sub>	M <sub>154</sub>	E <sub>157</sub>	V <sub>159</sub>	A <sub>171</sub>	R <sub>205</sub>	L <sub>207</sub>	P <sub>197</sub>	cWW (Jacques et al. 2015)		
CWWS1 <sub>D46488</sub>	V <sub>77</sub>	G <sub>79</sub>	V <sub>109</sub>	P <sub>111</sub>	L <sub>164</sub>	F <sub>229</sub>	F <sub>230</sub>	C <sub>242</sub>	M <sub>197</sub>	A <sub>200</sub>	A <sub>201</sub>	S <sub>204</sub>	K <sub>246</sub>	V <sub>248</sub>	P <sub>249</sub>	cWW (Jacques et al. 2015)		cWW
CWWS2 <sub>D46488</sub>	V <sub>27</sub>	G <sub>29</sub>	V59	P <sub>61</sub>	M <sub>113</sub>	F <sub>178</sub>	F <sub>179</sub>	C <sub>193</sub>	M <sub>146</sub>	E149	A <sub>150</sub>	A <sub>153</sub>	R <sub>197</sub>	I <sub>199</sub>	P <sub>200</sub>	cWW (Jacques et al. 2015)		cWW
CWWS1 <sub>NB2774</sub>	L <sub>29</sub>	G <sub>31</sub>	V <sub>61</sub>	A <sub>63</sub>	L <sub>115</sub>	F <sub>181</sub>	F <sub>182</sub>	A <sub>196</sub>	M <sub>148</sub>	H <sub>151</sub>	F <sub>152</sub>	S <sub>155</sub>	V <sub>200</sub>	M <sub>202</sub>	P <sub>203</sub>		cFX	cWW
CWWS1 <sub>NB5737</sub>	L <sub>28</sub>	G <sub>30</sub>	$V_{60}$	$A_{62}$	L <sub>114</sub>	$F_{180}$	$F_{181}$	$S_{195}$	$M_{147}$	$T_{150}$	F <sub>151</sub>	P <sub>154</sub>	Q199	I <sub>201</sub>	P <sub>202</sub>		cFX	cWW
CWWS1 <sub>NB5414</sub>	L35	G <sub>37</sub>	$V_{67}$	A <sub>69</sub>	L <sub>121</sub>	$F_{187}$	$F_{188}$	A <sub>200</sub>	$M_{154}$	${ m H}_{157}$	$F_{158}$	$S_{161}$	$V_{204}$	$M_{206}$	P <sub>207</sub>		cFX	cWW
CWPS1 <sub>NS1868</sub>	L32	$G_{34}$	I <sub>64</sub>												P <sub>211</sub>		cFX	cWP
CWLS1 <sub>NF5053</sub>	L36		V <sub>68</sub>		L <sub>122</sub>									A <sub>209</sub>	Q <sub>210</sub>		cFX	cWL
CWPS1 <sub>NF5123</sub>	L <sub>42</sub>		V <sub>74</sub>		L <sub>128</sub>									I <sub>214</sub>	D <sub>215</sub>		cFX	cWP
CWXS1 <sub>NS1868</sub>	L <sub>43</sub>	G <sub>45</sub>			L <sub>129</sub>										G <sub>227</sub>		cFX	cWA, cWP
CWXS1 <sub>NB3589</sub>	L <sub>30</sub>	G <sub>32</sub>			L <sub>116</sub>												cFX	cWY, cWF, cWW
CWXS1 <sub>NB24309</sub>	-	-	I <sub>30</sub>	A <sub>32</sub>	L <sub>84</sub>	F <sub>177</sub>	F <sub>178</sub>	S <sub>192</sub>	M <sub>117</sub>	I <sub>120</sub>	H <sub>121</sub>	G <sub>124</sub>	L <sub>196</sub>	T <sub>198</sub>	P <sub>199</sub>		cFX	cWY, cWF, cWW

Table 2 Amino acid residues of selected CDPSs constituting the two binding pockets

\*The products of the CDPSs of interest were predicted in a previous report (in bold) (Jacques et al. 2015) and in this study (in italic) according to the conserved residues suggested by Jacques et al. (Jacques et al. 2015)

#### Discussion

To find candidates for the formation of tryptophan-containing CDPs, we searched the database by using known cWW synthases as probes and carried out phylogenetic analysis. Gene expression and identification of CDP products led to identification of nine new members for the biosynthesis of tryptophan-containing CDPs. Inspection the phylogenetic tree (Fig. 1) revealed that the tryptophan-containing cyclodipeptide synthases from actinobacteria are located in two clades. With the exception for cyclo-L-Leu-L-Leu (cLL), the clade I comprises only cWX synthases, while the members of clade II are responsible for the formation of not only cWX, but also cYX and cFX. To prove the diversity of cWX clade II, we took two genes close to cYX synthases from this clade and expressed them in E. coli. As shown in Fig. S10, WP 031028810 from Streptomyces sp. NRRL F-5639 and BAU83478 from Streptomyces laurentii DSM 41684 were proven to be responsible for the formation of *cyclo*-L-Pro-L-Tyr (cPY). Together with the CDPSs for tryptophancontaining cyclodipeptide biosynthesis (Figs. 2, 3, and 4), these results provide evidence that phylogenetic analysis could be successfully used for prediction and finding of desired CDPS candidates. However, exact CDPS product cannot be predicted by just phylogenetic analysis. For example, the 13 specific cWW synthases are distributed in two cWX clades. One of the cWP synthases, CWPS1<sub>N51868</sub>, which is again closer to CWXS1<sub>NS1868</sub>. CWPS1<sub>NS1868</sub> and CWXS1<sub>NS1868</sub> share a sequence identity of 62% on the amino acid level, and the latter produces a mixture of cWP and cWA with a ratio of 15:7 (Figs. 2 and 4).

Based on crystal structure and mutagenesis experiments, Moutiez et al. proposed that two pockets of CDPSs are for aminoacyl-tRNA binding (Jacques et al. 2015; Moutiez et al. 2014a; Moutiez et al. 2014b). It was postulated that P1 is more specific for binding the first aminoacvl-tRNA, and the wider pocket P2 is responsible for the less specific binding of the second and often variable aminoacyl-tRNA (Moutiez et al. 2014a; Moutiez et al. 2014b). The amino acid residues of the two pockets were used for prediction of CDPS products (Jacques et al. 2015). With the help of the residues in the two pockets, the functions of the nine tryptophan-containing CDPSs identified in this study were predicted to be responsible for the formation of cFX (Table 2) (Jacques et al. 2015). However, as shown in Figs. 2, 3, and 4, only CWLS1<sub>NF5053</sub>, CWXS1<sub>NB3589</sub>, and CWXS1<sub>NB24309</sub> produce cWF as minor or second major product, with 1, 11, and 22% of total CDPs, respectively. No cFX was detected in other CDPS transformants. Comparing the amino acid residues in pockets 1 and 2 of tryptophancontaining cyclodipeptide synthases with each other and with those of cyclo-L-Phe-L-Leu (cFL) synthase AlbC (Table 2) revealed no clear indications for cWX synthases. In a previous study, we demonstrated that mutation of the related residues in the pocket P1 did not lead to the desired changes of product spectrum, but their product yields (Brockmeyer and Li 2017). This indicates that these prediction tools still need to be optimized by identification of more CDPS structures and amino acid residues in the binding pockets.

In summary, after confirmation of two known cWW synthases, we identified three new cWW, one cWL, and two cWP synthases from *Streptomyces*, which catalyze the formation of one predominant DKP. Three additional CDPSs produce one DKP like cWA or cWY as the major metabolite (Figs. 2 and 4). These CDPSs are thus ideal candidates for production of tryptophan-containing CDPs for further modification by tailoring enzymes like PTs. It should be also mentioned that cWV was not reported as CDPS product prior to this study. Therefore, our results expand significantly the product spectrum of tryptophan-containing cyclodipeptide synthases and raise hopes to find other members of this important enzyme group.

**Acknowledgements** We thank ARS Culture Collection (NRRL) for providing *Streptomyces* strains, S. Newel, and R. Kraut (University Marburg) for taking NMR and MS spectra.

**Funding information** The Bruker micrOTOF QIII mass spectrometer was financially supported in part by a grant from the Deutsche Forschungsgemeinschaft (INST 160/620-1 to S.-M. L.). J.L. and H.Y are scholarship recipients of China Scholarship Council (201608310118 and 201306220024).

#### **Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Human and animal rights** This article does not contain any studies with human participants or animals performed by any of the authors.

#### References

- Alkhalaf LM, Ryan KS (2015) Biosynthetic manipulation of tryptophan in bacteria: pathways and mechanisms. Chem Biol 22:317–328
- Borthwick AD (2012) 2,5-diketopiperazines: synthesis, reactions, medicinal chemistry, and bioactive natural products. Chem Rev 112:3641– 3716
- Brockmeyer K, Li S-M (2017) Mutations of residues in pocket P1 of a cyclodipeptide synthase strongly increase product formation. J Nat Prod 80:2917–2922
- Chu D, Peng C, Ding B, Liu F, Zhang F, Lin H, Li Z (2011) Biological active metabolite cyclo (L-Trp-L-Phe) produced by South China Sea sponge *Holoxea* sp. associated fungus *Aspergillus versicolor* strain TS08. Bioprocess Biosyst Eng 34:223–229
- Fan A, Winkelblech J, Li S-M (2015) Impacts and perspectives of prenyltransferases of the DMATS superfamily for use in biotechnology. Appl Microbiol Biotechnol 99:7399–7415
- Giessen TW, Marahiel MA (2014) The tRNA-dependent biosynthesis of modified cyclic dipeptides. Int J Mol Sci 15:14610–14631
- Giessen TW, von Tesmar AM, Marahiel MA (2013) A tRNA-dependent two-enzyme pathway for the generation of singly and doubly methylated ditryptophan 2,5-diketopiperazines. Biochemistry 52:4274– 4283
- Gondry M, Sauguet L, Belin P, Thai R, Amouroux R, Tellier C, Tuphile K, Jacquet M, Braud S, Courcon M, Masson C, Dubois S, Lautru S, Lecoq A, Hashimoto S, Genet R, Pernodet JL (2009) Cyclodipeptide synthases are a family of tRNA-dependent peptide bond-forming enzymes. Nat Chem Biol 5:414–420
- Grundmann A, Li S-M (2005) Overproduction, purification and characterization of FtmPT1, a brevianamide F prenyltransferase from *Aspergillus fumigatus*. Microbiology 151:2199–2207
- He F, Bao J, Zhang XY, Tu ZC, Shi YM, Qi SH (2013) Asperterrestide A, a cytotoxic cyclic tetrapeptide from the marine-derived fungus Aspergillus terreus SCSGAF0162. J Nat Prod 76:1182–1186
- Huang R, Zhou X, Xu T, Yang X, Liu Y (2010) Diketopiperazines from marine organisms. Chem Biodivers 7:2809–2829
- Jacques IB, Moutiez M, Witwinowski J, Darbon E, Martel C, Seguin J, Favry E, Thai R, Lecoq A, Dubois S, Pernodet JL, Gondry M, Belin P (2015) Analysis of 51 cyclodipeptide synthases reveals the basis for substrate specificity. Nat Chem Biol 11:721–727
- James ED, Knuckley B, Alqahtani N, Porwal S, Ban J, Karty JA, Viswanathan R, Lane AL (2015) Two distinct cyclodipeptide synthases from a marine actinomycete catalyze biosynthesis of the same diketopiperazine natural product. ACS Synth Biol 5:547–553
- Kieser T, Bibb MJ, Buttner MJ, Chater KF, Hopwood DA (2000) Practical Streptomyces genetics. John Innes Foundation, Norwich
- Kumar SN, Mohandas C, Nambisan B (2014) Purification, structural elucidation and bioactivity of tryptophan containing diketopiperazines, from *Comamonas testosteroni* associated with a rhabditid entomopathogenic nematode against major humanpathogenic bacteria. Peptides 53:48–58
- Li S-M (2010) Prenylated indole derivatives from fungi: structure diversity, biological activities, biosynthesis and chemoenzymatic synthesis. Nat Prod Rep 27:57–78
- Lu C, Xie F, Shan C, Shen Y (2017) Two novel cyclic hexapeptides from the genetically engineered Actinosynnema pretiosum. Appl Microbiol Biotechnol 101:2273–2279
- Maiya S, Grundmann A, Li S-M, Turner G (2006) The fumitremorgin gene cluster of *Aspergillus fumigatus*: identification of a gene encoding brevianamide F synthetase. Chembiochem 7:1062–1069
- Moutiez M, Belin P, Gondry M (2017) Aminoacyl-tRNA-utilizing enzymes in natural product biosynthesis. Chem Rev 117:5578–5618

- Moutiez M, Schmitt E, Seguin J, Thai R, Favry E, Belin P, Mechulam Y, Gondry M (2014a) Unravelling the mechanism of non-ribosomal peptide synthesis by cyclodipeptide synthases. Nat Commun 5:5141
- Moutiez M, Seguin J, Fonvielle M, Belin P, Jacques IB, Favry E, Arthur M, Gondry M (2014b) Specificity determinants for the two tRNA substrates of the cyclodipeptide synthase AlbC from *Streptomyces noursei*. Nucleic Acids Res 42:7247–7258
- Sambrook J, Russell DW (2001) Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York
- Seguin J, Moutiez M, Li Y, Belin P, Lecoq A, Fonvielle M, Charbonnier JB, Pernodet JL, Gondry M (2011) Nonribosomal peptide synthesis in animals: the cyclodipeptide synthase of *Nematostella*. Chem Biol 18:1362–1368
- Walsh CT (2014) Biological matching of chemical reactivity: pairing indole nucleophilicity with electrophilic isoprenoids. ACS Chem Biol 9:2718–2728
- Walsh CT (2016) Insights into the chemical logic and enzymatic machinery of NRPS assembly lines. Nat Prod Rep 33:127–135
- Winkelblech J, Fan A, Li S-M (2015) Prenyltransferases as key enzymes in primary and secondary metabolism. Appl Microbiol Biotechnol 99:7379–7397
- Wohlgemuth V, Kindinger F, Xie X, Wang BG, Li S-M (2017) Two prenyltransferases govern a consecutive prenylation cascade in the biosynthesis of echinulin and neoechinulin. Org Lett 19:5928–5931
- Xu W, Gavia DJ, Tang Y (2014) Biosynthesis of fungal indole alkaloids. Nat Prod Rep 31:1474–1487

CORRECTION



# Correction to: Expanding tryptophan-containing cyclodipeptide synthase spectrum by identification of nine members from *Streptomyces* strains

Jing Liu<sup>1</sup> • Huili Yu<sup>1</sup> • Shu-Ming Li<sup>1</sup>

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Correction to: Applied Microbiology and Biotechnology https://doi.org/10.1007/s00253-018-8908-6

The original version of this article contained mistake. After careful re-examination of the LC-MS data, the products of CDPSs "WP\_031028810" and "BAU83478" should be cFL instead of cPY. We apologize for any inconvenience that this may have caused.

Correct presentations given below:

The sixth sentence of the first paragraph in the **Discussion** Section:

"As shown in Fig. S10, WP\_031028810 from *Streptomyces* sp. NRRL F-5639 and BAU83478 from *Streptomyces laurentii* DSM 41684 were proven to be responsible for the formation of *cyclo*-L-Pro-L-Tyr (cPY)."

should be changed to

"As shown in Fig. S10, WP\_031028810 from *Streptomyces* sp. NRRL F-5639 and BAU83478 from *Streptomyces laurentii* DSM 41684 were proven to be responsible for the formation of *cyclo*-L-Phe-L-Leu (cFL)."

Jing Liu and Huili Yu contributed equally to this work.

The online version of the original article can be found at https://doi.org/ 10.1007/s00253-018-8908-6

Shu-Ming Li shuming.li@staff.uni-marburg.de

<sup>&</sup>lt;sup>1</sup> Institut für Pharmazeutische Biologie und Biotechnologie, Philipps-Universität Marburg, Robert-Koch-Straße 4, 35037 Marburg, Germany




Fig. 1 Phylogenetic analysis of CDPSs from actinobacteria. The main CDPS products are given in parenthesis. Enzymes investigated in this study are highlighted in red

#### Table 1 Information on CDPSs identified in this study

CDPS	Accession number	Protein length (aa)	Primer sequences (5'-3')	Cloning constructs in pGEM-T easy	Cloning sites in pET28a	Expression constructs
CWWS1 <sub>D46488</sub>	WP_014141671	278	AACATATGCACGACAACGGTCATCGGCCC TTGGATCCTTACGTCACCGGCT	pHY02	NdeI BamHI	pHY34
CWWS2 <sub>D46488</sub>	WP_014140974	234	GC <u>CATATG</u> CTGCATCGAACGTCCTT TAGGATCCTCACGGCTCGGCGGGCAGTT	pHY01	NdeI BamHI	pHY11
CWWS1 <sub>NB2774</sub>	WP_078950527	265	CATATGACGATCACAGCTGACGCATCATTC GGATCCTCAAGCTGCTCGACGCTCAT	pHY72	NdeI BamHI	pHY82
CWWS1 <sub>NB5737</sub>	WP_019889609	239	GCCATATGACTCTCATCGAAGACAC GGATCCTCAAGCGGCTCGACGGTCAT	pHY08	NdeI BamHI	pHY09
CWWS1 <sub>NB5414</sub>	WP_063768158	273	CATATGAGGGCGATCACACAGGTGAC GGATCCTCAAGCTGCTCGACGCTCAT	pHY77	NdeI BamHI	pHY83
CWPS1 <sub>NS1868</sub>	WP_078873129	241	CATATGAACACTTCCCTCGCTGC GAATTCTCAGCGTTCGGCCGCCCGGTC	pHY103	NdeI EcoRI	pHY107
CWLS1 <sub>NF5053</sub>	WP_051847149	243	CATATG TGCGAGGGGCGCCGATGTGC GGATCCTCAGGATTCGTCCACCGG	pJL03	NdeI BamHI	pJL26 <sup>a</sup>
CWPS1 <sub>NF5123</sub>	WP_052397358	263	CATATG GAATTCTCACGGAAGCAGCCGGAAAC	pHY100	NdeI EcoRI	pHY105
CWXS1 <sub>NS1868</sub>	WP_078872750	267	CATATG GCCACACACGCCTCCGC GAATTCTCACTGCTGCGTCACGTGGTC	pHY101	NdeI EcoRI	pHY106
CWXS1 <sub>NB3589</sub>	KOG90878	255	CATATGGGGGGCCCCGCAGCCC GGATCCTCACGTCAAGTCCCTTTCTCC	pJL02	NdeI BamHI	pJL25
CWXS1 <sub>NB24309</sub>	WP_078624487	282	GCGCATATGAGTGCATCGCAGGCTGCTG GGATCCTCACGTCACG	pJL01	NdeI BamHI	pJL24 <sup>b</sup>
FLS1 <sub>NF5639</sub>	WP_031028810	278	CATATGAACCGCCGCTGTTCCTTCG GGATCCTCATGCTCCTGGGGCACTG	pJL04	NdeI BamHI	pJL29
CFLS1 <sub>D41684</sub>	BAU83478	224	CGCATATGAACCAGTTCGACGTGCTGCC GGATCCCCCGGACCACGAGGAAGCC	pJL05	NdeI BamHI	pJL30 <sup>c</sup>

Restriction sites for cloning are underlined in primer sequences

a The 12 base pairs at the 5'-end of the sequence coding for WP\_051847149 were not included in the expression construct pJL26

b The 96 base pairs at the 5'-end of the sequence coding for WP\_078624487 were not included in the expression construct pJL24

c According to the annotation in database, BAU83478 comprises 484 amino acids and consists of CDPS sequence at its N-terminus and that for a putative methyltransferase at its C-terminus. The sequence coding for amino acids 1 - 224 of BAU83478 was cloned into pET28a generating pJL30

## **Applied Microbiology and Biotechnology**

## **Supplementary Materials**

# Expanding Tryptophan-containing Cyclodipeptide Synthase Spectrum by Identification of Nine Members from *Streptomyces* Strains

Jing Liu<sup>1</sup>, Huili Yu<sup>1</sup>, and Shu-Ming Li<sup>1</sup>

<sup>1</sup> Institut für Pharmazeutische Biologie und Biotechnologie, Philipps-Universität Marburg, Robert-Koch-Straße 4, 35037 Marburg, Germany

\*Corresponding author

Email: <u>shuming.li@staff.uni-marburg.de</u> Tel/Fax:+49 6421 2822461/+49 6421 2825365

## Content

Table S1 Streptomyces strains used in this study	<b>S</b> 3
Table S2 The yields of the main products of the 11 CDPSs under six different	S4
conditions	
Table S3 HR-EI-MS data of the CDPS products	S5
Table S4 <sup>1</sup> H NMR data of the isolated cyclodipeptides	S6-S7
Fig. S1 Phylogenetic tree of known CDPSs from actinobacteria prior to this study	<b>S</b> 8
Fig. S2 <sup>1</sup> H NMR spectrum of cyclo-(L-Trp-L-Trp) in DMSO-d6	S9
Fig. S3 <sup>1</sup> H NMR spectrum of <i>cyclo</i> -(L-Trp-L-Pro) in CDCl <sub>3</sub>	<b>S</b> 10
Fig. S4 <sup>1</sup> H NMR spectrum of <i>cyclo</i> -(L-Trp-L-Leu) in CDCl <sub>3</sub>	<b>S</b> 11
Fig. S5 <sup>1</sup> H NMR spectrum of cyclo-(L-Trp-L-Tyr) in DMSO-d6	S12
Fig. S6 <sup>1</sup> H NMR spectrum of cyclo-(L-Trp-L-Phe) in DMSO-d6	<b>S</b> 13
Fig. S7 <sup>1</sup> H NMR spectrum of <i>cyclo</i> -(L-Trp-L-Ala) in CD <sub>3</sub> OD	S14
Fig. S8 <sup>1</sup> H NMR spectrum of <i>cyclo</i> -(L-Trp-L-Met) in CD <sub>3</sub> OD	S15
Fig. S9 <sup>1</sup> H NMR spectrum of cyclo-(L-Trp-L-Val) in DMSO-d6	S16
Fig. S10 LC-MS analysis of recombinant E. coli strains with empty vector and	S17
expression constructs for cFL	
References	S18

Table S1	Streptomyces	strains	used ir	this study
	St. ep 10.1. jees			· ······

Strains	Source	Cultivation Media
Streptomyces cattleya DSM 46488	DSMZ	GYM
Streptomyces lavendulae NRRL B-2774	NRRL	GYM
Streptomyces purpureus NRRL B-5737	NRRL	ISP4
Streptomyces xanthophaeus NRRL B-5414	NRRL	ISP4
Streptomyces sp. NRRL S-1868	NRRL	ISP4
Streptomyces sp. NRRL F-5053	NRRL	ISP4
Streptomyces sp. NRRL F-5123	NRRL	GYM
Streptomyces varsoviensis NRRL B-3589	NRRL	GYM
Streptomyces monomycini NRRL B-24309	NRRL	GYM
Streptomyces sp. NRRL F-5639	NRRL	ISP4
Streptomyces laurentii DSM 41684	DSMZ	GYM

DSMZ: Deutsche Sammlung von Mikroorganismen und Zellkulturen

NRRL: ARS Culture Collection

CDPSs Temperature -IPTG final conc.	CWWS1 <sub>D46488</sub> (cWW)	CWWS2 <sub>D40</sub> (cWW)		S1 <sub>NB2774</sub> (W)	CWWS1 <sub>NB5737</sub> (cWW)	CWWS1 <sub>NB5414</sub> (cWW)
20 °C - 0.2 mM	77.0	33.7		0.2	18.8	55.1
20 °C - 0.5 mM	88.8	33.7	85	5.8	24.4	48.8
30 °C - 0.2 mM	88.2	59.1			41.2	34.3
30 °C - 0.5 mM	95.5	51.8	98	3.6	63.7	34.5
37 °C - 0.2 mM	81.9	19.5	82	2.6	9.0	3.4
37 °C - 0.5 mM	89.7	28.5	65	5.0	11.3	-
CDPSs	CWPS1 <sub>NS1868</sub>	CWPS1 <sub>NF5123</sub>	CWXS1 <sub>NS1868</sub>	CWLS1 <sub>NF5053</sub>	CWXS1 <sub>NB3589</sub>	CWXS1 <sub>NB24309</sub>
Temperature -IPTG final conc.	(cWP)	(cWP)	(cWA)	(cWL)	(cWY)	(cWY)
20 °C - 0.2 mM	144.9	69.2	69.3	93.9	141.4	51.7
20 °C - 0.5 mM	173.8	85.8	75.5	96.4	111.8	64.7
30 °C - 0.2 mM	131.4	95.8	68.1	104.9	25.8	55.8
30 °C - 0.5 mM	198.2	98.6	74.7	104.2	44.9	54.9
37 °C - 0.2 mM	146.3	82.6	14.7	104.9	94.6	15.5
37 °C - 0.5 mM	128.4	65.0	12.1	84.7	106.1	13.4

**Table S2** The yields (mg/L culture) of the main products of the 11 CDPSs under six different conditions

	Chemical	[M+H		
Compound	Formula	Calculated	Measured	Deviation (ppm)
cWA	$C_{14}H_{15}N_{3}O_{2}$	258.1237	258.1224	5.0
cWY	$C_{20}H_{19}N_{3}O_{3}$	350.1499	350.1495	1.1
cWM	$C_{16}H_{19}N_3O_2S$	318.1271	318.1289	-5.7
cWV	C16H19N3O2	286.1550	286.1536	4.9
cWW	$C_{22}H_{20}N_4O_2$	373.1659	373.1636	6.2
cWF	C20H19N3O2	334.1550	334.1545	1.5
cWL	C17H21N3O2	300.1707	300.1709	-0.7
cWP	$C_{16}H_{17}N_3O_2$	284.1394	284.1417	-8.1
cFL	$C_{15}H_{20}N_2O_2$	261.1598	261.1619	-8.0

Table S3 HR-EI-MS data of the CDPS products


	$\begin{array}{c} & 0 \\$	$\begin{array}{c} & & & \\ & & & & \\ & & & \\ & & & \\ & & & & \\ & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & &$	$\begin{array}{c} & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$	$\begin{array}{c} & & & & \\ & & & & \\ & & & & \\ & & & & $
Comp.	cyclo-(L-Trp-L-Trp) (DMSO-d6)	cyclo-(L-Trp-L-Phe) (DMSO-d6)	cyclo-(L-Trp-L-Leu) (CDCl <sub>3</sub> )	cyclo-(L-Trp-L-Pro) (CDCl <sub>3</sub> )
Pos.	$\delta_{\rm H}$ , multi., J [Hz]	δ <sub>H</sub> , multi., <i>J</i> [Hz]	δ <sub>H</sub> , multi., J [Hz]	$\delta_{\rm H}$ , multi., J [Hz]
1	10.81, s	10.90, s	8.15, s	8.55, s
2	6.61, d, 2.3	7.00, d, 2.3	7.11, d, 2.3	7.06, d, 2.1
4	7.35, d, 8.0	7.52, dd, 8.0, 1.1	7.63, dd, 8.0, 1.0	7.58, dd, 8.0, 1.0
5	6.95, ddd, 8.0, 7.0, 1.1	7.02, ddd, 8.0, 7.0, 1.1	7.15, ddd, 8.0, 7.1, 1.0	7.13, ddd, 8.0, 7.0, 1.0
6	7.04, ddd, 8.1, 7.0, 1.1	7.10, ddd, 8.1, 7.0, 1.1	7.23, ddd, 8.2, 7.1, 1.0	7.22, ddd, 8.1, 7.0, 1.1
7	7.28, dt, 8.1, 1.1	7.35, dt, 8.1, 1.1	7.39, dt, 8.2, 1.0	7.38, dt, 8.1, 1.1
10	2.71, dd, 14.3, 4.2	2.84, dd, 14.5, 5.9	3.49, ddd, 14,7, 3.1, 0.7	3.75, ddd, 15.1, 3.8, 1.0
	2.20, dd, 14.3, 6.7	2.57, m	3.21, dd, 14.7, 8.4	2.97, dd, 15.1, 10.7
11	3.87, m	4.00, m	4.32, m	4.37, ddd, 10.7, 3.8, 1.0
12	7.66, d, 2.5	7.90, d, 2.4	5.88, s	5.83, s
14	3.87, m	3.89, m	3.89, m	4.06, bt, 7.4
15	7.66, d, 2.5	7.71, d, 2.5	5.86, s	-
17	2.71, dd, 14.3, 4.2	2.50, m	1.51, m	2.31, m
	2.20, dd, 14.3, 6.7	1.92, dd, 13.6, 7.1	1.48, m	2.01, m
18	-	-	0.98, m	1.96, m
	-	-	-	1.89, m
19	6.61, d, 2.3	6.76, dd, 8.0, 2.0	0.84, d, 6.5	3.65, m
	-	-		3.58, m
20	10.81, s	7.20 <sup>a</sup>	0.81, d, 6.5	-
21	-	7.20 <sup>a</sup>	-	-
22	7.28, dt, 8.1, 1.1	7.20 <sup>a</sup>	-	-
23	7.04, ddd, 8.1, 7.0, 1.1	6.76, dd, 8.0, 2.0	-	-
24	6.95, ddd, 8.0, 7.0, 1.1	-	-	-
25	7.35, d, 8.0	-	-	-

# Table S4 <sup>1</sup>H NMR data of the isolated cyclodipeptides


#### Table S4 (continued)


	$\begin{array}{c} & & & \\ & & & & \\ & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & &$	$\begin{array}{c} \begin{array}{c} & & & \\ & & & & \\ & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & $	$\begin{array}{c} & & & 0 \\ & & & & 10 \\ & & & & 10 \\ & & & & & 10 \\ & & & & & & 10 \\ & & & & & & 10 \\ & & & & & & & 10 \\ & & & & & & & & 10 \\ & & & & & & & & & & 10 \\ & & & & & & & & & & & & & \\ & & & & $	$\begin{array}{c} & & & \\ & & & & \\ & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & &$
Comp.	cyclo-(L-Trp-L-Ala) (CD <sub>3</sub> OD)	cyclo-(L-Trp-L-Tyr) (DMSO-d6)	cyclo-(L-Trp-L-Met) (CD <sub>3</sub> OD)	cyclo-(L-Trp-L-Val) (DMSO-d6)
Pos.	δ <sub>H</sub> , multi., <i>J</i> [Hz]	δ <sub>H</sub> , multi., <i>J</i> [Hz]	δ <sub>H</sub> , multi., <i>J</i> [Hz]	$\delta_{\rm H}$ , multi., <i>J</i> [Hz]
1	-	10.90, d, 1.5	-	10.85, s
2	7.05, s	7.00, d, 1.5	7.04, s	7.11, d, 2.4
4	7.58, dt, 8.0, 1.0	7.51, dd, 7.9, 1.0	7.59, dt, 8.0, 1.0	7.63, d, 7.9
5	6.97, ddd, 8.0, 7.1, 1.0	7.02, ddd, 7.9, 7.0, 1.0	6.96, ddd, 8.0, 7.0, 1.0	6.97, ddd, 7.9, 7.1, 1.0
6	7.05, ddd, 8.1, 7.1, 1.0	7.09, ddd, 8.1, 7.0, 1.0	7.05, ddd, 8.1, 7.0, 1.1	7.05, ddd, 8.1, 7.1, 1.0
7	7.30, dt, 8.1, 1.0	7.34, dt, 8.1, 1.0	7.30, dt, 8.1, 1.1	7.32, d, 8.1
10	3.44, dd, 14.6, 4.1	2.83, dd, 14.5, 4.2	3.47, dd, 14.7, 3.5	3.24, dd, 14.5, 5.0
	3.12, dd, 14.6, 4.5	2.49 <sup>b</sup>	3.09, dd, 14.7, 4.6	3.11, dd, 14.5, 4.5
11	4.25, ddd, 4.5, 4.1, 1.3	3.97, m	4.27, ddd, 4.6, 3.5, 1.4	4.17, m
12	-	7.80, d, 2.5	-	7.96, s
14	3.67, qd, 7.1, 1.2	3.81, m	3.77, ddd, 7.4, 4.7, 1.3	3.52, m
15	-	7.62, d, 2.6	-	7.87, s
17	0.32, d, 7.1	2.45 <sup>b</sup>	1.17, m	1.68, m
	-	1.86, dd, 13.6, 4.5	0.60, m	-
18	-	-	1.63, m	0.64, d, 7.1
19	-	6.61, dt, 8.6, 2.0	-	0.25, d, 6.8
20	-	6.56, dt, 8.6, 2.0	1.73, s	-
22	-	6.56, dt, 8.6, 2.0	-	-
23	-	6.61, dt, 8.6, 2.0	-	-
24	-	9.18, s	-	
<sup>a, b</sup> : Signa	ls with the same letter overlapping with ea	ch other	·	·


The data correspond well to those reported for cWA (Caballero et al. 1998), cWY (Kumar et al. 2014), cWV (He et al. 2013), cWL (Kumar et al. 2014), cWW (Giessen et al. 2013a; Lu et al. 2017), cWF (Kumar et al. 2014), and cWP(Grundmann and Li 2005), respectively.



**Fig. S1** Phylogenetic tree of known CDPSs from actinobacteria prior to this study (Brockmeyer and Li 2017; Giessen et al. 2013a; Giessen et al. 2013b; Jacques et al. 2015; James et al. 2015)











Fig. S5 <sup>1</sup>H NMR spectrum of in *cyclo*-(L-Trp-L-Tyr) in DMSO-d6






Fig. S7 <sup>1</sup>H NMR spectrum of *cyclo*-(L-Trp-L-Ala) in CD<sub>3</sub>OD






Fig. S8 <sup>1</sup>H NMR spectrum of cyclo-(L-Trp-L-Met) in CD<sub>3</sub>OD



**Fig. S9** <sup>1</sup>H NMR spectrum of *cyclo*-(L-Trp-L-Val) in DMSO-d6



**Fig. S10** LC-MS analysis of recombinant *E. coli* strains with empty vector (A and B) and expression constructs (C-F). Black lines are UV absorptions at 258 nm and the red lines refer to extracted positive ion chromatograms (EIC).

# References

- Brockmeyer K, Li S-M (2017) Mutations of residues in pocket P1 of a cyclodipeptide synthase strongly increase product formation. J Nat Prod 80:2917-2922
- Caballero E, Avendaño C, Menéndez JC (1998) Stereochemical issues related to the synthesis and reactivity of pyrazino[2',1'-5,1]pyrrolo[2,3-b]indole-1,4-diones. Tetrahedron: Asymmetry 9:967-981
- Giessen TW, von Tesmar AM, Marahiel MA (2013a) A tRNA-dependent two-enzyme pathway for the generation of singly and doubly methylated ditryptophan 2,5-diketopiperazines. Biochemistry 52:4274-4283
- Giessen TW, von Tesmar AM, Marahiel MA (2013b) Insights into the generation of structural diversity in a tRNA-dependent pathway for highly modified bioactive cyclic dipeptides. Chem Biol 20:828-838
- Grundmann A, Li S-M (2005) Overproduction, purification and characterization of FtmPT1, a brevianamide F prenyltransferase from *Aspergillus fumigatus*. Microbiology 151:2199-2207
- He R, Wang B, Wakimoto T, Wang M, Zhu L, Abe I (2013) Cyclodipeptides from metagenomic library of a Japanese marine sponge. J Braz Chem Soc 24:1926-1932
- Jacques IB, Moutiez M, Witwinowski J, Darbon E, Martel C, Seguin J, Favry E, Thai R, Lecoq A, Dubois S, Pernodet JL, Gondry M, Belin P (2015) Analysis of 51 cyclodipeptide synthases reveals the basis for substrate specificity. Nat Chem Biol 11:721-727
- James ED, Knuckley B, Alqahtani N, Porwal S, Ban J, Karty JA, Viswanathan R, Lane AL (2015) Two distinct cyclodipeptide synthases from a marine actinomycete catalyze biosynthesis of the same diketopiperazine natural product. ACS Synth Biol 5:547-553
- Kumar SN, Mohandas C, Nambisan B (2014) Purification, structural elucidation and bioactivity of tryptophan containing diketopiperazines, from *Comamonas testosteroni* associated with a rhabditid entomopathogenic nematode against major human-pathogenic bacteria. Peptides 53:48-58
- Lu C, Xie F, Shan C, Shen Y (2017) Two novel cyclic hexapeptides from the genetically engineered *Actinosynnema pretiosum*. Appl Microbiol Biotechnol 101:2273-2279

4.2 Coupling of guanine with *cyclo*-L-Trp-L-Trp mediated by a cytochrome P450 homologue from *Streptomyces purpureus*.



# Coupling of Guanine with cyclo-L-Trp-L-Trp Mediated by a Cytochrome P450 Homologue from Streptomyces purpureus

Huili Yu,<sup>†</sup> Xiulan Xie,<sup>‡</sup> and Shu-Ming Li<sup>\*,†</sup>

<sup>†</sup>Institut für Pharmazeutische Biologie und Biotechnologie, Philipps-Universität Marburg, Robert-Koch-Straße 4, 35037 Marburg, Germany


<sup>‡</sup>Fachbereich Chemie, Philipps-Universität Marburg, Hans-Meerwein-Straße 4, 35032 Marburg, Germany

Supporting Information

ABSTRACT: A cyclo-L-Trp-L-Trp tailoring P450 with novel function from Streptomyces purpureus was identified by heterologous expression in S. coelicolor and in vitro assays the recombinant protein. Structural elucidation revealed that this enzyme catalyzes the transfer of a guanine moiety to the indole ring of the cyclodipeptide via a C-N bond. Adduct products of CDP and guanine are unprecedented in nature, and CDP modification by coupling with guanine has not been reported prior to this study.

2,5-Diketopiperazine (DKP) scaffold-containing natural products have gained increasing attention in recent years for their diverse and interesting biological and pharmacological activities ranging from antibacterial,<sup>1,2</sup> antifungal,<sup>3,4</sup> antitumor,<sup>5,6</sup> and immunosuppressive<sup>7</sup> to anti-inflammatory<sup>8</sup> activities. These compounds were prepared by chemical synthesis<sup>9,10</sup> or isolated from natural sources. In nature, cyclodipeptides (CDPs) are biosynthesized by large multimodular nonribosomal peptide synthetases (NRPSs) or small cyclo-dipeptide synthases (CDPSs).<sup>11-13</sup> CDPSs with typical polypeptide chains of 200-300 residues hijack aminoacyltRNAs from the ribosomal protein synthetic machinery and use them as substrates to form CDPs.<sup>14</sup> The CDPSs are genetically associated with a variety of tailoring enzymes, such as cytochromes P450 (P450s), methyltransferases, and cyclodipeptide oxidases, which has drawn remarkable attention for identification of new modified CDP derivatives and pathways.<sup>11</sup> Tryptophan-containing cyclodipeptides (cWXs) are the richest precursors of DKPs with pharmaceutical interest due to the various modification possibilities on the indole ring.<sup>9,15</sup> Very recently, several CDPSs that are responsible for the formation of cWXs have been identified in different Streptomyces strains, including cWW synthases in S. purpureus, S. lavendulae, and S. xanthophaeus.<sup>16-18</sup> In these strains, the cWW-forming CDPS gene is located directly upstream of a putative cytochrome P450 gene with the same orientation. Both genes are flanked by a putative calcium-binding and YncE family protein (Figure 1). The three P450 homologues share sequence identities of more than 75% on the amino acid level with each other (Table S1). It could be therefore speculated that these three clusters encode biosynthetic pathways of very similar DKP derivatives.

P450s constitute a superfamily of ubiquitous hemoproteins that catalyze a large variety of reactions via a complex multistep






Figure 1. CDPS- and P450-containing gene clusters from three Streptomyces strains.

mechanism.<sup>19</sup> They are the major biocatalysts in the biosynthesis of steroids and bile acids as well as in the metabolism of drugs and xenobiotics.<sup>20,21</sup> With extraordinarily broad substrate spectra and regio- and stereoselectivity, they also play key roles in the biosynthesis of natural products.<sup>19,2</sup> In addition to typical P450 reactions such as hydroxylation and epoxidation, they also catalyze unusual reactions such as arylaryl coupling, bond cleavage or migration and ring opening, nitration, or rearrangement.<sup>23,24</sup> Until now, several CDP tailoring P450s have been functionally characterized in the biosynthesis of mycocyclosin,<sup>25</sup> pulcherriminic acid,<sup>26</sup> and (-)-ditryptophenaline.<sup>27</sup> They catalyze intramolecular C–C bond formation of cYY, double N-oxide formation and aromatization of the DKP ring in cLL, and dimerization of cWF, respectively.  $^{25-27}$ 

After identification of cWW as the sole product of the three CDPSs deposited in Figure 1, we were interested in the function of the P450 homologues in these clusters, termed in this study P450<sub>NB5737</sub>, P450<sub>NB2774</sub>, and P450<sub>NB5414</sub>, respectively.


Received: June 30, 2018 Published: August 3, 2018

Alignments of their sequences with those of known P450s from bacteria revealed the presence of the three P450 featuring motifs (Figure S1): (i) the highly conserved A/  $G^{241}G^{242}XXT^{245}$  motif with Thr as a critical residue for the H-bonding network<sup>22</sup> (this residue is replaced by a Ser in the CDP tailoring P450s),  $^{25}$  (ii)  $E^{280}XXR^{283}$  motif found in the K helix with the two invariant Glu and Arg to ensure correct tertiary structure and stabilization of the heme within the protein,  $^{19}$  and (iii)  $G^{347}XXXC^{351}$  motif in the heme-binding loop harboring the invariant and catalytically most important Cys.<sup>22</sup> Phylogenetic analysis of functionally characterized P450s from bacteria (Figure S2) indicated that the CDP tailoring P450s of interest distribute in the same subclade as CYP121 from Mycobacterium tuberculosis, which catalyzes the intramolecular aryl-aryl coupling of cYY.<sup>25</sup> They are also closely related to P-450mel, CYP158A1, and CYP158A2, which catalyze dimerization of hydroxynaphthalenes/naphthoquinones via aryl-aryl coupling in Streptomyces.<sup>28-30</sup> Based on these bioinformatics results, we speculated initially that P450<sub>NB5737</sub>, P450<sub>NB2774</sub>, and P450<sub>NB5414</sub> could also be responsible for intramolecular or intermolecular aryl-aryl coupling of cWW.

For functional proof, we chose the cluster from S. purpureus NRRL B5737 for expression. First, CDPS<sub>NB5737</sub> was cloned alone or together with  $P450_{NB5737}$  into the integrative vector pSET152<sup>31</sup> (Table S2) and expressed in S. coelicolor M1146.<sup>32</sup> The transformants were cultivated in GYM liquid media at 28 °C for 7 days. The ethyl acetate extracts of the cell cultures were subjected to LC-MS analysis (Figure 2). In comparison to that of the wild-type strain M1146 (Figure 2i), CDPS<sub>NB5737</sub> transformant showed the sole product peak with the expected  $[M + H]^+$  ion for cWW (1) at m/z 373.1659 (Figure 2ii), which is consistent with the results obtained from E. coli transformants (Scheme 1).<sup>16</sup> In the CDPS<sub>NB5737</sub> and P450<sub>NB5737</sub> coexpressing strain, one additional product peak 2 was detected by UV 277 nm at 18.5 min, and two additional product peaks for 2 and 2' were detected by MS with [M + H]<sup>+</sup> ions at m/z 522.1997 (Figure 2iii). Expression of CDPS<sub>NB5737</sub> alone or together with P450<sub>NB5737</sub> in S. coelicolor M1146 with the replicative vector pPWW50<sup>33</sup> led to nearly identical results (Figure 2iv,v).

To confirm the metabolism of 1 by  $P450_{NB5737}$ , we cloned its coding sequence in pPWW50 and expressed it in S. coelicolor M1146. As shown in Figure 2vii, neither 1 nor 2 or 2' was detected in the transformant with P450<sub>NB5737</sub>. A 2-day-old  $P450_{NB5737}$  transformant was then fed with 80  $\mu$ M of 1 and cultivated further for 7 days. LC-MS analysis indicated that 1 was completely consumed, and 2 and 2' with a similar ratio as in the coexpression transformant of CDPS<sub>NB5737</sub> and P450<sub>NB5737</sub> were detected as products (Figure 2iii,viii). In comparison, feeding 1 into M1146 did not lead to any conversion to 2 or 2' (Figure 2vi). These results prove that cWW produced by  $\text{CDPS}_{\text{NB5737}}$  was metabolized by P450<sub>NB5737</sub> to adduct products with an unknown reaction partner rather than to intra- or intermolecular coupling products within one or between two cWW molecules. This was deduced from the  $[M + H]^+$  ion of 1 at m/z 373.1659 and those of 2 and 2' at m/z 522.1997.

For structure elucidation, approximate 13 mg of **2** was isolated from 4 L 7 day-old culture of M1146 transformant harboring pHY48 for expression of  $CDPS_{NB5737}$  and  $P450_{NB5737}$  in GYM and subjected to NMR analysis including <sup>1</sup>H, <sup>13</sup>C APT, DQF-COSY, HSQC, and HMBC (Table S3, Figures




**Figure 2.** LC–MS analysis of the expression of *CDPS* and *P450* from *S. purpureus* in *S. coelicolor* M1146. Detection was carried out at UV 277 nm and EIC for  $[M + H]^+$  ions of **1** and **2**.

S3–S8). Interpretation of the NMR spectra revealed that a guanine moiety was attached via its C8' to N1 of 1, resulting in the downfield shifting of H2 to  $\delta$  7.75 and H7 to  $\delta$  8.63 ppm, respectively. In comparison to those of 1, five additional <sup>13</sup>C signals were detected at  $\delta$  156.8 (C2'), 150.0 (C4'), 116.4 (C5'), 161.1 (C6'), and  $\delta$  153.1 (C8'), which can be assigned to those of a guanine residue (Table S3).<sup>34,35</sup> The key correlation between H2 and C8' in HMBC spectrum confirmed the connection of the two moieties via N1–C8' (Scheme 1). The production yield of **2** of the 7 day-old culture was calculated to be 8 mg/L. Due to the low quantity, the

#### **Organic Letters**

Scheme 1. Biosynthesis and Metabolism of cWW in S. purpureus NRRL B-5737



structure of 2' cannot be determined in this study. From the HR-EIMS data, it could be, however, speculated that 2' is also a coupling product of guanine with 1.

Taking the structure information on **2** and the results obtained from heterologous expression and biotransformation into consideration, we postulated that  $P450_{NB5737}$  catalyzes a transfer reaction of guanine (3) to 1 (Scheme 1). To prove this hypothesis, the coding sequence of  $P450_{NB5737}$  was cloned into pET28a (+) (Table S2) and expressed in *E. coli* Rosetta (DE3). Induction with 0.5 mM IPTG at 18 °C for 20 h and purification with Ni-NTA agarose resulted in an apparently homologous protein with a yield of 3.5 mg/L culture (Figure S9).

Most bacterial P450s belong to a class I redox system consisting of three separate and soluble proteins, i.e., ferredoxin, ferredoxin reductase, and P450.<sup>36</sup> Usually, bacterial P450s, especially those from *Streptomyces*, also accept electrons from heterologous redox partners.<sup>19</sup> We investigated therefore the P450<sub>NB5737</sub> activity by using commercially available spinach ferredoxin and ferredoxin-NADP<sup>+</sup> reductase for electron transport. Incubation of the purified P450<sub>NB5737</sub> with 1 and 3 in the presence of these redox partners and NADPH led to the detection of 2 (Figure 3i), which was identified by comparison of its retention time, UV spectrum,  $[M + H]^+$  ion, fragmentation pattern in MS<sup>2</sup> mode with those of the isolated product described above.

No product formation was observed in negative controls with heat-inactivated protein, without 1 or 3 (Figures 3ii-iv). However, only low conversion of approximate 1% was achieved under the tested condition. Increasing the concentration of ferredoxin, ferredoxin reductase, or both to 5-fold did not change the conversion yield (data not shown). Using GTP instead of guanine as donor, a trace of 2 was also detected (Figure 3v), but only approximately 2.3% of that with guanine (Figure 3i). It cannot be excluded that this amount was also a product of 1 with 3 as impurity or hydrolytic product of GTP.

UV-vis spectroscopic analysis of  $P450_{NB5737}$  in the presence of sodium dithionite and carbon monoxide<sup>37-39</sup> revealed strong absorption at 415 nm of an inactive form and only a very weak shoulder peak around 446 nm of the active form (Figure S10). Addition of DTT to the mixture did not increase the intensity of the absorption at 446 nm (data not shown). In

EIC: 373.1659±0.005 50000 EIC: 522. 1997±0. 005 40000 30000 20000 i + P450<sub>NB5737</sub> 2 + cWW + guanine 10000 50000 40000 30000 ii + heat-inactivated P450<sub>NB5737</sub> 20000 + cWW + guanine 10000 5000 4000 30000 iii + P450<sub>NB5737</sub> + cWW 20000 10000 50000 40000 3000 iv + P450<sub>NB5737</sub> + guanine 20000 10000 20000 15000 1 10000 v + P450<sub>NB5737</sub> 5000 + cWW +GTP 15 20 10 [min]

Letter

Figure 3. In vitro enzyme assays of recombinant P450<sub>NB5737</sub>.

the case of TxtE, an atypical P450 catalyzing L-tryptophan nitration in the biosynthesis of thaxtomin A, the absorption at 447 nm strongly benefited from the added DTT.<sup>37</sup> All of these results indicate the presence of only a small portion of the active  $P450_{NB5737}$  in the purified protein.

As aforementioned, P450s also catalyze intra- and intermolecular aryl-aryl coupling via radial intermediates.<sup>25,27–30,40</sup> In analogy, we proposed that the radicals of **1** at N1 and **3** at C8'are key intermediates (Figure 4). In this hypothesis, the two radicals (compound II) are formed parallel via oxidation of Fe<sup>II</sup> via Fe<sup>III</sup> and ferryl-oxo intermediate (Fe<sup>IV</sup>=O, compound I).<sup>19</sup> Coupling of the two radicals led to the formation of **2**.

In conclusion, we identified in this study a P450 enzyme from *Streptomyces* that catalyzes an unusual coupling reaction of a cyclodipeptide with a nucleobase, leading to unprecedented adducts of cyclodipeptide with guanine. This represents one additional rare atypical P450 example catalyzing the coupling of two different substrates.<sup>40,41</sup> Intramolecular carbon–nitrogen bond formation between a sugar and its aglycone core was reported for StaN, a cytochrome P450 in the biosynthesis of staurosporine.<sup>24,42</sup> Coupling of guanine with *cyclo*-L-Trp-L-Trp increases significantly the CDP diversity and opens new prospective pathway in natural product discovery. To the best of our knowledge, modification of peptides by a nucleobase has not been reported prior to this study. Although P450<sub>NB5737</sub> is phylogenetically located closely to CYP121<sup>25</sup> and

4923




Figure 4. Proposed mechanism for the  $\rm P450_{NB5737}\text{-}mediated$  intermolecular coupling reaction of cWW and guanine.

near to P-450mel, CYP158A1, and CYP158A2,<sup>28-30</sup> it uses clearly diverse substrates and catalyzes a distinct reaction as these enzymes. More importantly, this special P450 enzyme is obviously able to bind two significantly different structures as substrates and transfer them to radical intermediates for a coupling reaction. This indicates the presence of novel active site(s) differing from those of known P450s, which should be investigated in the future.

## ASSOCIATED CONTENT

## **Supporting Information**

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.or-glett.8b02051.

Experimental details, spectroscopic data (PDF)

## AUTHOR INFORMATION

### **Corresponding Author**

\*E-mail: shuming.li@staff.uni-marburg.de. Tel/Fax: + 49-6421-28-22461/25365.

## ORCID <sup>©</sup>

Shu-Ming Li: 0000-0003-4583-2655

# Notes

The authors declare no competing financial interest.

## ACKNOWLEDGMENTS

We thank the ARS Culture Collection (NRRL) for providing *Streptomyces* strains, R. Kraut (University Marburg) for LC–MS analysis, and Prof. Wenhan Lin (Peking University) for comments on the manuscript. The Bruker micrOTOF QIII mass spectrometer was financially supported in part by a grant from the Deutsche Forschungsgemeinschaft (INST 160/620-1 to S.-M.L.). H.Y. is a scholarship recipient of the China Scholarship Council (201306220024).

## REFERENCES

(1) Cain, C. C.; Lee, D.; Waldo, R. H., III; Henry, A. T.; Casida, E. J., Jr.; Wani, M. C.; Wall, M. E.; Oberlies, N. H.; Falkinham, J. O., III *Antimicrob. Agents Chemother.* **2003**, *47*, 2113.

(2) Magyar, A.; Zhang, X.; Kohn, H.; Widger, W. R. J. Biol. Chem. 1996, 271, 25369.

(3) Ström, K.; Sjögren, J.; Broberg, A.; Schnürer, J. Appl. Environ. Microbiol. 2002, 68, 4322.

(4) Musetti, R.; Polizzotto, R.; Vecchione, A.; Borselli, S.; Zulini, L.; D'Ambrosio, M.; di Toppi, L. S.; Pertot, I. *Micron* **200**7, *38*, 643.

(5) Yamazaki, Y.; Tanaka, K.; Nicholson, B.; Deyanat-Yazdi, G.; Potts, B.; Yoshida, T.; Oda, A.; Kitagawa, T.; Orikasa, S.; Kiso, Y.; Yasui, H.; Akamatsu, M.; Chinen, T.; Usui, T.; Shinozaki, Y.; Yakushiji, F.; Miller, B. R.; Neuteboom, S.; Palladino, M.; Kanoh, K.; Lloyd, G. K.; Hayashi, Y. J. Med. Chem. 2012, 55, 1056.

(6) Kanzaki, H.; Yanagisawa, S.; Kanoh, K.; Nitoda, T. J. Antibiot. 2002, 55, 1042.

(7) Waring, P.; Beaver, J. Gen. Pharmacol. 1996, 27, 1311.

(8) Minelli, A.; Grottelli, S.; Mierla, A.; Pinnen, F.; Cacciatore, I.; Bellezza, I. *Int. J. Biochem. Cell Biol.* **2012**, *44*, 525.

(9) Borthwick, A. D. Chem. Rev. 2012, 112, 3641.

(10) González, J. F.; Ortín, I.; de la Cuesta, E.; Menéndez, J. C. Chem. Soc. Rev. 2012, 41, 6902.

(11) Giessen, T. W.; Marahiel, M. A. Int. J. Mol. Sci. 2014, 15, 14610.
(12) Belin, P.; Moutiez, M.; Lautru, S.; Seguin, J.; Pernodet, J. L.; Gondry, M. Nat. Prod. Rep. 2012, 29, 961.

(13) Mishra, A. K.; Choi, J.; Choi, S. J.; Baek, K. H. Molecules 2017, 22, E1796.

(14) Jacques, I. B.; Moutiez, M.; Witwinowski, J.; Darbon, E.; Martel, C.; Seguin, J.; Favry, E.; Thai, R.; Lecoq, A.; Dubois, S.; Pernodet, J. L.; Gondry, M.; Belin, P. Nat. Chem. Biol. 2015, 11, 721. (15) Li, S. M. Nat. Prod. Rep. 2010, 27, 57.

(16) Liu, J.; Yu, H.; Li, S.-M. Appl. Microbiol. Biotechnol. 2018, 102, 4435.

(17) Liu, J.; Yu, H.; Li, S.-M. Appl. Microbiol. Biotechnol. 2018, 102, 5787.

(18) Gondry, M.; Jacques, I. B.; Thai, R.; Babin, M.; Canu, N.; Seguin, J.; Belin, P.; Pernodet, J. L.; Moutiez, M. Front. Microbiol. **2018**, *9*, 46.

(19) Rudolf, J. D.; Chang, C. Y.; Ma, M.; Shen, B. Nat. Prod. Rep. 2017, 34, 1141.

(20) Guengerich, F. P. Chem. Res. Toxicol. 2001, 14, 611.

(21) Kelly, S. L.; Kelly, D. E. Philos. Trans. R. Soc., B 2013, 368, 20120476.

(22) Podust, L. M.; Sherman, D. H. Nat. Prod. Rep. 2012, 29, 1251.

(23) Zhang, X.; Li, S. Nat. Prod. Rep. 2017, 34, 1061.

(24) Greule, A.; Stok, J. E.; De Voss, J. J.; Cryle, M. J. Nat. Prod. Rep. 2018, DOI: 10.1039/C7NP00063D.

(25) Belin, P.; Le Du, M. H.; Fielding, A.; Lequin, O.; Jacquet, M.; Charbonnier, J. B.; Lecoq, A.; Thai, R.; Courcon, M.; Masson, C.; Dugave, C.; Genet, R.; Pernodet, J. L.; Gondry, M. *Proc. Natl. Acad. Sci. U. S. A.* **2009**, *106*, 7426.

(26) Cryle, M. J.; Bell, S. G.; Schlichting, I. *Biochemistry* **2010**, *49*, 7282.

(27) Saruwatari, T.; Yagishita, F.; Mino, T.; Noguchi, H.; Hotta, K.; Watanabe, K. *ChemBioChem* **2014**, *15*, 656.

### **Organic Letters**

(28) Funa, N.; Funabashi, M.; Ohnishi, Y.; Horinouchi, S. J. Bacteriol. 2005, 187, 8149.

(29) Zhao, B.; Guengerich, F. P.; Bellamine, A.; Lamb, D. C.; Izumikawa, M.; Lei, L.; Podust, L. M.; Sundaramoorthy, M.; Kalaitzis, J. A.; Reddy, L. M.; Kelly, S. L.; Moore, B. S.; Stec, D.; Voehler, M.;

Falck, J. R.; Shimada, T.; Waterman, M. R. J. Biol. Chem. 2005, 280, 11599. (30) Zhao, B.; Lamb, D. C.; Lei, L.; Kelly, S. L.; Yuan, H.; Hachey,

(30) Zhao, B.; Lamo, D. C.; Lei, L.; Keny, S. L.; Huan, H.; Hachey, D. L.; Waterman, M. R. *Biochemistry* **200**7, *46*, 8725.

(31) Kieser, T.; Bibb, M. J.; Buttner, M. J.; Chater, K. F.; Hopwood, D. A. *Practical Streptomyces Genetics*, 2nd ed.; John Innes Foundation: Norwich, UK, 2000.

(32) Gomez-Escribano, J. P.; Bibb, M. J. Microb. Biotechnol. 2011, 4, 207.

(33) Doumith, M.; Weingarten, P.; Wehmeier, U. F.; Salah-Bey, K.; Benhamou, B.; Capdevila, C.; Michel, J.-M.; Piepersberg, W.; Raynal, M.-C. *Mol. Gen. Genet*. **2000**, 264, 477.

(34) Marzilli, L. D.; de Castro, B.; Solorzano, C. J. Am. Chem. Soc. 1982, 104, 461.

(35) Teijeira, M.; Santana, L.; Uriarte, E. Magn. Reson. Chem. 1997, 35, 806.

(36) Hannemann, F.; Bichet, A.; Ewen, K. M.; Bernhardt, R. Biochim. Biophys. Acta, Gen. Subj. 2007, 1770, 330.

(37) Barry, S. M.; Kers, J. A.; Johnson, E. G.; Song, L.; Aston, P. R.; Patel, B.; Krasnoff, S. B.; Crane, B. R.; Gibson, D. M.; Loria, R.; Challis, G. L. *Nat. Chem. Biol.* **2012**, *8*, 814.

(38) Omura, T.; Sato, R. J. Biol. Chem. 1964, 239, 2370.

(39) Shenkman, J. B.; Jansson, I. Spectral analyses of cytochrome P450. In *Cytochrome P450 Protocols*, 2nd ed.; Phillips, I. R., Shephard, E. A., Eds.; Humana Press Inc: Totowa, NJ, 2006; pp 11–18.

(40) Lin, H.-C.; McMahon, T. C.; Patel, A.; Corsello, M.; Simon, A.; Xu, W.; Zhao, M.; Houk, K. N.; Garg, N. K.; Tang, Y. J. Am. Chem. Soc. **2016**, 138, 4002.

(41) Agarwal, V.; El Gamal, A. A.; Yamanaka, K.; Poth, D.; Kersten, R. D.; Schorn, M.; Allen, E. E.; Moore, B. S. *Nat. Chem. Biol.* **2014**, *10*, 640.

(42) Onaka, H.; Asamizu, S.; Igarashi, Y.; Yoshida, R.; Furumai, T. Biosci., Biotechnol., Biochem. 2005, 69, 1753.

# **Supporting information**

# Coupling of Guanine with *cyclo*-L-Trp-L-Trp Mediated by a Cytochrome P450 Homologue from *Streptomyces purpureus*

Huili Yu<sup>†</sup>, Xiulan Xie<sup>‡</sup>, and Shu-Ming Li<sup>†\*</sup>

<sup>+</sup> Institut für Pharmazeutische Biologie und Biotechnologie, Philipps-Universität Marburg, Robert-Koch-Straße 4, 35037 Marburg, Germany

<sup>‡</sup> Fachbereich Chemie, Philipps-Universität Marburg, Hans-Meerwein-Straße 4, 35032 Marburg, Germany

Table of Contents	
Experimental Procedures	Page
Computer-assisted sequence analysis	S3
Plasmids, bacterial strains, and culture conditions	S3
Genetic manipulation, PCR amplification, and gene cloning	S3
Gene expression	S4
LC-MS analysis	S4
Isolation and structural elucidation of P450 product	S4-S5
Determination of production yield of compound <b>2</b> in <i>Streptomyces</i>	S5
Production and purification of P450 <sub>NB5737</sub> in <i>E. coli</i>	S5-S6 S6
UV-Vis spectroscopic analysis of P450 <sub>NB5737</sub>	S6
In vitro assays of P450 <sub>NB5737</sub>	30
Supplementary Tables	
Table S1. Comparison of CDPSs and P450s in three Streptomyces strains	S7
Table S2. Cloning and expression constructs used in this study.	S7
Table S3. <sup>1</sup> H (500 MHz) and <sup>13</sup> C NMR (125 MHz) data of the isolated compound <b>2</b>	S8
in DMSO- <i>d</i> 6	
Supplementary Figures	
Figure S1. Alignments of P450s from this study and structurally defined natural	S9
product P450s from bacteria.	
Figure S2. Phylogenetic analysis of P450s from this study and functionally	S10
characterized P450s from bacteria.	
Figure S3. <sup>1</sup> H NMR spectrum of compound <b>2</b> (DMSO- <i>d</i> 6, 500 MHz).	S11
Figure S4. <sup>13</sup> C APT spectrum of compound <b>2</b> (DMSO- <i>d</i> 6, 125 MHz).	S12
Figure S5. DQF-COSY spectrum of compound 2 (DMSO-d6, 500 MHz, 500 MHz).	S13
Figure S6. HSQC spectrum of compound 2 (DMSO-d6, 500 MHz, 125MHz).	S14
Figure S7. HMBC spectrum of compound 2 (DMSO-d6, 500 MHz, 125MHz).	S15
Figure S8. Section of HMBC spectrum of compound <b>2</b> (DMSO- <i>d</i> 6, 500 MHz,	S16
	047
Figure S9. SDS-PAGE analysis of the purified P450 <sub>NB5737</sub> .	S17 S17
Figure S10. Spectroscopic analysis of P450 <sub>NB5737</sub> .	517
Supplementary References	S18

# Supplementary References

# **Computer-assisted sequence analysis**

Nucleotide and protein sequences used in this study were downloaded from NCBI databases (http://www.ncbi.nlm.nih.gov). Protein sequences were compared with each other by using BLAST programs (http://blast.ncbi.nlm.nih.gov/). Multiple sequence alignments were performed using the ClustalW and visualized with by program ESPript 3.0 (http://endscript.ibcp.fr/ESPript/cgi-bin/ESPript.cgi) to identify strictly conserved amino acid residues (Figure S1). The phylogenetic tree in Figure S2 was created by MEGA version 5.0 (http://www.megasoftware.net).

# Plasmids, bacterial strains, and culture conditions

Plasmids and constructs used in this study are listed in Tables S2. *E. coli* DH5α was used as host for cloning and *E. coli* Rosetta (DE3) for P450 production. *Streptomyces* strains mentioned in Figure 1 and Table S1 were obtained from the ARS Culture Collection (NRRL). *S. coelicolor* M1146<sup>1</sup> was kindly gifted by Prof. Bibb (John Innes Centre). Recombinant *E. coli* strains were cultivated in liquid/solid LB or TB media containing 100 µg/mL ampicillin, 50 µg/mL apramycin or 50 µg/mL kanamycin. The *Streptomyces* strains were maintained at 28 °C in GYM (glucose 4.0 g/L, yeast extract 4.0 g/L, malt extract 10.0 g/L, agar 15.0 g/L, pH 7.3) or ISP4 media (soluble starch 10.0 g/L, K<sub>2</sub>HPO<sub>4</sub> 1.0 g/L, MgSO<sub>4</sub> •7H<sub>2</sub>O 1.0 g/L, NaCl 1.0 g/L, (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> 2.0 g/L, CaCO<sub>3</sub> 1.0 g/L, trace element solution<sup>2</sup> 1.0 mL/L, agar 15.0 g/L, pH 7.2.).

# Genetic manipulation, PCR amplification, and gene cloning

Genetic manipulation in *E. coli* was carried out according to the protocol by Sambrook and Russell.<sup>3</sup> Isolation of genomic DNA from *Streptomyces* was performed as described previously.<sup>2</sup> The genes encoding CDPS and P450 were amplified by PCR from genomic DNA by using primers listed in Table S2 and Phusion® High-Fidelity DNA Polymerase from New England Biolabs (NEB). The generated PCR fragments were cloned into pGEM-T Easy vector and the sequence integrity was confirmed by sequencing. After sequencing, the fragments were cut off with the appropriate restriction endonucleases from pGEM-T Easy and ligated into pSET152, pPWW50 or pET28a (+) vector. They were digested with the same enzymes, previously. The generated plasmids (Table S2) were transformed into *S. coelicolor* M1146 and *E. coli* Rosetta (DE3) for gene expression and P450 protein production, respectively.

## **Gene expression**

For gene expression, the constructs of CDPSs and P450s were transformed into *S. coelicolor* M1146 by conjugation.<sup>2</sup> The exconjugants were selected with 1 mg apramycin and 0.5 mg trimethoprim in 1 mL H<sub>2</sub>O. The spores of the *S. coelicolor* M1146 transformants were inoculated to 30 mL of GYM liquid media supplied with 30  $\mu$ g/mL of apramycin in 250 mL baffled flask and cultured at 28 °C, 180 rpm for 7 days. In the biotransformation experiments, the spores of M1146 harboring the P450 expression plasmid pHY44 were inoculated into GYM liquid media (30  $\mu$ g/mL of apramycin) and cultivated for 2 days. After addition of 80  $\mu$ M of cWW, the bacterial cultures were maintained further for 7 days. 1 mL of culture was extracted with one volume of ethyl acetate for three times. The organic phases were combined, evaporated, and the residues were afterward dissolved in 30  $\mu$ L of methanol. 5  $\mu$ L of such samples were taken for LC-MS analysis.

## LC-MS analysis

The ethyl acetate extracts were analyzed on an Agilent HPLC 1260 series equipped with a photo diode array detector and a Bruker microTOF QIII mass spectrometer by using an Agilent Eclipse XDB C18 column (5  $\mu$ m, 4.6 x 150 mm). A linear gradient of 5 -100% acetonitrile in water, both containing 0.1% formic acid, in 40 min and a flow rate at 0.25 mL/min were used. The column was then washed with 100% acetonitrile containing 0.1% formic acid for 5 min and equilibrated with 5% acetonitrile in water for 5 min. The parameters of the spectrometer were set as following: electrospray positive ion mode for ionization, capillary voltage with 4.5 kV, collision energy with 8.0 eV.

## Isolation and structural elucidation of P450 products

For isolation of the P450 products, the CDPS and P450 coexpression transformant was cultivated on a large scale (4 L) at 28 °C for 7 days. The culture supernatant was extracted with equal volume of ethyl acetate for three times. The organic phases were combined, evaporated, and dried in a freezing dryer. The extracts were loaded on a silica gel column (45×3.5 cm) filled with 120 g silica gel 60 (230-400 mesh, Carl Roth GmbH, Karlsruhe, Germany) and eluted with mixtures of  $CH_2Cl_2$ : MeOH in ratios of 100:2, 100:3, 100:5, 100:10 (1000 mL each). The products were detected in the fraction eluted with the mixture of 100:10. Fractions containing product **2** was further separated on an Agilent HPLC 1260 series equipped with a photo diode array detector by using a semipreparative Multospher 120 RP-18 column (10 x 250 mm, 5  $\mu$ m)

with 30% ACN in water. The flow rate was set to 2.5 mL/min. Finally, 13 mg of **2** was obtained as pale yellow powder and subjected to NMR analysis.

NMR experiments were performed at room temperature on a Bruker AVIII spectrometer equipped with a 5 mm BBO cryo probe Prodigy with z-gradient. All spectra were processed with MestReNova 5.2.2 (Metrelab Research, S5 Santiago de Compostella, Spain). NMR data and spectra of the product **2** were provided as Table S3 and Figures S3-S8, respectively.

# Determination of production yield of compound 2 in Streptomyces

For quantification, an Agilent HPLC 1200 series equipped with a photo diode array detector and the same column with that used in LC-MS was used. A linear gradient of 10 to 100% acetonitrile in water without acid in 40 min was followed by 100% acetonitrile for 5 min and 10% acetonitrile in water for 5 min. The flow rate was 0.5 mL/min. The absorption at 277 nm was used for quantification. 3 mg of compound **2** was dissolved in 250  $\mu$ L DMSO and used as standard. 2 mL culture of the M1146 transformant carrying pHY48 for CDPS<sub>NB5737</sub> and P450<sub>NB5737</sub> expression was extracted with 1 mL ethyl acetate for 3 times. The organic fractions were combined and dried. The residue was dissolved in 50  $\mu$ L of methanol and analyzed on HPLC. The production yield was calculated to be 8 mg/L in *S. coelicolor* M1146.

# Production and purification of P450<sub>NB5737</sub> in *E. coli*

*E. coli* Rosetta (DE3) cells harboring pHY99 were cultivated in 50 mL LB media (50 µg/mL kanamycin) for 16 h as preculture. Five milliliters of the preculture were transferred to 500 mL TB media (50 µg/mL kanamycin) in 2 L-Erlenmeyer flask and grown at 37 °C, 230 rpm to an absorption of 0.6 at 600 nm. The gene expression was induced with 0.5 mM IPTG at 18 °C for 20 h. The bacterial cultures were harvested by centrifugation (4500 rpm, 15 min, 4 °C) and the cells were resuspended in lysis buffer (10 mM imidazole, 50 mM NaH<sub>2</sub>PO4, 300 mM NaCl, pH 8.0) with 2–5 mL/g wet weight. Lysozyme from the chicken egg white was added at a final concentration of 1 mg/mL and incubated on ice for 30 min. The cells were lysed by sonication on ice. Cell debris was removed by centrifugation at 13,000 rpm and 4 °C for 30 min. One-step purification of the recombinant His<sub>6</sub>-tagged protein was performed by using Ni-NTA agarose (Macherey-Nagel, Düren, Germany) according to the manufacturer's instructions. The storage buffer was changed to 50 mM Tris-HCl (pH 7.5) containing 15% (v/v) glycerol through a NAP-5 column (GE Healthcare, Freiburg, Germany), which had been equilibrated with the same buffer. The obtained protein was stored frozen at -80 °C. Protein concentration was determined on

Nanodrop C 2000 (Thermo Scientific, Braunschweig, Germany) and 3.5 mg/L culture of  $P450_{NB5737}$  was obtained. The purity of obtained protein was proven with 12% (w/v) SDS-PAGE (Figure S9).

# UV-Vis spectroscopic analysis of P450<sub>NB5737</sub>

To measure the typical absorbance of P450 ferrous CO complex after reduction, carbon monoxide gas was bubbled into the P450<sub>NB5737</sub> solution (10.5 µM in 0.1 M potassium phosphate buffer containing 20% glycerol, pH 7.4) for 2 min. After addition of 0.1 mg/mL of sodium dithionite, a UV-Vis spectrum between 350 and 550 nm was taken on a Multiskan<sup>™</sup> GO Microplate Spectrophotometer (Thermo Scientific, Dreieich, Germany) by using Greiner UV-Star® 96 well plates (Greiner Bio-One GmbH, Frickenhausen, Germany). UV-Vis spectra of P450<sub>NB5737</sub> without treatment and after addition of sodium dithionite were also taken as controls. The spectra are shown in Figure S10.

# In vitro assays of P450<sub>NB5737</sub>

P450<sub>NB5737</sub> activities toward cWW and guanine or GTP were measured in 50  $\mu$ L system containing 5  $\mu$ M purified P450<sub>NB5737</sub>, 1 mM cWW, 0.5 mM guanine or GTP, 1  $\mu$ M spinach ferredoxin (Sigma-Aldrich), 0.1 unit/mL spinach ferredoxin-NADP<sup>+</sup> reductase (Sigma-Aldrich), and 1 mM NADPH in 50 mM Tris-HCI at pH 7.5. The reaction mixtures were incubated at 30 °C for 16 h. The negative controls with heat-inactivated P450<sub>NB5737</sub>, without cWW or guanine were performed under the same conditions. The reactions were stopped by addition of 200  $\mu$ L MeOH each. The supernatants after centrifugation were dried in Speedvac and redissolved in 30  $\mu$ L MeOH. 5  $\mu$ L of these samples were taken for LC-MS analysis.

Drotoin (longth in co) of	Identity to proteins	Protein function	
Protein (length in aa) of <i>Strptomyces purpureus</i> NRRL B-5737	Streptomyces lavendulae NRRL B-2774	Streptomyces xanthophaeus NRRL B-5414	
WP_019889609 (239)	WP_078950527 (265) 58	WP_063768158 (273) 58	CDPS (cWW synthase)
WP_019889608 (398)	WP_051841251 (416) 75	WP_031150378 (412) 75	Putative P450

 Table S2. Cloning and expression constructs used in this study.


Protein	Accession number	Primer sequences (5'-3')	pGEM-T easy construct	Cloning sites	Expression vector	Expression construct
CDPS <sub>NB5737</sub>	WP_ 019889609	GC <u>CATATG</u> ACTCTCATCGAAGACAC <u>TCTAGA</u> CTAAGCGGCTCGACGGTCAT	pHY40	Ndel/ Xbal Ndel/Xbal	pPWW50 pSET152	pHY42 pHY43
P450 <sub>NB5737</sub>	WP_	CATATGACCGTCGAGCCGCTTGA TCTAGACTACCACAACACCGGCAGCC	pHY41	Ndel/Xbal	pPWW50	pHY44
1 430 <sub>NB5737</sub>	019889608	CATATGACCGTCGAGCCGCTTGA GAATTCTCACCACAACACCGGCAGC	pHY98	Ndel/EcoRI	pET28a(+)	pHY99
(CDPS+ P450) <sub>NB5737</sub>	-	GC <u>CATATG</u> ACTCTCATCGAAGACAC <u>TCTAGA</u> CTACCACAACACCGGCAGCC	pHY46	Ndel/Xbal Ndel/Xbal	pPWW50 pSET152	pHY47 pHY48

	5 4 7 8 7'N 0 5' 6 1' HN 2' NH	$\begin{array}{c} 0 \\ 9 \\ 3 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1$
Pos.	$\delta_{\rm H}$ , multi., <i>J</i> [Hz]	δ <sub>C</sub>
1	-	-
2	7.75, s	125.6
3	-	109.6
4	7.38, d, 7.9	118.5
5	7.00, dd, 7.6, 2.9	119.1
6	7.12, t, 7.6	121.3
7	8.63, d, 8.3	114.8
8	-	134.5
9	-	128.9
10 a	2.80, dd, 14.4, 4.4	29.0
10 b	2.56, dd, 14.4, 5.4	
11	4.04, t, 4.4	55.2
12	7.99, d, 1.7	-
13	-	167.09
14	3.99, t, 5.4	55.0
15	7.79, d, 1.9	-
16	-	167.10
17 a	2.77, dd, 14.4, 4.4	29.1
17 b	2.46, dd, 14.4, 6.1	
18	-	108.6
19	6.59, d, 1.9	124.1
20	11.12, br	-
21	-	136.0
22	7.29, d, 8.1	111.3
23	6.99, dd, 7.6, 2.9	120.7
24	6.90, t, 7.5	118.2
25	7.35, d, 8.0	118.3
26	-	127.5
1'	10.00, br	-
NH2-2'	5.59, s	156.8
3'	-	-
4'	-	150.0
5'	-	116.4
6'	-	161.1
7'	-	-
8'	-	153.1
9'	Not observed	-

Table S3. <sup>1</sup>H (500 MHz) and <sup>13</sup>C NMR (125 MHz) data of the isolated compound 2 in DMSO-d6

_		1	10	20	30	40	50	60 70	80 90
eryF		MTTV <b>P</b> D	LESDSFHVI					LRLSSDPKKKYPGVEVEFPAYL	GFP.EDVRNY <mark>F</mark> ATN <b>M</b>
TamI	MPML								
PikC	.MRRTQQG.TTASPPV	<mark>1</mark> 0 <mark>l</mark> G		D P Y P T Y A R <mark>L R</mark> A F		<b>g</b> DE <mark>VWLV</mark>			AEAA <mark>L</mark> NHN <mark>M</mark>
CYP154A1	MTOETTTL.IGOSPPP	ATQQPA	LVLDPTGA	D H H T E H R T <mark>L R</mark> E G	GG <mark>PA</mark> T <mark>WV</mark> D	VLGVQ <mark>AWSV</mark>	SDPVLLKQLLTS	SDVSKDARAHWPAFGEVVGTW.	PLALWVAVENM
CYP158A1 CYP158A2		VRDWPA VrdWPA		EFDPVLAE <mark>LM</mark> RE DEDDVLTE <b>LM</b> RE	EG <b>PL</b> TRVRLPH EG <b>PV</b> TRISLPN	GELLLLGWAWLA	TRYDDVKALINI	PRFGRAEVIQ.RQITRLAPHFK PRFGREAVMD.RQVTRLAPHFI	PRPGSL
PimD	MILSUAVPP			KLSPLLBALODI	RGPIHRVRTPA	G	TREAFLKOLLET	PRIGRIAVAD.ROVIKLAPHFI DERIGRIHPDPPSAAQYV	RS. PELDLUISDAD
Stap		FD. LM.	GWDKKDIAI	DPYPVYRR <mark>YR</mark> E/	AAPVERTASCE	GKPDTYYV	FTYDDVVRVLSN	NRRLGRNARVASG.DTDTAPVPI	PTEHRALRTVVENWL
CYP170A1	MTVESVNPETRAPAAPGAPE	LREP <b>P</b> VAGGGVP	LLGHGWRLARI	DPLAFMSQ <mark>LR</mark> DI	HG <mark>DV</mark> V <b>RI</b> KLGP	K T <mark>VYAV</mark>	TNPELTGALALN	PDYHIAG	SLEGLL <mark>g</mark> keg <mark>v</mark>
CYP134A1								P <mark>D</mark> IFTTKSLVERAEPV	
CYP121	MTAT.V							<mark>)</mark> R <mark>R</mark> FSMKETAAAGAPRLNALT.V	PPE <mark>V</mark> VNN <mark>M</mark>
WP_019889608.1 WP 051841251.1	MSVEOLEGTOER.GPEPE.P	TLEFPL	SRRGD	VMPAECAA <mark>lr</mark> ef	KAPVARVRTLT KAPVARVRTLT	G DSAWLV	SHALAKQVLEL	DERFSLRHIASEGVPRQYALT.I DERFSLKDTANAGVPRQYALT.I	PPEVVNNM
WP_031150378.1	MSVEQLEGIQER.GPEPE.P	LDEPL	SPRCD	V LPEECSWLREF VLPEECGWLREF	KAPVAKVKILI Kapuakurtit	GDPAWLV	SSYALAKOVIEL	DERFSLKDIANAGVPROYALT.I	PPEVVNNM
W2_001100070.1	NOTEQ110Q.0101010.	<u>-</u>						SPW SEKSIYAYOVI KÇIYET.I	
	100 110	120	130	140	0 150	160	170	180	190
eryF	GISDPPTHTRLRKLVSOEFT							LVMDPERA	
TamI	LHSDPPDHTRLRKLVNKAFT							VSGDSP.	
PikC	LESDPPRHTRLRKLVAREFT				LMESLAWPLPI			VFPD	
CYP154A1	FTAYGPN <mark>H</mark> RK <mark>LRRLV</mark> AP <b>AFS</b>	A R R V D A M R P A V E	AMVTGLVDRL	AELPAGEP <mark>VD</mark> .	LRQEL <b>A</b> Y <b>P</b> LP <b>I</b>			FDTTLD.Q	
CYP158A1	- AFADQPD <mark>H</mark> NR <mark>LRRAV</mark> AG <mark>AFT</mark>		EI <mark>L</mark> DG <mark>LVD</mark> G <mark>I</mark>	LAEGPP <mark>AD</mark> . <mark>1</mark>				LISTSGG.A	
CYP158A2	GFLDPPDHTRLRRSVAAAFT		GMLDELVDAM					LSSS	
PimD	AESGRRQ <mark>H</mark> AE <mark>TRRLL</mark> TP <b>LFS</b> VFLDPPH <b>H</b> TE <b>LRSLL</b> TT <b>EFS</b>		EAADTLLDAF	IAQGPP <mark>GD</mark> .I RAORR <b>PD</b> .I	LHGEL <mark>TVP</mark> FA <b>L</b>	T <mark>V</mark> LCE <mark>VIGVP</mark> PQR		AKLDDR	
Stap CYP170A1	ATANGPLHRECRSLITEFS		ELASALLDRL EEAHALTERW		LVEGF <b>A</b> APLPI Isesedvavdv	A DOLLAR COMMUNE		VFRGMYRRMVVPLGPLYRLPLPA	
CYP134A1	. OMHGKEHSAKRRIVVRSFI		ONAENTLAPY	L ERGKSD	LVNDFGKTFAV	CVTMDMLGLDKRD	HEKISE, WHSG	ADFITSISOSPEAR	AHS.LWCSEOLSOYL
CYP121	GNIADAGLRKAVMKAIT	PKA.PGLEOFLE	DTANSLLDNL	I. TEGAPAD.	LRNDFADPLAT			AFMSSADPI	
WP_019889608.1	GNINSAGLRSAVMKALN	P <b>R</b> A.AG <mark>L</mark> TEW <b>L</b> F	ATADE <b>LID</b> AL		RAGEADPESA	A <mark>l</mark> her <b>vigvp</b> ég <mark>e</mark>		AFMTSAEPF	
WP_051841251.1	GNIN <mark>S</mark> AG <mark>LRNAV</mark> MK <mark>ALN</mark>							<b>N</b> FMTA	
WP_031150378.1	GNIN <mark>S</mark> AG <mark>LRNAV</mark> MK <b>ALN</b>	P <b>R</b> Q.KG <mark>L</mark> QDW <mark>L</mark> F	AKAGE <b>LVD</b> QI	VAEGGP <mark>AD</mark> . <mark>1</mark>	LRAGE <mark>A</mark> D <mark>P</mark> ES <mark>A</mark> ,	A <mark>l</mark> hcQ <b>VlGVP</b> fe <b>D</b>	WRRLMS.GLDV	• FMTA	ADS.ALNWYKDVG <mark>¥F</mark>
				2				280 <b>b</b>	
	200 210								
_		220	230	249 <b>a</b>	250		70		290
eryF	LD <b>LV</b> ER <b>R</b> RTEPGD <b>DLL</b> S	ALIRVQDDDD	GR <b>LS</b> ADE <b>LT</b> S	IALVLLLAGFE/	250 SVSLIGIGTY	L <b>lthpd</b> q <b>l</b> al <b>vr</b>	RDPSALP	NAVEEILRYI	APPETTT <mark>R</mark> F <b>A</b> AE <mark>E</mark>
TamI	LD <mark>LV</mark> ER <b>R</b> RTEPGD <b>DLL</b> S GD <b>LI</b> ER <b>K</b> RRTPTD <b>DVL</b> A	ALIR <mark>V</mark> QDDDD ALVSARDVD	GR <b>LS</b> ADE <b>LT</b> S DR <b>LT</b> ETE <b>LV</b> S	IALVLLLAGFE/ MAFLLFIGGHEI	250 ASV <b>S</b> LIGIGTY ITVNTLGNGTL. ITVNLIANGMY	L <b>lthpd</b> Q <b>l</b> al <b>vr</b> H <b>lmrnld</b> Qwea <b>lr</b>	RDPSA <mark>L</mark> P QDRSL <b>L</b> P	NAVEEILRYI 	APPETTT <mark>R</mark> F <b>A</b> AE <mark>E</mark>
TamI PikC	LD <b>LVERR</b> RTEPGD <b>DLL</b> S GD <b>LIERK</b> RRTPTD <b>DVL</b> A SR <b>LI</b> DS <b>K</b> RGQDGE <b>DLL</b> S	ALIRVQDDDD ALVSARDVD ALVRTSDEDG	GR <b>LS</b> ADE <b>LT</b> S DR <b>LT</b> ETE <b>LV</b> S SR <b>LT</b> SEE <b>LL</b> G	IALVLLLAGFE/ MAFLLFIGGHET MAHILLVAGHET	ASVSLICIGTY TVNTLGNGTL TVNLIANGMY	LLTHPDQLALVR HLMRNLDQWEALR ALLSHPDQLAALR	RDPSA <mark>L</mark> P QDRSL <b>L</b> P ADMTL <b>L</b> D	NAVEEILRYI GAVEEELRE GAVEEMLRYE	APPETTT <mark>R</mark> F <b>A</b> AE <mark>E</mark>
TamI	LDIVERRRTEPGDDIIS GDIIERKRRTPIDDVIA SRLIDSKRQDGEDIIS DCLIAAKRATPGDDMTS TEIVRARAGSEGCDVYS	ALIRVODDDD ALVSARDVD ALVRTSDE.DC LLIAARDDEGDC MLGAAVGR	GR <b>LS</b> ADE <b>LT</b> S DR <b>LT</b> ETE <b>LV</b> S SR <b>LT</b> SEE <b>LL</b> G DR <b>LS</b> PEE <b>LR</b> D GE <b>VG</b> ETE <b>AV</b> G	IALVLLLAGFE/ MAFLLFIGGHET MAHILLVAGHET TLLLMISAGYET LACPLOIGG.E/	ASVSLICICTY TVNTLGNGTL	LLTHPDQLALVR HLMRNLDQWEALR ALLSHPDQLAALR TLLTRPDQLAALVR LLTRRELMARMR	R DP SALP QDR SLLP ADMT LLD KGEVTWA ERP GARG	NAVEZILRYI GAVEZFLRLE GAVEZFLRLE CAVEZHLRYE DVVEZTLRHE TALDZLLRWI	APPETTT <mark>R</mark> F <b>A</b> AE <mark>E</mark>
TamI PikC CYP154A1 CYP158A1 CYP158A2	LDIVERRREPGDDLIS GDIIERKRRTPTDVIA SRLIDSKRGQDGEDLIS DCLIAAKRATPGDDMTS TETVRARASEGCDVYS SDLIGLSSSAGEDVTS	ALIRVQDDDE ALVSARDVD ALVRTSDE.DC LLIAARDDEGDC MLCAAVGR	GRLSADELTS DRLTETELVS SRLTSEELLG DRLSPEELRD GEVGETEAVG DELTLSEAVG	IALVLLLAGFE/ MAFLLFIGGHET MAHILLVAGHET ILLMISAGYET LAGPLOIGG.E/ LAVLLOIGG.E/	ASVSLIGIGTY TVNTLGNGTL TVNLLANGMY TVNVIDQAVH VIHNVGOMLY AVINNSGOMFH	LLTHPDQLALVR HLMRNLDQWEALR ALLSHPDQLAALR TLLTRPDQLALVR LLTRRELMARMR LLSRPELAERK	RDPSALP QDRSLLP ADMTLLD KGEVTWA ERPGARG SEPEIRP	NAVE FIRYI GAVE BELRE CAVE MIRYE DVVEDILRHE TALDELLRHI RAIDELLRHI	APPETTT <mark>R</mark> F <b>A</b> AE <mark>E</mark>
TamI PikC CYP154A1 CYP158A1 CYP158A2 PimD	LOIVERRATEPGODII GELIERKARTPTODVIA SRLIDSKRGQDGEDII OCLIAAKRATPGODNTS TETVRARAGSEGOVYS SDLIGLRSDSAGEDVT ACLVEEKRAPPGPDITS	ALIRVODDE ALVSARDVD ALVSTSDE.DC LLIAARDDEGDG MLGAAVGR LLGAAVGR	GRLSADELTS DRLTETELVS SRLTSEELLG DRLSPEELRD GEVGETEAVG DEITLSEAVG GGELTEDRVAH	IALVLLLAGFE/ MAFLLFIGGHET MAHILLVAGHET TLLLMISAGYET LAGPLQIGG.E/ LAVLLQIGG.E/ LAMGLLFAGLDS	ASVSLIGIGTY TTVNTLGNGTL TTVNLIANGMY TTVNVIDQAVH AVTHNVGQMLY	LLLTHPDQLALVR HLMRNLDQWEALR ALLSHPDQLAALR TLLTRPDQLALVR LLLTRREMARMR LLSRPELAERLR LLARPDQRAAL	RDPSALP ODRSLLP ADMTLL KGEVTWA ERPGARG SEPEIRP ADPDVMA.	NAVEDILRYI GAVEDILRYI CAVEDILRYE CAVEDILRYE DVVEDILRYI TADDILLRYI RAIDELLRYI RAIDELLRYI RAIDELLRYI	APPET.TTRFAAEE SPLKHA.TFRCATED GPVESA.TYRFPVEP PAVKHL.PLRYAVTD SHRTSVGLARIALED PHRNAVGLSRIALED PHRNAVGLSRIALED
TamI PikC CYP154A1 CYP158A1 CYP158A2 PimD Stap	LDIVERRTEPGDDIS GDIERKRRTPTDVVA SRIDSKRGDGEDIS DCITAAKRATPGDDMTS JCIVARAGSEGGDVYS SDIIGLRSDSAGEDVTS AGLVEBKRAEPGEDIS REVDRKGGDDRDDIS	ALIRVQDDDE ALVSARDVD ALVRTSDE.DC LLIAARDDEGDG MLGAAVGR LLGAAVGR LLURARDTG	GR LS ADE LTS DR LTETELVS SR LTSEELLO DR LSPEELRD GE VGETEAVC GE LTEDRVA GE LTEDRVA SP LSV DG LVG	IALVLLLAGFE/ MAFLLFIGGHET MAHILLVAGHET TLLLMISAGYET LAGPLGIGG.E/ LAVLLQIGG.E/ LAMGLLFAGLDS TCVHLLTAGHET	A S V S L I G I G T Y I T V N L G A G T L I T V N L I A A CMY. I T V N V I D O A V H A V T N N S G OMF H S V A S I M D A G V V I T T N F L A K A V L	LLLTHPDQLALVR HLMRNLDQWEALR ALLSHPDQLAALR TLLTRPDQLALVR LLLTRREMARMR LLSRPELAERLR LLARPDQRAAL	RDPSALP ODRSLLP ADMTLL KGEVTWA ERPGARG SEPEIRP ADPDVMA.	NAVEDILRYI GAVEDILRYI CAVEDILRYE CAVEDILRYE DVVEDILRYI TADDILLRYI RAIDELLRYI RAIDELLRYI RAIDELLRYI	APPET.TTRFAAEE SPLKHA.TFRCATED GPVESA.TYRFPVEP PAVKHL.PLRYAVTD SHRTSVGLARIALED PHRNAVGLSRIALED PHRNAVGLSRIALED
TamI PikC CYP154A1 CYP158A1 CYP158A2 PimD Stap CYP170A1	LDIVERRATEPGDDIS GDITERKARTPTDDVIA SRLIDSKRGQDGEDIS DCITAAKRATPGDDMIS STETVRARAGEEGDVYS SBLIGLRSDSAGEDVTS AGLVEHKRAEPGEDIS RREVDRRGGDDRDDLIT DEITAER.ASGCMPDDLI	ALINVQDDE ALVSARDVD ALVRTSDE.DC LLIAARDDEGDG MLGAAVGR LLGAAVGR LLVRARDTG ALLEAKDD.NG	CRESADELTS DRLTETELVS SRLTSEELLC CRLSPEELRD GEVGETEAVC DEITLSEAVG GELTEDRVAH SPLSVDGIVG DPIGEQEIHD	IALVLLLAGFE/ MAFLLFIGGHET TLLLMISAGYET LAGPLOIGG.2/ LAVLLQIGG.2/ LAVLLQIGG.2/ TCVHLLTAGHET OVVALLTPGSET	ASVSLIGIGTY TVNTLGNGTL TVNLLANGMY TVNVIDQAVH VIHNVGOMLY AVINNSGOMFH	LLITHPDQLALVR HLMRNLDQWEALR LLSHPDQLAALR LLITRPDQLALVR LLITRPELMARMR LLSRPELAERN LLAHPDQRAAL TLRAHRDVLDELR LAHPDQR	RDPSALP. QDRSILP. ADMTILD. KGEVTWA. ERPGARG. SEPEIRP. ADPDVMA. TTPESTP. DEVEAWTGGRPV.	NAVE FIRY I GAVE CIRLE CAVE MIRYE DVUE FIRE TALD LIRWI RAID LIRWI RAVE VIRTA AVE LIMWI VAFEDVRKIRTGNVIVE AMRLR	APPET.TTRFAAEE SPLKHA.TFRCATED GPVESA.TYRFPVEP PAVKHL.PLRYAVTD SHRTSVGLARIALED PHRNAVGLSRIALED PHRNAVGLSRIALED
TamI PikC CYP154A1 CYP158A1 CYP158A2 PimD Stap	LDIVERRTEPGODIS GDIERKRRTPTOVIA SRIJOSKRGOD.CEDIS DCIIAAKRATPGODNTS TETVRAGSE.CCDVYS SDIIGLRSDSAGEDVTS AGIVEHKRAEPGPDTIS REVORKGGDDRODIT DEIIAERR.ASGCKPDDIS	ALIRVQDDE ALVSARDVE ALVRTSDE.DC LIAARDDEGDC MLCAAVGR LLGAAVGR LLGAAVGR LLYRARDTG ALLEAKDD.NG LLCASVEG	GRLSADELTS DRLTSEELLC GEVGETEAVC GEVGETEAVC GEUGETEAVG GELTEDRVAN SPLSVDGIVG DPIGEQEIHD MALSOKDILA	IALVILLAGFE/ MAFLLFIGGHET TLLLMISAGYET LAGPLQIGG E/ LAVLLQIGG E/ LAVLLQIGG E/ LAVLLQIGG E/ LAVLLGIGG E/ LAVLLFAGLDS CVVALLTAGET	A S V S L I G I G T Y I T V N L G A G T L I T V N L I A A CMY. I T V N V I D O A V H A V T N N S G OMF H S V A S I M D A G V V I T T N F L A K A V L	LLITHPDQLALVR HLMRNLDQWEALR LLSHPDQLAALR LLITRPDQLALVR LLITRPELMARMR LLSRPELAERN LLAHPDQRAAL TLRAHRDVLDELR LAHPDQR	RDPSATP. QDRSITP. ADMTITD. KGEVTWA. ERPGARG. SEPEIRP. ADPDVWA. TTPESTP. DEVEAVTGGRPV. ADRSIVP.	NAVEDIRYI GAVEDIRYE CAVEDAIRYE DVVECIRHE TAIDILRWI RAIDILRWI RAVEUNRYA XAVEDWRYA XAFEDVRKIRIGNVIVGAAMELR RANDTIRYE	APPET.TTRFAAEE SPLKHA.TFRCATED GPVESA.TYRFPVEP PAVKHL.PLRYAVTD SHRTSVGLARIALED PHRNAVGLSRIALED PHRNAVGLSRIALED
TamI PikC CYP154A1 CYP158A1 CYP158A2 PimD Stap CYP170A1 CYP134A1 CYP121 WP 019889608.1	LDIVERRREPGODIS GDIERKREPTOVIA SRIJOSKEGOD.GEDIS DCIIAAKRATPGODNTS TETVRAGSE.GCDVTS SDIIGLRSDSAGEDVTS AGLVEHKRAEPGPDIS REVORRGGDDRODIS DETAERR.ASGCKPDIST	ALIRVQDDE ALVSARDVE ALVRTSDE.DC LIAARDDEGDC MLCAAVGR LLGAAVGR LLGAAVGR LLYRARDTG ALLEAKDD.NG LLCASVEG	CRESADELTS DRLTETELVS SRLTSEELLC CRLSPEELRD GEVGETEAVC DEITLSEAVG GELTEDRVAH SPLSVDGIVG DPIGEQEIHD	IALVILLAG BJ MARLIFIGGHET TLLMISAGHET LACPLOIGG EJ LACPLOIGG EJ LACPLOIGG EJ LACLUGIGG EJ LAVLLOIGG EJ LAVLLOIGG EJ LAVLLOIGG EJ LAVLLAG EJ VALLFAG EJ LILNVLLAG EJ LUNVLLAGES	NEVELECICTY TEVNILGNGTL TEVNILONCMY, TEVNILONCMY, NUTHNUCOMIY VINNSCOMEN SVASIMONGVU TETNFLAKAVL TASIMULQ PADKTLALMIY SCSFLITALI SESFLUTAVL	L LITHPD OTAL VR HIMRNDO OMEALR ALLSHDO LAALR ILSHDO LAALVR LLTRPDO LAALVR LLTRPE ALAR RR LLSREL AS R LR LLSREL AS R LR HALAO HDE RADRIR HLSNIER AD RIR HLLNIE OMN D'LL SLIQREQLENILLH ALQHEEL CYLR	RDPSALP. ODRSILP. ADMTILD. KGEVTWA. ERPGARG. SEPEIRP. ADPDVMA. TTPESTP. DEVEAVTGGRPV. ADRSIVP. EKFELP. EHPERMD.	NAVEDILRYI GAVEDILRYI CAVEDHIRYE CAVEDHIRYE TAIDILIRVI RAIDILRWI RAIDILRWI RAVEDVIRTA AVEDVIRTA RAVEDLRYI RAFEDVRKIRHIGNVIVEAMRIR RAIADILRYI RAVELLRYN	APPET.ITRFAAEE SPLEMA.IFRCATED GPVESA.TYRFPVEP PAVKHL.PLRYAVID PHRNAVGLSRIALED PHRNAVGLSRIALED PHRVAVGLSRIALED PPVVCA.VTRWAVED PAVWV.LTRRAVAE PAVWV.LTRRAVAE DPVVCL.IPRIACSD LSFADG.LPRIATED
TamI PikC CYP154A1 CYP158A2 PimD Stap CYP170A1 CYP134A1 CYP134A1 CYP1389608.1 WP_051841251.1	LDIVERRREPGDDIS GDIERKREPGDDIS SRIDSKEGDGEDIS DCITAAKRATPGDDMTS SDIGLRSDSAGEDVTS SDIGLRSDSAGEDVTS SCIGLRSDSAGEDVTS REVDRKGGDDRDDIT DEITAERR.AGGOKPDDIS MPVIKERVNPGSDIS AGILENPNITSING VERINAPPERESSIC	ALUR VODD. DE ALVERSV. L ALVERSV. L LURARDEGDG MLCARVGR. LLGAVGR. LLGAVGR. LLVERADT. G ALLLERDD. NG LLVERADT. G ALLLERDD. NG LLCTSEYE. C ELSRLERD. PAY ALARLERE FESS	GR LS A DELTS DR LTETELVS SR LTSEELLS GEVGETEAVC GEVGETEAVC GELTEDRVA SP LSVGIVG SP LSVGIVG SA LSOKDILA SHVSDELFAT AH LTDEMLAT	IAUVILLAGE BJ MARLLFIGGH BJ MARLLFIGGH BT TLLLMISAGY BE LACFLOICGEJ LAVILOICGEJ LAVILIFGGEJ LAVILIFGGEJ UVATLFGGEV UVVILLAGT LUVIFGGGV VAVILFGAGN MI	NEVELECICTY TEVNILGNGTL TEVNILGNGTU TEVNIGNGM VENNGGMEH VENNGGMEH SEASIMONGEV TENELAKAVL TENELAKAVL TENELAKAVL GEFLITALI SEESFLUDAVL	I LITHPO OTAL VR HUMRNID OMEALR ALLSHPO JAALR LLSHPO JAALVR LLIRREIMARMR LLSREIMARMR LLARPE AARD RAHPO ORAAAL TAAHPO ORAAAL LAHPE HAD VI SLIQHPE TOYLR ALLOHPE LGYLR ALLOHPE LGYLR	RDPSATP. QDRSILP. ADMTILD. KGEVTMA ERPGARC. SEPEIRP. ADPDVMA TTPSSTP. DEVEAVTGRPP. DEVEAVTGRPP. EKPELP. EKPERMC.	NAVE DIR YI GAVE DIR YI GAVE DIR YE CAVE DIR YE CAVE DIR YE TALDILLEWI RAVE DUR TA VAFEDVRITA RAVE DUR YD VAFEDVRLEHIGNVIV DAM RL RAGVE DLR YK AGVE DLR YN RAVE DLR WN AVD DLLR WN	APPET.ITRFAARE SPLKHA.IFRCATED GPVESA.TYRFPVEP PAVKHL.PLRTAVTD SHRTSVGLARIALED RAGGSVLPPRYASED PHRNAVGLSRIALED PAVWV.LTRRAVAE PAVWV.LTRRAVAE PAVWV.LTRRAVAE DPVQL.IFROMSCD LSFADG.LPRLATAD LSYCDG.LPRLAMAD
TamI PikC CYP154A1 CYP158A1 CYP158A2 PimD Stap CYP170A1 CYP134A1 CYP121 WP 019889608.1	LDIVERRREPGDDIS GDIERKREPGDDIS SRIDSKEGDGEDIS DCITAAKRATPGDDMTS SDIGLRSDSAGEDVTS SDIGLRSDSAGEDVTS SCIGLRSDSAGEDVTS REVDRKGGDDRDDIT DEITAERR.AGGOKPDDIS MPVIKERVNPGSDIS AGILENPNITSING VERINAPPERESSIC	ALUR VODD. DE ALVERSV. L ALVERSV. L LURARDEGDG MLCARVGR. LLGAVGR. LLGAVGR. LLVERADT. G ALLLERDD. NG LLVERADT. G ALLLERDD. NG LLCTSEYE. C ELSRLERD. PAY ALARLERE FESS	GR LS A DELTS DR LTETELVS SR LTSEELLS GEVGETEAVC GEVGETEAVC GELTEDRVA SP LSVGIVG SP LSVGIVG SA LSOKDILA SHVSDELFAT AH LTDEMLAT	IAU VILLAGE E/ MAR LIFIGGE E/ MAR LIFIGGE E/ LIFIGGE E/ LACELOIGGE E/ LACELOIGGE E/ LAVILOIGGE E/ LAVILOIGGE E/ LAVILOIGGE E/ LAVILOIGGE E/ LAVILOIGE E/ LAVILE E/ LAVILOIGE E/ LAVICE E/ LVICE E/ LVICE/	N S V S L S I G T Y T Y N T L G N G T L T Y N I L N N G M Y T Y N V I D O A V H V V T H N V S O M L Y S V A S I M D N G V Y T T N P L A K A V L C A S T I M U L Q. P A B K T L A L M I Y S T S P L Y L A V L S T S P L Y L A V L S T S P L Y L A V L S T S P L Y L A V L S T S P L Y L A V L S T S P L Y L A V L S T S P L Y L A V L	I LITHPO CIAL VR HIMRNID CMEALR ALLSHPO JIAALR LLSHPO JIAALVR LLITRPE MARMR LLSRPE MARMR LLSRPE MARMR LAAHPO CRAAAL TRAHPO RAAAL LAHPE HAD VI SLIQAPE CINNL LLNNPE OMND VI SLIQAPE LCYLR ALLQHPE LCYLR	RDPSATP. QDRSILP. ADMTILD. KGEVTMA ERPGARC. SEPEIRP. ADPDVMA TTPSSTP. DEVEAVTGRPP. DEVEAVTGRPP. EKPELP. EKPERMC.	NAVE DIRY I GAVE DIR LE CAVE MIRYE DVVE DIR LE TALD LIRVI RAID DILRVI RAID DIRWI RAID LIRVI AVE DUR TA AVE DUR TA RAIADIRYE RAIADIRYE RAIADIRYE RAIADIRYE RAVE DILRVN AVD DIRWN	APPET.ITRFAARE SPLKHA.IFRCATED GPVESA.TYRFPVEP PAVKHL.PLRTAVTD SHRTSVGLARIALED RAGGSVLPPRYASED PHRNAVGLSRIALED PAVWV.LTRRAVAE PAVWV.LTRRAVAE PAVWV.LTRRAVAE DPVQL.IFROMSCD LSFADG.LPRLATAD LSYCDG.LPRLAMAD
TamI PikC CYP154A1 CYP154BA1 CYP154BA2 PimD Stap CYP170A1 CYP134A1 CYP124 WP_051841251.1 WP_031150378.1	LDIVERRRTEPGDUIS GDIIERKRRTPTDVVIA SRLIDSKRGQDCEDIS DCLIAAKRATPGDDNTS TETVRARAGSEGDVVTS SBLIGLRSDSAGEDVTS ACLVENKRAEPGFDIG RREVDRRGGDDRDDILT DEIIAERR.ASGOKPDULT MPVTKERRVNPGSDIS AGINAPPERSGIL ACALNAPPERSGILG ADAFKAQLARTAEERTGILG SDOLRAQLALPAEERTGILG	ALIRVODD.DC ALVSARDVDC ALVSARDVDC LLIARDDEGDG MLGANVGRL LLGANGRD LLVRARDTG ALLEAKDDG ALLEAKDDG ALLEAKDDG ALLEAKDDG ALLEAKDDG ALANLKEE.KES KFACLKEADFES KFACLKEADFES	GRLSADELTS DRLTETELVS SRLTSEELS DRLSPEELS GEVGETEVC GEVGETEVC GEVGETAVC GEVGETAVC SPUSVDGIVG SPUSVDGIVG SHUSDELFAT AHLTDEMFAT	IAL VILLAGE 2/ MAR LIFIGG 2/ MAR LIFIGG 2/ ILL MISAGY2 LLAFIQIGG 2/ LAVILOIGG 2/ LAVILOIGG 2/ LAVILOIGG 2/ LAVILOIGG 2/ CVHLITAGE 2/ CVHLITAGE 2/ CVHLITAGE 2/ CVHLITAGE 2/ VAVILFG AGAV2 VAVILFG AGAV2 VAVILFG AGAV2	N S V S LIC I CT Y           C Y N I LG N GT L           C Y N I LG N GT L           C Y N I D O A VH           V T D V D O A VH           V T D N S G OM L           V Y N N S G OM L           V Y N N S G OM L           V T D A X H           V T D A X H           V T D A X H           V T D A X H           V T N S G OM L           V T N L A KA V L           C T N F LA KA V L           C T S F L X L M Y           S T S F L V L A V L           S T S F L V L A V L           S T S F L V L A V L           S T S F L V L A V L	L LTHPD OTAL VR HIMRNID OMBALR ALSHDOIAALR TLLTRPOIAALVR LLTRPOIAALVR LLTRPOIAAVR LLTRPOIAAVR LLTRPOIAAVR LLTRPOIAARL ALANHOVIORAAL TLAHHOVIORAAL LAOHPEHADRIR HLLNNEGANNOVIDELT SLIQRPOLNNLLH ALLQRPELTGYLR ALQREELTGYLR	RDP SATP ODRSITP ADMTITD KSEVTMA ERPGARG SEPEIRP DEVEAVTGGRP ADPSIVP DEVEAVTGGRP ADPSIVP EKPEIRP EHPERMG EHPERMG	NAVEDILRYI GAVEDILRYI CAVEDHIRYE CAVEDHIRYE TAIDDILRWI RAIDDILRWI RAIDDILRWI RAIDDILRWI RAIDDILRWI RAIDDILRWN RAIADILRYN RAIADIRYK RAIADIRYK RAIADIRYK RAIADIRYK RAIADIRYK RAIADIRYK RAIADIRYK RAIADIRYK RAIADIRYK RAVDILRWN AAVDILRWN AAVDILRWN	APPET.ITRFAAFE SPLEMA.IFRCATED GPVESA.TYRFPVPP PAVKHL.PLRYAVTD PHRNAVGLSRIALED PHRNAVGLSRIALED PHRVAV.LTRRAVAE PPVQL.VTRWAYED PPVQL.IFRCASC LSFADG.LPRIACED LSVGDG.LPRIACED LSVGDG.LPRIALAD
TamI PikC CYP154A1 CYP158A2 PimD Stap CYP170A1 CYP134A1 CYP124A1 CYP124A1 CYP124A1 CYP124A1 CYP124A1 CYP124A1 CYP124A1 CYP124A1 CYP134A1 CYP134A1 CYP134A1 CYP134A1 CYP134A1 CYP154A1 CY	LDIVERRRTEPGODIS GDIERKRRTPJODVIA SRLIDSKRGQDCEDIS DCIEAKRATPGODNTS IFTVRARAGSEGEDVTS SDLIGLRSDSAGEDVTS AGLVEHKRAEPGPDIS REVDRKGGDDRDDIS AGLVEHKRAEPGPDIS SAGLINAPPERS GDIC ADAFKAQLARTAEERS GIG SDQIRAQLALPAEERS GIG	ALUR VODD. DE ALUSARDV. DE ALUSARDV. DE LURARDEGDG MLCARVGR. DE LLURARDT. G ALLEAKDD. NG LLURARDT. G ALLEAKDD. NG ELSRURKD. FAY ALANDREE. RES KFACLREADPES 320 33	GR LS A DELTS DR LTE TELVS SR LTS EELRUS SR LTS EELRUS DR LS PEELRUS DE ITLSEAVS GE LTEDRVAH SP LSVDGIVG ODP IGE QEI HD NA LSDKDIJAA SH VTDELFAT AH LTDDMFAT	IAL VILLAGE 2/ MAR LIFIGG 2/ TILLIFIGG 2/ TILLIMISAGY2 LANG LIFIGG 2/ LANG LIFIGG 2/ LANG LIFIGG 2/ LANG LIFIGG 2/ LANG LIFIGG 2/ 20VA LIFIG 2/ 20VA LIFIG 2/ 20VA LIFIGAGAV2 20VA LIFIGAGAV2 VANC LIFIGAGAV2 VANC LIFIGAGAV2	Caso	L LITPD OLAIVR HIMKNID OMEALR ALLSHDOIAALR ILSHDOIAALR LLSHDOIAALVR LLITRE OALAVR LLITRE MARME LLSRPELAZER LLSRPELAZER LLSRPELAZER LLSRPELAZER LSRPELS LSPELRI LLSPELRI LLSPELRI LLSPELRI LLSPELRI LLSPELRY LLSPELS	RDPSATP. QDRSILP. ADMTILD. KGEVTWA ERPGARG. SEPEIRP. ADPDVMA TTPSSTP. DEVEAVTGRA. DEVEAVTGRA. BHPEND. EHPERMG. EHPERMG.	NAVE DILT Y I GAVE DITT GAVE DITT CAVE MIRYE CAVE MIRYE CAVE MIRYE DVVE DITTE TALD DITT NATO TALD DITTE RAVE DUTTE RAVE DUTTE RAVE DUTTE RAVE DITTE RAVE D	APPET.ITRFAAE SPLKHA.IFRCATED GPVESA.TYRFPVEP PAVKHL.PLRYAVTD PHRNAVGLSRIALED PHRNAVGLSRIALED PHRNAVGLSRIALED PAVWV.LTRRAVAE PPVQA.VTRNAVED PAVWV.LTRRAVAE DPVQL.IRROLSGD LSFADG.LPRIALED LSVGDG.LPRIALED SOO
TamI PikC CYP154A1 CYP158A2 PimD Stap CYP170A1 CYP134A1 CYP121 WP_051841251.1 WP_031150378.1 : eryF	LDIVERRTEPGDIIS GDIIERKRETPTDVIA SRIDSKRGDDGEDIIS DDIIAAKRATPGDINTS DDIIAKRACSEGEVYS SDIIGLRSDSAGEVYS SDIIGLRSDSAGEVYS SGIIGLRSDSAGEVYS AGUVEKRACPGPDIIS AGUVEKRACPGDIIS AGUIENPNITSING VURELNAPPERSGIC ADAFAAQLARTAERTGIG SDOIRAQLALPAEERTGIG SDOIRAQLALPAEERTGIG SOO 310 VEIGGVANPENSIVVAANG	ALIRVODD. DE ALVERDV. DE ALVERDV. DE LLARDDEGDE MLCARVGR LLARDDEGDE MLCARVGR LLARDDEGDE MLCARVGR LLARDD. NG LLVERRED. NG LLESLERED. NG LLESLERED. NG LSLERED. NG KEACLREADFES KEACLREADFES S20 33 ANRDEKOFPDE	GR LS ADELTS DR LTETELVS SR LTSEELLG GEVGETEAVC DE IT LSEAVC GE LTEDRVAN MALSOKDILA SHVSDELFAT AHLTDEMFAT AHLTDEMFAT AHLTDEMFAT	IALVILLAGE B/ MARLLFIGGHEY MARLLFIGGHEY LAGPLQICG B/ LAGPLQICG B/ LAVLLQICG B/ LAVLLQICG B/ LAVCLLFAGLDE QUVATLTPGCEY QUVATLTPGCEY QUVATLTPGCEY QUVATLFGAGAV VAVCLFGAGAV VAVCLFGAGAV VAVCLFGAGAV VAVCLFGAGAV	NEVELECICTY TEVNILGNGTL TEVNILGNGTU TEVNILGNGTU TEVNIDOAVH VEINNSOMLY SUNSIMONGVV TETNFLAKAVL TENFLAKAVL TENFLAKAVL SESFLYLAVL SESFLYLAVL SESFLYLAVL	I LITHPO OTAL VR HUMRNIDO MEALR ALLSHPO OTAALVR ILLTRPO OTAALVR ILLTRPE IMARMR ILLSRPE IMARMR ILLSRPE IMARMR ILLSRPE MNDVI SUORPO INNI VI SUORPO INNI VI SUORPO INNI VI SUORPO INNI VI SUORPO INNI VI SOO MGREMAKTEGE VA	RDPSATP. QDRSIP ADMTID KGEVTMA ERFGARC. SEPEIRP ADPDVMA TTPESTP DEVEAWTGGRP EKFELP EKFELP EKFELP EKFELP EKFENG EKFENG EKFENG TRATIORFPAN	NAVE DELRY I GAVE SE LR LE CAVE MIRYE CAVE MIRYE CAVE DILRWI RADDLLRWI RADDLLRWI RAVE DURYD VAFEDVRLRHTGNVIVFAMRLRY RAVE DLRWN AGVE DLRWN AAVD DLLRWN AAVD DLLRWN AAVD DLLRWN AAVD DLLRWN AAVD DLLRWN AAVD DLLRWN AAVD DLLRWN AAVD DLLRWN	APPET. TTRFAAFE SPLKHA. IFRCATED GPVESA. TYRFPVEP PAVKHL, PLRYAVTD SHRTSVGLARIALED RAGGSVLPPRYASED PHRNAVGLSRIALED RAGGSVLPPRYASED PPVQA. VRWAYED DPVQA. VRWAYED DAVWV. LTRRAVAE PPVQL. IPROLSCD LSFADG. LPRLAAAD LSVGDG. LPRLAAD LSVGDG. LPRLAAD
TamI PikC CYP154A1 CYP156A2 PimD Stap CYP170A1 CYP134A1 CYP134A1 CYP134A1 CYP124A1 CYP124A1 CYP124A1 CYP124A1 CYP134A1 CYP134A1 CYP134A1 CYP134A1 CYP134A1 CYP134A1 CYP154A1 CY	LDIVERRRTEPGDDIS GDIERKRRTPTDVVIA SRLIDSKRGDDGEDIS DCIIAAKRATPGDDNTS TFTVRAGSEGDVYS SDIIGLRSDSAGEDVTS AGLVEHKRAEPGPDIS REVDRRGGDDRDDIS REVDRRGGDDRDDIS MELLNAPPERSOIC AGLYNAPPERSOIC AGAFKAQLARTAEERTGIG SDQJRAQLAETAEERTGIG SDQJRAQLAETAEERTGIG GDQJSIQ VEL.GGVAIPCYSTVIVARG	ALUR VODD. DE ALUSARDV. DE ALUSARDV. L LURARDDEGDG LLIARDDEGDG LLIARDDEGG LURARDT. G ALLDARDD. NG LURARDT. G ALLDARDD. NG LURARDT. G ALLDARDD. NG LURARDT. G ALLDARDD. NG LANDARE. REG KEAOLKEADPES SAN VDE KED C SP C SP C SP C SP C SP C SP C SP C SP	GR LS ADELTS DR LTETELVS SR LTSEELLS CS VETEDAVC DE ITLSEAVS DE ITLSEAVS DE ITLSEAVS DE ITLSEAVS DE ITLSEAVS DE ITLSEAVS HETDENEAT AH LTDENEAT AH LTDENEAT HETEDVTRD HRFDVTRD	IAL VILLAGE B/ MARILIFIGGHET MARILIFIGGHET ILLIMISAGYET LANGILIFIGGE LANGLIFIGGE LANGLIFIGGE LANGLIFIGGE LANGLIFIGGE LANGLIFIG VINCIFIGAGNE VINCIFIGAGNE VANCIFIGAGNE VANCIFIGAGNE VANCIFIGAGNE VANCIFIGAGNE	VENELO ICTY TENTIGNET TENTIGNET TENTIGNET TENTIGNET VENELOSOMIY VENESOMIY VENESOMIY VENESOMIY VENESOMIY VENESTINNLO SESFIVIAVI SESFIVIAVI SESFIVIAVI SESFIVIAVI SESFIVIAVI SESFIVIAVI	L LLTPPD OLAL VR HIMKNIDO MEALR ALLSPPD OLAALVR ILLTRPD OLALVR ILLTRPD OLALVR ILLTRPE AR BR ILLSRPEL MARMR ILLSRPE MARAAL ILANPPO NAAAL ILANPPO NAAAL ILANPE HADVIDELR ALADHPE HADVIDELR ILNIVE OMN DVI ILLNIVE OMN DVI ILLNIVE OMN DVI ILLNIVE OMN DVI ILLORPEL IGY LR ALLORPEL IGY LR ALLORPEL IGY LR G RE LAKLEGE VA	RDPSATP. QDRSTP ADMTILD. KGEVTMA KGEVTMA ERPGARC. SEPEIP ADFDIMA TTPESTP. DEVEAVTGRP DEVEAVTGRP EKPELTP. EHPERMG. EHPERMG. STO STO STO	NAVE DILLY I GAVE DILLY I GAVE DILLY I CAVE MILTYE DVVE DILLY I RAIDELLY I RAVE DULLY I RESEARCH I	APPET.ITRFAAEE SPLEMA.IFRCATED GPVESA.TYRFPVEP PAVKHL.PLRYAVTD PHRNAVGLSRIALED PHRNAVGLSRIALED PHRNAVGLSRIALED PHVQA.VTRNAVED PAVWV.LTRRAVAE PAVWV.LTRRAVAE DSVGDG.LPRIALAD LSVGDG.LPRIALAD LSVGDG.LPRIALAD
TamI PikC CYP154A1 CYP158A2 PimD Stap CYP170A1 CYP170A1 CYP121 WP_019889608.1 WP_051841251.1 WP_031150378.1 eryF TamI PikC	LDIVERRTEPGDIIS GDIIERKRETPTDVIA SRIDSKRGDDGEDIIS DDIIAAKRATPGDINTS DDIIAKRACSEGEVYS SDIIGLRSDSAGEVYS SDIIGLRSDSAGEVYS SGIIGLRSDSAGEVYS AGUVEKRACPGPDIIS AGUVEKRACPGDIIS AGUIENPNITSING VURELNAPPERSGIC ADAFAAQLARTAERTGIG SDOIRAQLALPAEERTGIG SDOIRAQLALPAEERTGIG SOO 310 VEIGGVANPENSIVVAANG	ALUR VODD. DE ALUSARDV. DE ALUSARDV. L LURARDDEGDG LLIARDDEGDG LLIARDDEGG LURARDT. G ALLDARDD. NG LURARDT. G ALLDARDD. NG LURARDT. G ALLDARDD. NG LURARDT. G ALLDARDD. NG LANDARE. REG KEAOLKEADPES SAN VDE KED C SP C SP C SP C SP C SP C SP C SP C SP	GR LS ADELTS DR LTE TELVS SR LTS EELLS DR LS PEELRO CEVGE TELVS GE LTE DAVC ODE IT LSE AVC GE LTE DEVIN MA LSO KOILA SH VS DE LFAT AH LTD EMFAT AH LTD EMFAT HET DOW FR HER DV TR DH REDV	IAL VILLAGE E/ MARLIFIGGE MARLIFIGGE ILLFIGGE ILLAGELOIGGE LAVILOIGGE LAVILOIGGE LAVILOIGGE LAVILOIGGE LAVILOIGGE LAVILOIGGE LAVILOIGGE UVA ILFGGG VIX VAVILFGGGA VIX VAVILFGGGA VAVILFGGGA VAVILFGGGA VAVILFGGGA VAVILFGGGA VAVILFGGGA VAVILFGGGA VAVILFGGGA VAVILFGGGA VAVILFGGGA VAVILFGGGA	NEVELECICTY TEVNILGNGTL TEVNILGNGTU TEVNILGNGMU TEVNICOMUY SUNSIMONGVU TENFIASVC ABETIMMLIO ABETIALMIY STERFULAVL STERFULAVL STERFULAVL STERFULAVL	L LITHPO OTAL VR HUMRNIDO MEALR ALLSHPO JAALR TLLIRPO JAALR LLSHPO JAALR LLSRPE MARMR LLSRPE MARMR LLSRPE MARMR LAAHPO ORAAAL TRAHPO ORAAAL SLIDHPE HID VID ELR SLIDHPE IS VID LLNNE OM DVID LLNNE OM DVID LLNNE OM DVID LLNNE OM DVID SLIDHPE IS VID SGO SGO	RDPSATP. QDRSTP ADMTILD. KGEVTMA ERPGARC. SEPEIRP. ADPDVMA TTPESTP. DEVEAVTGRPC. ERPERV EKPELP. EKPELP. EHPERMG. EHPERMG. EHPERMG. EHPERMG. EHPERMG. EHPERMG.	NAVE DILLY I GAVE DILLY I GAVE DILLY I CAVE MILTYE DVVE DILLY I RAIDELLY I RAVE DULLY I RESEARCH I	APPET.ITRFAARE SPLKHA.IFRCATED GPVESA.TYRFPVEP PAVKHL.PLRTAVTD SHRTSVGLARIALED RAGGSVLPPRYASED PHRNAVGLSRIALED RAGGSVLPPRYASED PHYOA.VTRMAVED PAVWV.LTRRAVAE PPVQL.IFRQLSCD LSFADG.LPRLATAD LSVGDG.LPRLATAD LSVGDG.LPRLATAD
TamI PikC CYP154A1 CYP154A1 CYP156A2 PimD Stap CYP170A1 CYP134A1 CYP134A1 CYP134A1 CYP134A1 CYP134A1 CYP134A1 CYP154A1 WP_051841251.1 WP_051841251.1 WP_031150378.1 : eryF TamI PikC CYP154A1	LDIVERRRTEPGDDIS GDIERKRRTPTDVVIA SRLIDSKRGDDGEDIS DCIIAAKRATPGDDNTS TFTVRAGSEGDVYS SDIIGLRSDSAGEDVTS AGLVEHKRAEPGPDIS REVDRRGGDDRDDIS REVDRRGGDDRDDIS MELLNAPPERSOIC AGLYNAPPERSOIC AGAFKAQLARTAEERTGIG SDQJRAQLAETAEERTGIG SDQJRAQLAETAEERTGIG GDQJSIQ VEL.GGVAIPCYSTVIVARG	ALUR VODD. DE ALUSARDV. DE ALUSARDV. L LURARDDEGDG LLIARDDEGDG LLIARDDEGG LURARDT. G ALLDARDD. NG LURARDT. G ALLDARDD. NG LURARDT. G ALLDARDD. NG LURARDT. G ALLDARDD. NG LANDARE. REG KEAOLKEADPES SAN VDE KED C SP C SP C SP C SP C SP C SP C SP C SP	GR LS A DELTS DR LTE TELVS SR LTS EELS CS LTS EELS GE VE EELS GE LTE DR VAH GE LTE DR VAH ALS DE LFAT AH LTD EMFAT AH LTD EMFAT HT D VIRD HRFDVIRD HRFDVIRD HRFDIRRD DTFDAR	IAL VILLAGE B/ MARILIFIGGHE MARILIFIGGHE ILLFIGGHE ILLAGELOIGGE/ LAVILIGIGGE/ LAVILIGIGGE/ LAVILIGIGGE/ LAVILIGIGGE/ LAVILIGGE/ LAVILIFGGE/ UVATILITAGHE OVVAILITAGE/ VAVILIFGAGAVE VAVILIFGAGAVE VAVILIFGAGAVE VAVILIFGAGAVE VAVILIFGAGAVE VAVILIFGAGAVE VAVILIFGAGAVE VAVILIFGAGAVE VAVILIFGAGAVE VAVILIFGAGAVE VAVILIFGAGAVE VAVILIFGAGAVE VAVILIFGAGAVE VAVILIFGAGAVE VAVILIFGAGAVE VAVILIFGAGAVE VAVILIFGAGAVE VAVILIFGAGAVE	VSUSICIST TUNISGOT TUNISGOT TUNISGOMEH VUENCOMU VUENCOMU VUENCOMU VUENCOMU VUENCOMU VUENCOMU VUENCOMU VUENCOMU VENCOU STOPICATAL STOPICA STOPICA VIENCA STOPICA VIENCO STOPICA VIENCO STOPICA STOPICA VIENCO STOPICA VIENCO STOPICA ST	L LITPED OLAL VR HIMKNIDO MEALR ALLSHED OLAALR TLITRED OLAALVR LLTRED OLAALVR LLTRED OLAALVR LLTREE AR RR LLSREL AR RR LLSREL AR RR LAAHED VIDELAR LAAHED VIDELAR LAAHED VIDELAR LAAHED VIDELAR LANE OMN DVI LANE OMN DVI LLNNE OMN DVI LLNNE LOY LR ALLQREL IGY LR ALLQREL IGY LR ALLQRE IGY LR GAELAR EGE VA GAELAR EGE VA IGAELAR EAR IA	RDPSATP. QDRSTP. ADMTILD. KGEVTMA. ERPGARC. ERPGARC. ERPETP. DEVEAVTGGRP ADFSIV. HPEENG. HPEENG. HPEENG. HPEENG. HPEENG. HPEENG. HPEENG. HPEENG. HPEENG. HPEENG. HPEENG. HPEENG.	NAVE DIN GAVE DIN GAVE DIN CAVE MIRYE CAVE MIRYE TAID DIN RAID DIN RAID DIN RAID DIN RAID DIN RAID DIN RAID DIN RAID DIN RAID DIN RAID DIN RAVE DUN RAID DIN RAVE DIN	APPET.ITRFAAEE SPLEMA.IFRCATED GPVESA.TYRFPVEP PAVKHL.PLRYAVTD PHRNAVGLSRIALED PHRNAVGLSRIALED PHRNAVGLSRIALED PHVQA.VTRNAVED PAVWV.LTRRAVAE PAVWV.LTRRAVAE DSVGDG.LPRIALAD LSVGDG.LPRIALAD LSVGDG.LPRIALAD
TamI PikC CYP154A1 CYP158A2 PimD Stap CYP170A1 CYP170A1 CYP121 WP_019889608.1 WP_051841251.1 WP_031150378.1 eryF TamI PikC	LDIVERRRTEPGDDIS GDIERKRRTPTDVVIA SRLIDSKRGDDGEDIS DCIIAAKRATPGDDNTS TFTVRAGSEGDVYS SDIIGLRSDSAGEDVTS AGLVEHKRAEPGPDIS REVDRRGGDDRDDIS REVDRRGGDDRDDIS MELLNAPPERSOIC AGLYNAPPERSOIC AGAFKAQLARTAEERTGIG SDQJRAQLAETAEERTGIG SDQJRAQLAETAEERTGIG GDQJSIQ VEL.GGVAIPCYSTVIVARG	ALUR VODD. DE ALUSARDV. DE ALUSARDV. L LURARDDEGDG LLIARDDEGDG LLIARDDEGG LURARDT. G ALLDARDD. NG LURARDT. G ALLDARDD. NG LURARDT. G ALLDARDD. NG LURARDT. G ALLDARDD. NG LANDARE. REG KEAOLKEADPES SAN VDE KED C SP C SP C SP C SP C SP C SP C SP C SP	GR LS A DELTS DR LTETELVS SR LTS EELS CS LTS EELS CS VG EVG EVG DE IT LSEAVS OD IT LSEAVS SD VD GIVG DV GEVG EVA HIS VD GIVG NALSOVED IA SH VTO ELFAT A H LT DEMFAT OHRFDV TR HRFDV TR HRFDV RP HRFDIRRD DTFDATT	IAL VILLAG FE/ MAR LIFIGG HE/ MAR ILIFIGG HE/ ILIMISAGYE ILIMISAGYE ILIMISAGYE ILIMISAGYE ILAFIQIGG E/ ILAFIQIGG E/ ILAFIQIG ILAF	VSIICICTY TYNIIGNGTL TYNIIGNGTL TYNIIGOAVH VYHNYSOMIY VYHNYSOMIY VYNNSOMIY VYNNSOMIY VYNNSOMIY VYNNSOMIY VYNNSSOMIY VYNNSSOMIY VYNNSSOMIY VYNNSSOMIY VYNNSSOMIY VYNNSSOMIY VYNNSSOMIY STAFIY VANTUAVL STAFIY VANTUAVL STAFIY VANTGGCIHFC HAAFGGCIHFC HAAFGGCHFPC	L LITPED OTAL VR HIMRNIDO MEALR ALISHEDO IAALR TILITREDO IAALVR ILITREDO IAALVR ILITREDO IAALVR ILITREDO IAALVR ILITREL AR RIP ILINREL AR RIP ILINRE AND VIDELR ALAO HERADI I DELR ALAO HERADI I DELR I DARIA I DELRI I DELR I DARI I DARI I DELRI I DELRI I I DARI DARI I DELRI I DELLI	RDPSATP. ODRSTP. ADMTILD. KGEVTWA KGEVTWA ERPGARC. SEPEIRP. ADPDVMA TTPESTP. DEVEAVTGRP. EKPEIRP. EKPEIRP. EKPEIRO. EHPERMG. EHPERMG. EHPERMG. EKPEICERPAL STO URALE RCPOLA V RALERCPOLA LESECRPOLA	NAVE DITY GAVE DITY GAVE DITY CAVE MIRYE CAVE MIRYE CAVE MIRYE TALDZLIRWI RAID DITW RAVE DURYD VAFEDVRIAMRYE RAVE DURYD RAVE DITY RAVE D	APPET.ITRFAAEE SPLENAAIFRCATED GPVESAITYRFPVEP PAVKHL.PLRYAVTD PHRNAVGLSRIALED PHRNAVGLSRIALED PHRAVGUSRIALED PPVVV.LTRRAVAE PAVWV.LTRRAVAE DPVVV.LTRRAVAE LSVGDG.LPRIALED LSVGDG.LPRIALED LSVGDG.LPRIALED LSVGDG.LPRIALED SVGDG.LPRIALED SVGDG.LPRIALED SVGDG.LPRIALED VRLNRP.ASSA
TamI PikC CYP154A1 CYP158A2 PimD Stap CYP170A1 CYP170A1 CYP170A1 CYP124A1 CYP121 WP_019889608.1 WP_051841251.1 WP_031150378.1 eryF TamI PikC CYP154A1 CYP156A1	LDIVERRRTEPGDDIS GDIERKRRTPTDVVIA SRLIDSKRGDDGEDIS DCIIAAKRATPGDDNTS TFTVRAGSEGDVYS SDIIGLRSDSAGEDVTS AGLVEHKRAEPGPDIS REVDRRGGDDRDDIS REVDRRGGDDRDDIS MELLNAPPERSOIC AGLYNAPPERSOIC AGAFKAQLARTAEERTGIG SDQJRAQLAETAEERTGIG SDQJRAQLAETAEERTGIG GDQJSIQ VEL.GGVAIPCYSTVIVARG	ALIR VOLD. DE ALVARSV. DE ALVARSV. DE LURARDEGDE LLIARDDEGDE LLIARDDEGDE LLIARDDEGDE LLIARDDEGDE LLIARDE. DE LLIARDE. DE LLICISEVE. C LLICISEVE. C L	GR LS A DELTS DR LTE TELVS SR LTS EELRO DE LS PEELRO DE LTEDRVA SP LS VOGIVG ODE LTEDRVA SH VS DELFAT A H LTD EMFAT A H LTD EMFAT H TD VTRD H RFDVTRD HRFDIRRD HRFDIRRD DTFDATRT. SH STDARRA	IAL VILLAGE 2/ MAR LIFIGG 2/ MAR LIFIGG 2/ TILLM SAGYE ILLAG 1GG 2/ LAV LLOIGG 2/ LAV LLOIGG 2/ LAV LLOIGG 2/ LAV LLOIGG 2/ LAV LLAG 2/ CVALLAGE 2/ VAV LFG 4/ VAV 1/ FG 4/ FG 4/ VAV 1/ FG 4/ FG 4/ FG 4/ FG 4/ FG 4/ FG 4/ FG 4/	VSIICICTY TYNIIGNGTL TYNIIGNGTL TYNIIGOAVH VYNNSGOMIH VYNNSGOMIH VYNNSGOMIH VYNNSGOMIH VYNNSGOMIH VYNNSGOMIH VYNNSGOMIH VYNNSGOMIH VYNNSGOMIH VYNNSGOMIH STEFFI STEFFI VANTUAVL STEFFI STEFFI VANTUAVL STEFFI VANTGGCIHFC HAAFGGCIHFC HAAFGGCHFFC	L LITHPD OLAL VR HUMRNDOOMEALR ALLSHDOIAALR ILSHDOIAALR LLSHDOIAALVR LLITREDOIAALVR LLITRELMARMR LLSRPELAZRARM LLSRPELAZRARM LLSRPELAZRARM LLSRPELST SLOPPELST SLOPPELST SCO SCO SCO SCO SCO SCO SCO SCO SCO SCO	RDPSATP ODRSTP ADMTILD KSEVTMA ERFGARG SEPEIR POVENTGRP DEVEAVTGGRP DEVEAVTGGRP DEVEAVTGGRP ENPERMG ENPERMG ENPERMG SCVLDGRPAN ENPERMG ENPERMG SCVLDGRPAN ENPERMG ULSIGRPAN USAUDORFD	NAVE DILRYI GAVE DILRYI CAVE MIRYE CAVE MIRYE CAVE MIRYE TALDELLRWI RAIDELLRWI RAVE DURYA VAFEDVRKIRIGNVIV AAMRLR RAVE DURYA RAVE DURYA RAVE DURY RAVE DILRWN RAVE RE RAVE RAVE RE RE RAVE RAVE RE	APPET.ITRFAAEE SPLEMA.IFRCATED GPVESA.TYRFPVEP PAVKHL,PLRYAVTD SHRTSVGLARIALED RAGGSVLPPRYASED PHENAVGLSRIALED PAVWV.LTRRAVAE PPVGA.VTRMAVED PAVWV.LTRRAVAE DSVGDG.LPRIALAD LSVGDG.LPRIALAD LSVGDG.LPRIALAD CO PVRLDG.
TamI PikC CYP154A1 CYP154A1 CYP154A2 PimD Stap CYP170A1 CYP134A1 CYP124A1 CYP124A1 WP_051841251.1 WP_03150378.1 eryF TamI PikC CYP154A1 CYP154A1 CYP154A1 CYP154A2 PimD Stap Stap	LDIVERRRTEPGDDIS GDIERKRRTPTDVIA SRLIDSKRCDDCEDIS DCLIAAKRATPGDDNTS TFVRARAGSE.CGDVYS SDLIGLRSDSAGEDVTS ACLVENKRAEPGFDIG REVDRRGGDDRDDIS DPVIKERRNPGSDIS ACLINAPPERS GDIG ADAFKAQLAETAEERTGLIG SDO 310 VERINAPPERS GDIG ADAFKAQLAETAEERTGLIG SDO 310 VERINAPPERS GDIG ADAFKAQLAETAEERTGLIG SDO 310 VERINAPPERS GDIG ADAFKAQLAETAEERTGLIG SDO 310 VERI	ALIR VOLD. DE ALVARSV. DE ALVARSV. DE LURARDEGDE LLIARDDEGDE LLIARDDEGDE LLIARDDEGDE LLIARDDEGDE LLIARDE. DE LLIARDE. DE LLICISEVE. C LLICISEVE. C L	GR LS A DELTS DR LTETELVS SR LTS EELSUS SR LTS EELSUS DR LS PEELSUS GE VE DUGIVG GE VE DUGIVG SP US VDGIVG MALSOKDIDA AH LTOEMFAT AH LTOEMFAT HEREDIRRO HREDIRRD DTEDART DRIDLORD DRIDLRS EEFDART	IAL VILLAG FE/ MAPLLFIGG HE/ MAPLLFIGG HE/ TILLMISAGYE/ ILLMISAGYE/ LAVIUGIGG E/ LAVIUGIGG E/ LAVIUGIGG E/ LAVIUGIGG E/ LAVIUGIGG E/ CVHLITAGHE/ CVVALIFGGOY VAVGLFGAGYE/ VAVGLFGAGAYE VAVGLFGAGAYE VAVGLFGAGAYE VAVGLFGAGAYE VAVGLFGAGAYE VAVGLFGAGAYE VAVGLFGAGYE VE	VSUSIT TUNISONGTU TUNISONGTU TUNISONGTU TUNUSONU VIENVSOMU VIENVSO	L LITHPD OTAL VR HIMRNID OMEALR ALSHDOIAALR ILSHDOIAALVR LLTRDOIAALVR LLTRDOIAAVR LLTRDOIAAVR LLTRPOIAR LLTRREAM LLTRREAM LANDVIDELAR LANDVIDELAR LANDVIDELAR LANDVIDELAR LANDVIDELAR LANDVIDELAR LORPELIGYLR ALLORELIGYLR ALLORELIGYLR ALLORELIGYLR LGAPLARLARIA LGAPLARMOTELL GAPLARMOTELL GAPLARMOTELL GAPLARLESELIGYLR	RDPSATP ODRSTIP ADMTILD KSEVTMA SEPEAR SEPEAR SEPEAR SEPEAR SEPEAR SEPEAR SEPEAR SEPEAR SEPEAR SEPERA SEPERA SEPEAR SEPERA SE	NAVE DIN GAVE DIN GAVE DIN CAVE MINYE CAVE MINYE CAVE MINYE CAVE MINYE CAVE MINYE CAVE MINYE RAID DIN RAID DIN RAID DIN RAID DIN RAID DIN RAVE DIN	APPET.ITRFAAEE SPLEMA.IFRCATED GPVESA.TYRFPVEP PAVKHL,PLRYAVTD SHRTSVGLARIALED RAGGSVLPPRYASED PHENAVGLSRIALED PAVWV.LTRRAVAE PPVGA.VTRMAVED PAVWV.LTRRAVAE DSVGDG.LPRIALAD LSVGDG.LPRIALAD LSVGDG.LPRIALAD CO PVRLDG.
TamI PikC CYP154A1 CYP158A2 PimD Stap CYP170A1 CYP134A1 CYP134A1 CYP124 WP_05184251.1 WP_051841251.1 WP_031150378.1 : eryF TamI PikC CYP156A1 CYP156A1 CYP156A2 PimD Stap CYP170A1	LDIVERRRTEPGDDIS GDIERKRRTPTDVIA SRLIDSKRCDDCEDIS DCLIAAKRATPGDDNTS TFVRARAGSE.CGDVYS SDLIGLRSDSAGEDVTS ACLVENKRAEPGFDIG REVDRRGGDDRDDIS DPVIKERRNPGSDIS ACLINAPPERS GDIG ADAFKAQLAETAEERTGLIG SDO 310 VERINAPPERS GDIG ADAFKAQLAETAEERTGLIG SDO 310 VERINAPPERS GDIG ADAFKAQLAETAEERTGLIG SDO 310 VERINAPPERS GDIG ADAFKAQLAETAEERTGLIG SDO 310 VERI	ALIR VOLD. DE ALVARSV. DE ALVARSV. DE LURARDEGDE LLIARDDEGDE LLIARDDEGDE LLIARDDEGDE LLIARDDEGDE LLIARDE. DE LLIARDE. DE LLICISEVE. C LLICISEVE. C L	GR LS A DELTS DR LTETELVS SR LTS EELSUS SR LTS EELSUS DR LS PEELSUS GE VE DUGIVG GE VE DUGIVG SP US VDGIVG MALSOKDIDA AH LTOEMFAT AH LTOEMFAT HEREDIRRO HREDIRRD DTEDART DRIDLORD DRIDLRS EEFDART	IAL VILLAG FE/ MAPLLFIGG HE/ MAPLLFIGG HE/ TILLMISAGYE/ ILLMISAGYE/ LAVIUGIGG E/ LAVIUGIGG E/ LAVIUGIGG E/ LAVIUGIGG E/ LAVIUGIGG E/ CVHLITAGHE/ CVVALIFGGOY VAVGLFGAGYE/ VAVGLFGAGAYE VAVGLFGAGAYE VAVGLFGAGAYE VAVGLFGAGAYE VAVGLFGAGAYE VAVGLFGAGAYE VAVGLFGAGYE VE	VSUSIT TUNISONGTU TUNISONGTU TUNISONGTU TUNUSONU VIENVSOMU VIENVSO	L LLTHPD OLA LVR HUMRNDOOMEALR ALLSHPOOLAALVR ILLTRPOOLAALVR ILLTRPOOLAALVR ILLTRPEALMERMR ILLSRPELMERR ILLSRPEAMER ILLSRPEAMER ILARHPOORE ILARHPOORE ILARHPOORE ILARHPOORE ILARHPOORE ISAN IGAPLAR ISAN IGAPLAR ISAN IGAPLAR ISAN IGAPLAR ISAN IGAPLAR ISAN IGAPLAR ISAN ISAN ISAN ISAN ISAN ISAN ISAN ISAN	RDPSATP. QDRSTP ADMTILD. KGEVTMA KGEVTMA ERPGARC. ERPGARC. ERPGARC. ERPGARC. ERPENP BHPENMG. EHPENMG. EHPENMG. EHPENMG. EHPENMG. EHPENMG. ERFENCTIONTFPAMG. VRALERCPOL VCRALERCPOL VCRALERCPOL VCRALERCPOL VCRALERCPOL VCRALERCPOL VCRALERCPOL VCRALERCPOL CALLER	NAVE DILRYI GAVE DILRYI CAVE MIRYE CAVE MIRYE CAVE MIRYE TALDELLRWI RAIDELLRWI RAVE DURYA VAFEDVRKIRIGNVIV AAMRLR RAVE DURYA RAVE DURYA RAVE DURY RAVE DILRWN RAVE RE RAVE RAVE RE RE RAVE RAVE RE	APPET.TTRFAAE SPLKHA.IFRCATED COVEGA.TYRFDVEP PAVKHL.PLRYAVTD SHRTSVCLARIALED RAGGSVLPPRYASED PHRNAVGLSRIALED PAVWV.LTRRAVAE PPVCA.VTRWAVED PAVWV.LTRRAVAE DSVCDG.LPRLATAD LSVCDG.LPRLATAD LSVCDG.LPRLATAD LSVCDG.LPRLATAD SO PVRLDG.
TamI PikC CYP154A1 CYP158A2 PimD Stap CYP170A1 CYP170A1 CYP124A1 CYP124A1 WP_051841251.1 WP_031150378.1 eryF TamI PikC CYP154A1 CYP158A1 CYP158A1 CYP158A2 PimD Stap CYP170A1 CYP170A1 CYP170A1	LDIVERRRTEPGDDIS GDIERKRRTPTDVIA SRLIDSKRCDDCEDIS DCLIAAKRATPGDDNTS TFVRARAGSE.CGDVYS SDLIGLRSDSAGEDVTS ACLVENKRAEPGFDIG REVDRRGGDDRDDIS DPVIKERRNPGSDIS ACLINAPPERS GDIG ADAFKAQLAETAEERTGLIG SDO 310 VERINAPPERS GDIG ADAFKAQLAETAEERTGLIG SDO 310 VERINAPPERS GDIG ADAFKAQLAETAEERTGLIG SDO 310 VERINAPPERS GDIG ADAFKAQLAETAEERTGLIG SDO 310 VERI	ALIR VOLD. DE ALVARSV. DE ALVARSV. DE LURARDEGDE LLIARDDEGDE LLIARDDEGDE LLIARDDEGDE LLIARDDEGDE LLIARDE. DE LLIARDE. DE LLICISEVE. C LLICISEVE. C L	GR LS A DELTS DR LTE TELVS SR LTS EELR DR LS PEELR DC LS PEELR OC VG UG UG E VG UG UG DF IG SP VG UG HT LS DE LFAT A H LT DE MFAT A H LT DE MFAT A H LT DE MFAT O HT LD V RP HT LD V RP DR ID LDR DR ID LDR DV LDV HRA. LEFDF DR RED V FN HREDL	IAU VILLAGE B/ MAR LIFIGG B/ MAR LIFIGG B/ ILLFIGG B/ ILLFIGG B/ ILLFIGG B/ ILLFIGG B/ ILAFILOIGG B/ ILAFILOIGG B/ ILAFILOIGG B/ VAVIF GG	V V V I C I CT Y C V N I LG N GT Y C V N I LG N GT Y C V N I LG N CM Y C V N I D O AVH T V N V D O AVH V T N Y V V N N SO MIY V T N Y V V N N SO MIY V T N Y V V N N SO MIY V V N Y V V Y C S FI V A S I M V C S FI V A S I M V C S FI V A S I V A S	L LITHPD OTAL VR HIMKNND OMEALR ALSHDOIAALR ILSHDOIAALR LISHDOIAALVR LLTRPDOIAALVR LLTRPDIE AS RE LLTRPE AS RE LLTRPE AS RE LLTRPE AS RE LLTRPE AS RE LLARHDVIDE LR LAHDVIDE LR LAHDVIDE LR LAHDVIDE LR LAHDVIDE LR LALDRE LR LANDE OMNOUT SLIQHPE LGYLR ALLQRE LGYLR LGAPLARNE A VA LGAPE LARIES LL IGAPLARNE Y LA LGAPLARNE Y LL IGAPLARNE Y LL IGAPLARNE Y LL IGAPLARNE TEL FGCMLARGE LESELL IGAPLARNE TEL SCANDARNE TEL	RDPSATP. QDRSTP ADMTILD. KGEVTMA KGEVTMA ERPGARC. SEPEIRP ADPDVMA TTPSTP. DEVEAVTGRP. ERPERMG. EHPERMG. EHPERMG. EHPERMG. EHPERMG. ULLERCPD. ULRIEGEPOL VRALERCPD. VRALERCPD. VRALERCPD. USING PA. STO TALLERCPD. LESLICCPD. LESLICCPD. LESLICCPD. LESLICCPD. LICSLICCPD. LICSLICCPD. LICSLICCPD. TKLFTRLPC. TALLTYPE.	NAVE DIN GAVE DIN GAVE DIN CAVE MINYE CAVE MINYE CAVE MINYE CAVE MINYE CAVE MINYE TAID LILWI RAID LILWI RAID LILWI RAID LIRWN RAVE MINYE CAPEDVRKLRHIGNVIVEAM RAVE DIN RAVE DI	APPET.ITRFAAFE SPLENA.IFRCATED GOVESA.TYRFPVPP PAVKHL.PLRYAVID PHRNAVGLSRIALED PHRNAVGLSRIALED PHRNAVGLSRIALED PHVOLA.IVRWAYED PAVWV.LIRRVAE PPVQL.IFRQUSCD LSFADG.LPRIAVAE DEVCLG.LPRIALAD LSVCDG.LPRIALAD LSVCDG.LPRIALAD DVRLDG. PVRLNAP. PVRLNAP. PIRWRRGREAGRATG PVILNAG. PVRLNAG. PVILNAG. PVILNAG. PVILNAG. PVILNAG. PVILNAG. PVILNAG. PVILNAG. PVILNAG. PVILNAG. PVILNAG. PVILNAG. PVILNAG. PVILNAG. PVILNAG. PVILNAG. PVILNAG. PVILNAG. PVILNAG. PVIN.
TamI PikC CYP154A1 CYP158A2 PimD Stap CYP170A1 CYP134A1 CYP134A1 CYP124A1 CYP124A1 WP_051841251.1 WP_051841251.1 WP_031150378.1 : eryF TamI PikC CYP154A1 CYP154A1 CYP154A1 CYP154A1 CYP154A1 CYP154A1 CYP154A1 CYP154A1 CYP154A1 CYP154A1 CYP154A1 CYP154A1 CYP154A1 CYP154A1 CYP134A1 CYP	LDIVERRRTEPGDDIS GDIERKRRTPTDVIA SRLIDSKRCDDCEDIS DCLIAAKRATPGDDNTS TFVRARAGSE.CGDVYS SDLIGLRSDSAGEDVTS ACLVENKRAEPGFDIG REVDRRGGDDRDDIS DPVIKERRNPGSDIS ACLINAPPERS GDIG ADAFKAQLAETAEERTGLIG SDO 310 VERINAPPERS GDIG ADAFKAQLAETAEERTGLIG SDO 310 VERINAPPERS GDIG ADAFKAQLAETAEERTGLIG SDO 310 VERINAPPERS GDIG ADAFKAQLAETAEERTGLIG SDO 310 VERI	ALIR VOLD. DE ALVARSV. DE ALVARSV. DE LURARDEGDE LLIARDDEGDE LLIARDDEGDE LLIARDDEGDE LLIARDDE GR LLEAVGR. DE LLEAVGR. DE LLEAVGR. DE LLEAVGR. DE LLEAVGR. DE LLEAVGR. DE LLEAVGR. DE SANRDE KOFF DA SCHEREGDE SANRDE KOFF DA SCHEREGDE JANRE EK OFF DA SCHEREGDE JANRE EK OFF DA SCHEREGDE JANRE EK OFF DA SCHEREGDE JANRE EK OFF DA SCHEREGDE JANRE VF DU	GR LS A DE LT S DR LT E TELVS SR LT SE EELAV DE IT LSE AVS OE VG EVG EVAV SP US VDG IVG DD IG EQE DE LAVS SP US VDG IVG SP US VDG IVG SP US DE LFAT A H LT DE MFAT A H LT DE MFAT H T DE VT R H RF DV T R H RF DV R DT FDA R DT FDA R DT FDA R DT FDA R DT FDA R DR ID LDR DR ID LDR DT V DF N H R DV LDV H A. LEFD P DR WLP V	IAL VILLAG FE/ MARLIFIGG HE/ MARLIFIGG HE/ ILLIFIGG HE/ ILLIMISAGYE ILLIMISAGYE ILLIMISAGYE ILLIMISAGYE ILAVILG IGG E/ ILAVILG ILAVILG IGG E/ ILAVILG ILAVILG IGG E/ ILAVILG ILAVILG IGG E/ ILAVILG ILAVILG I/ ILAVILG ILAVILG I/ ILAVILG ILAVILG I/ ILAVILG ILAVILG I/ ILAVILG ILAVILG I/ ILAVILG	VS LICITY TYNILGNGT TYNILGNGT TYNILGNGT TYNILGOAVH VTHNYGOAVH VTHNYGOAVH VASIMONGY VAS	L LITHPD OLAL VR HIMRNDO OMEALR ALSHDO JAALR ILSHDO JAALR ILSHDO JAALR ILLTRED OLAALVR ILLTRED OLAALVR ILLTRED ELAVR ILLTRE VILO VA ILLTRE VILO VA ILLTRE VILO VA ILLTRE VILO VA ILLANED VALDE IL SLIQAROL ROMNOVI ILANED OMNOVI SLIQAROL ROMNOVI ILLNIE ICYIR ALLQRE LIGYIR ALLQRE IGYIR ALLQRE IGYIR IGAPIARIE GU IGAPIARIE VIL IGAPIARIE VIL	RDPSATP. QDRSTP ADMTILD. KGEVTMA KGEVTMA ERPGARC. SEPEIRP ADPDVMA TTPSTP. DEVEAVTGRP. ERPERMG. EHPERMG. EHPERMG. EHPERMG. EHPERMG. ULLERCPD. ULRIEGEPOL VRALERCPD. VRALERCPD. VRALERCPD. USING PA. STO TALLERCPD. LESLICCPD. LESLICCPD. LESLICCPD. LESLICCPD. LICSLICCPD. LICSLICCPD. LICSLICCPD. TKLFTRLPC. TALLTYPE.	NAVE DIN GAVE DIN GAVE DIN CAVE MINYE CAVE MINYE CAVE MINYE CAVE MINYE CAVE MINYE TAID LILWI RAID LILWI RAID LILWI RAID LIRWN RAVE MINYE CAPEDVRKLRHIGNVIVEAM RAVE DIN RAVE DI	APPET.ITRFAAEE SPLEMA.IFRCATED GPVESA.TYRFPVEP PAVKHL,PLRYAVTD SHRTSVGLARIALED RAGGSVLPPRYASED PHENAVGLSRIALED PAVWV.LTRRAVAE PPVGA.VTRMAVED PAVWV.LTRRAVAE DSVGDG.LPRIALAD LSVGDG.LPRIALAD LSVGDG.LPRIALAD CO PVRLDG.
TamI PikC CYP158A1 CYP158A2 PimD Stap CYP170A1 CYP134A1 CYP121 WP_019889608.1 WP_051841251.1 WP_051841251.1 WP_031150378.1 eryF TamI PikC CYP154A1 CYP158A1 CYP158A1 CYP158A1 CYP158A1 CYP158A1 CYP158A1 CYP158A1 CYP158A1 CYP158A1 CYP158A1 CYP158A1 CYP158A1 CYP158A1 CYP158A1 CYP158A1 CYP158A1 CYP158A1 CYP158A2 PimD	LDIVERRREPGDDIS GDIERKREPGDDIS SRIDSKRGDDGEDIS SRIDSKRGDDGEDIS SRIDSKRGDDGEDIS SDIGERSDSAGEDVTS SGLIGLRSDSAGEDVTS AGLVENKRAEPGPDIS REVDRGGDDRDDIT DEIAER.ASGCKPDDIS AGLVNAPERSGIG SAGLINAPERSGIG SAGLINAPERSGIG SAGLYRANAPERSGIG SAGLYRA	ALIR VODDE ALVARDVDE ALVARDVDC LLIARDDEGDG LLIARDDEGG LLIARDDEGG LLIARDDEGG LLIARDDEGG LLIARDDEGG LLIARD.NG LLIARD.NG LLIARD.NG LLIARD.NG LLIARD.NG LLIARD.NG LLIARD.NG LLIARD.NG LLIARDES SANCDES SANCE ALVAREE.FES SANCE SANCE ANCE SANC	GR LS A DE LT S DR LT E TELVS SR LT SE EELAV DE IT LSE AVS OE VG EVG EVAV SP US VDG IVG DD IG EQE DE LAVS SP US VDG IVG SP US VDG IVG SP US VDG IVG A H LT DE MFATT A H LT DE MFATT A H LT DE MFATT O HRF DV TR HRF DV RRP HRF DI RRD DT FDARTT DR ID LDRD DR ID LRS SEFDART DR HAL DR HAL DR HAL SEFDART DR HAL SEFDART SEFDA	IAL VILLAG FE/ MARLIFIGG HE/ MARLIFIGG HE/ ILLIFIGG HE/ ILLIMISAGYE ILLIMISAGYE ILLIMISAGYE ILAVILGIGG E/ ILAVILGIGG E/ ILAVILGIGG E/ ILAVILGG E/ OVVAILFGG E/ VAVSIFG E/ VAVSIF	VS LICITY TYNILGNGT TYNILGNGT TYNILGNGT TYNILGOAVH VTHNYGOAVH VTHNYGOAVH VASIMONGY VAS	L LITHPD OLAL VR HIMRNDO OMEALR ALSHDO JAALR ILSHDO JAALR ILSHDO JAALR ILLTRED OLAALVR ILLTRED OLAALVR ILLTRED ELAVR ILLTRE VILO VA ILLTRE VILO VA ILLTRE VILO VA ILLTRE VILO VA ILLANED VALDE IL SLIQAROL ROMNOVI ILANED OMNOVI SLIQAROL ROMNOVI ILLNIE ICYIR ALLQRE LIGYIR ALLQRE IGYIR ALLQRE IGYIR IGAPIARIE GU IGAPIARIE VIL IGAPIARIE VIL	RDPSATP ODRSTIP ADMTILD KGEVTMA KGEVTMA ERFGARG SEPEIRP DEVEAWTGGRPA ADPDUMA TTPESTP DEVEAWTGGRPA ADFDIR EKFELIP EKFELIP EKFELIP KGEVLIDTFPAM GUIDTFPAM CULDTFP	NAVE DIN GAVE DIN GAVE DIN GAVE DIN CAVE MINYE CAVE MINYE CAVE MINYE CAVE DIN RAID DIN RAID DIN RAID DIN RAID DIN RAID DIN RAVE D	APPET. ITRFAAEE SPLENA. IFRCATED GOVESA. TYRFPVEP PAVKNL.PLRVAVID PHRNAVGLSRIALED PHRNAVGLSRIALED PHRNAVGLSRIALED PHVOL.IFRCAMA PPVQL.IRRAVAE PPVQL.IRRAVAE PPVQL.IRRAVAE PVVQL.IRRAVAE PVVQL.IRRAVAE PVVQL.IRRAVAE PVQLA.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.
TamI PikC CYP154A1 CYP158A2 PimD Stap CYP170A1 CYP134A1 CYP134A1 CYP124A1 CYP124A1 WP_051841251.1 WP_051841251.1 WP_031150378.1 : eryF TamI PikC CYP154A1 CYP154A1 CYP154A1 CYP154A1 CYP154A1 CYP154A1 CYP154A1 CYP154A1 CYP154A1 CYP154A1 CYP154A1 CYP154A1 CYP154A1 CYP154A1 CYP134A1 CYP	LDIVER RREPGDUIS GDIERKRREPTDVIA SRLIDSKRCDDCEDIS DCLIAAKRATPGDDNTS TFVRARAGSEGDVTS SDLIGLRSDASGEDVTS ACLVENKRAEPGPDIC REVDRGGDDRDDLIT DEIIAER.ASGCKPDDLIT MPVIKERRNPGSDLIS AGLINAPPERS GLIG SDOURALAEPAERTGLIG SDOURALAEPAERTGLIG SDOURALAEPAERTGLIG SDOURALAEPAERTGLIG SDOURALAEPAERTGLIG SDOURALAEPAERTGLIG SDOURALAEPAERTGLIG SDOURALAEPAERTGLIG SDOURALAEPAERTGLIG SDOURALAEPAERTGLIG SDOURALAEPAERTGLIG SDOURALAEPAERTGLIG SDOURALAEPAERTGLIG SDOURALAEPAERTGLIG SDOURALAEPAERTGLIG SDOURALAEPAERTGLIG SDOURALAEPAERTGLIG SDOURAEPAERTGLIG SDOURALAEPAERTGLIG SDOURAEPAERTGLIG SDOURAEPAERTGLIG SDOURAEPAERTGLIG SDOURAEPAERTGLIG SDOURAEPAERTGLIG SDOURAEPAERTGLIG SDOURAEPAERTGLIG SDOURAEPAERTGLIG	ALUR VOD. DE ALUSARDY. DE ALUSARDY. EL LURARDEGO LLIARDDEGO LLINARDDEGO LLIVARDEGO LLIVARDEGO LLIVARDEGO LLIVARDE DE LLIVARDE DE LLIVARDE DE LLICISEYE. C LLICISEYE. C LICISEYE. C LLICISEYE. C LLICISEY	GR LS A DE LT S DR LT E TELVS SR LT SE EELR DE IT LSEAVS GE VE EELR DE IT LSEAVS GE VE EVA SP LS VDG IVS SH VSDELFAT A H LT DEMFAT A H LT DEMFAT H RF DV T R H RF DV R H RF DV R DF FDA T T DT FDA R R DV LDV R DR LD L R C SH VSDELFAT A H LT DEMFAT C SH ST DE S SH ST S SH ST S SH SH S SH SH S SH SH S SH SH S SH SH	IAL VILLAG FE/ MARLIFIGG HE/ MARLIFIGG HE/ ILLIFIGG HE/ ILLIFIGG HE/ ILLIMISAGYE ILAVILG GG E/ ILAVILG GG E/ ILAVILFAGLOS TCVHLITAGHE/ OVVAILFGGAD ICVHLITAGHE/ OVVAILFGGAGAW VAVSIFGGAGAW VAVSIFGGAGAW VAVSIFGGAGAW VAVSIFGGAGAW VAVSIFGGAGAW VAVSIFGGAGAW VAVSIFGGAGAW VAVSIFGAGAW VAVSIFGAGAW VAVSIFGAGAW VAVSIFGAGAW VAVSIFGAGAW VAVSIFGAGAW VAVSIFGAGAW VAVSIFGAGAW VAVSIFGAAM VAVSIFGAAM	VSLICICTY TYNILGNGTY TYNILGNGTY TYNILGOWY TYNICOWY VD OAVH VD NNSGOMPH VD NNSGOGIPFC VD NSGOGIPFC VD NSGOGPH VD NSGOGPH	L LITHPD OIAL VR HIMRNID OMEALR ALSHDOIAALR ILSHDOIAALR ILSHDOIAALR LLSHDOIAALR LLSRELAEMARME LLSRELAEMAR ILLSRELAEMAR ILANHDORAAL ILANHDORAAL ILANHDORAAL ILANHDORAAL ILANHDORAAL ILANHDORAAL ILANHDORAAL ILANHDORAAL ICARELICH I	RDPSATP ODRSTIP ADMTILD KGEVTMA SEPEGRE SEPEGRE SEPEGRE SEPEGRE SEPEGRE SEPERE ODEVEAVTGGRE HPEEMG SEPERE	NAVE DIN GAVE DIN GAVE DIN CAVE MINYE CAVE MINYE CAVE MINYE CAVE MINYE CAVE MINYE TAID LILWI RAID LILWI RAID LILWI RAID LIRWN RAVE MINYE CAPEDVRKLRHIGNVIVEAM RAVE DIN RAVE DI	APPET.ITRFAAE SPLENAAIFRCATED GOVESAITYRFPVEP PAVKHL.PLRYAVTD PHRNAVGLSRIALED PHRNAVGLSRIALED PHRAVGLSRIALED PPVCA.VTRWAVED PPVCA.VTRWAVED PAVWV.LTRRAVAE LSVGDG.LPRIALED LSVGDG.LPRIALED LSVGDG.LPRIALED LSVGDG.LPRIALED LSVGDG.LPRIALED LSVGDG.LPRIALED LSVGDG.LPRIALED LSVGDG.LPRIALED LSVGDG.LPRIALED LSVGDG.LPRIALED VRENRESEASRETG PVRENRESEASRETG PVILHAC. PCTW. PVILW LVAC. LVADGA. LVADGA.

**Figure S1**. Alignments of P450s from this study (blue box) and structurally defined natural product P450s from bacteria. Residues are numbered according to the sequence of EryF.<sup>4</sup> a: A/G<sup>241</sup>G<sup>242</sup>XXT<sup>245</sup> motif, the highly conserved residue A/G241, G242 and T245 are marked with "•". b: E<sup>280</sup>XXR<sup>283</sup> motif, the strictly conserved residues E280 and R283 are marked with "\*". c: G<sup>347</sup>XXXC<sup>351</sup> motif, the strictly conserved residues G347 and C351 are marked with "▲".



**Figure S2**. Phylogenetic analysis of P450s from this study (•) and functionally characterized P450s from bacteria. Scale bar, 0.2 substitutions per site. The protein sequneces were downloaded from NCBI database.




Figure S3. <sup>1</sup>H NMR spectrum of compound 2 (DMSO-*d*6, 500 MHz).




Figure S4. <sup>13</sup>C APT spectrum of compound 2 (DMSO-*d*6, 125 MHz).




Figure S5. DQF-COSY spectrum of compound 2 (DMSO-*d*6, 500 MHz, 500 MHz).




Figure S6. HSQC spectrum of compound 2 (DMSO-d6, 500 MHz, 125MHz).




Figure S7. HMBC spectrum of compound 2 (DMSO-*d*6, 500 MHz, 125MHz).





Figure S8. Selected region of HMBC spectrum of compound 2 (DMSO-d6, 500 MHz, 125MHz).



**Figure S9**. SDS-PAGE analysis of the purified  $P450_{NB5737}$ . The proteins were separated on a 12% polyacrylamide gel and stained with Coomassie brilliant blue R-250. Lane 1: Protein marker, lane 2: purified  $P450_{NB5737}$ .




Figure S10. Spectroscopic analysis of P450<sub>NB5737</sub>.

# **References:**

(1) Gomez-Escribano, J. P. and Bibb, M. J. *Microb.Biotechnol.* 2011, 4, 207.

(2) Kieser, T.; Bibb, M. J.; Buttner, M. J.; Chater, K. F.; Hopwood, D. A. *Practical Streptomyces Genetics;* 2nd ed.; John Innes Foundation: Norwich, UK, 2000.

(3) Sambrook, J.; Russell, D. W. *Molecular cloning: a laboratory manual;* 3rd ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor: New York, 2001.

(4) Cupp-Vickery, J. R. and Poulos, T. L. Nat.Struct.Biol. 1995, 2, 144.

4.3 Tyrosine *O*-prenyltransferases TyrPT and SirD displaying similar behavior toward unnatural alkyl or benzyl diphosphate as their natural prenyl donor dimethylallyl diphosphate.

BIOTECHNOLOGICALLY RELEVANT ENZYMES AND PROTEINS

## Tyrosine *O*-prenyltransferases TyrPT and SirD displaying similar behavior toward unnatural alkyl or benzyl diphosphate as their natural prenyl donor dimethylallyl diphosphate

Huili Yu • Mike Liebhold • Xiulan Xie • Shu-Ming Li

Received: 16 December 2014/Revised: 23 January 2015/Accepted: 31 January 2015/Published online: 24 February 2015 © Springer-Verlag Berlin Heidelberg 2015

Abstract Prenyltransferases of the dimethylallyltryptophan synthase (DMATS) superfamily are involved in the biosynthesis of secondary metabolites and contribute as modification enzymes significantly to structural diversity of natural products. They show usually broad specificity toward their aromatic substrates with regiospecific prenylations on aromatic rings. However, most members of this superfamily exhibit a high specificity toward their prenyl donors and usually accept exclusively dimethylallyl diphosphate (DMAPP). Recently, several indole prenyltransferases from this family were also demonstrated to accept unnatural DMAPP analogs such as methylallyl, 2-pentenyl and benzyl diphosphate for alkylation, or benzylation of the indole ring. Partial or complete shift of the substitution position was observed for these enzymes. In this study, we report the acceptance of these DMAPP analogs by two tyrosine O-prenyltransferases TyrPT from Aspergillus niger and SirD from Leptosphaeria maculans for alkylation or benzylation of tyrosine and derivatives. NMR and mass spectrometry (MS) analyses of nine isolated enzyme products confirmed the regiospecific O- or N-alkylation or benzylation at position C-4 of the aromatic ring, which is the same prenvlation position of these enzymes in the presence of DMAPP.

**Electronic supplementary material** The online version of this article (doi:10.1007/s00253-015-6452-1) contains supplementary material, which is available to authorized users.

H. Yu • M. Liebhold • S.-M. Li (⊠) Institut für Pharmazeutische Biologie und Biotechnologie, Philipps-Universität Marburg, Deutschhausstrasse 17A, 35037 Marburg, Germany e-mail: shuming.li@staff.uni-marburg.de

X. Xie

Fachbereich Chemie, Philipps-Universität Marburg, Hans-Meerwein-Straße 4, 35032 Marburg, Germany **Keywords** DMATS superfamily · Unnatural alkyl donors · Tyrosine and derivatives · Enzyme catalysis

#### Introduction

Attachment of a prenyl moiety to an aromatic core plays an important role for creation of structural diversity of secondary metabolites (Heide 2009). Prenyltransferases catalyzing such attachments are found in many living organisms including plants, bacteria, and fungi and can be classified in different subgroups based on their amino acid sequences and biochemical properties (Heide 2009; Yazaki et al. 2009; Yu and Li 2012). The members of the dimethylallyltryptophan synthase (DMATS) superfamily catalyze the transfer reactions of prenyl moiety from prenyl donors, usually dimethylallyl diphosphate (DMAPP), to diverse aromatic substrates (Chooi et al. 2012; Yu and Li 2012). The resulted prenylated products often show interesting biological and pharmacological activities distinct from their non-prenylated precursors, which makes these enzymes to be interesting biocatalysts for pharmaceutical and medicinal research (Li 2010; Wollinsky et al. 2012). So far, more than 40 such enzymes have been characterized biochemically by using heterologously overproduced and purified proteins (Fan et al. 2014; Pockrandt et al. 2014; Wunsch et al. 2015; Yu and Li 2012). The majority of these enzymes accepts indole derivatives (Yu and Li 2012), while several members use tyrosine or nitrogen-free aromatic compounds as natural substrates (Fan et al. 2014; Kremer and Li 2010; Pockrandt et al. 2012, 2014). Until now, two L-tyrosine prenyltransferases have been identified and characterized biochemically. The first one, SirD, is involved in the biosynthesis of sirodesmin PL in Leptosphaeria maculans (Fig. 1) (Gardiner et al. 2004; Kremer and Li 2010). The very recently identified TyrPT from an unknown biosynthetic pathway in Aspergillus niger (Fig. 1) showed similar biochemical features




Fig. 1 Prenylations catalyzed by TyrPT and SirD and their role in nature

as SirD (Fan et al. 2014). Both enzymes catalyze the same *O*-prenylation of the hydroxyl group at the benzene ring (Fan et al. 2014; Kremer and Li 2010).

One common feature of the DMATS superfamily enzymes is their high flexibility toward aromatic substrates. In addition to tryptophan derivatives, indole prenyltransferases also accept distinct structures such as hydroxynaphthalenes (Yu et al. 2011), flavonoids (Yu and Li 2011), or xanthones (Tarcz et al. 2014) as prenyl acceptors. The tryptophan C4-(FgaPT2) and C7-prenyltransferase (7-DMATS) have also been demonstrated to accept tyrosine and derivatives as substrates (Fan et al. 2015; Fan and Li 2014). Similar to the behavior of indole prenyltransferases, the tyrosine prenyltransferases SirD and TyrPT also accept a number of tyrosine derivatives and catalyze the O-prenylation of the hydroxyl or N-prenylation of the amino group at the aromatic rings (Fan et al. 2014; Kremer and Li 2010; Zou et al. 2011). Furthermore, they also catalyze prenylation reactions of tryptophan and derivatives (Fan et al. 2014; Kremer and Li 2010; Rudolf and Poulter 2013).

In contrast to their high substrate flexibility for acceptors, most of the DMATS enzymes show a restricted specificity toward their prenyl donors, accepting usually DMAPP as prenyl donor (Yu and Li 2012). Only a few enzymes use GPP, DMAPP and GPP, or DMAPP, GPP, and FPP as prenyl donors (Chooi et al. 2010; Pockrandt et al. 2014; Pockrandt and Li 2013; Tarcz et al. 2014). This feature prohibits their application as biocatalysts in chemoenzymatic synthesis. To broaden their specificity for alkyl donors, the acceptance of the unnatural analogs, methylallyl diphosphate (MAPP), 2pentenyl diphosphate (2-pen-PP), and benzyl diphosphate (benzyl-PP), was tested with two tryptophan prenyltransferases FgaPT2 and 5-DMATS as well as five cyclic dipeptide prenyltransferases BrePT, FtmPT1, AnaPT, CdpNPT, and CdpC3PT in our laboratory (Liebhold et al. 2012, 2013; Liebhold and Li 2013). Our results demonstrated that the tested enzymes also used such donors for alkylation or benzylation. However, the restricted regioselectivity observed with their natural prenyl donor DMAPP has been broken. Partial or complete shifts of alkylation or benzylation were detected in these reactions (Liebhold et al. 2012, 2013; Liebhold and Li 2013). After availability of SirD and TyrPT, we decided to test the behavior of tyrosine *O*-prenyltransferases toward MAPP, 2-pen-PP, and benzyl-PP.

#### Materials and methods

#### Chemicals

MAPP, 2-pen-PP, and benzyl-PP were synthesized (Liebhold et al. 2012; Liebhold and Li 2013) following the protocol described for geranyl diphosphate (Woodside et al. 1988). Tyrosine and derivatives used for the enzyme assays were purchased from Bachem (Bubendorf, Switzerland), Sigma-Aldrich (Steinheim, Germany), Alfa Aesar (Karlsruhe, Germany), and TCI (Zwijindrecht, Belgium).

Bacterial strains, plasmids, culture conditions, overproduction, and purification of His-tagged TyrPT and SirD

pGEM-T easy used for cloning and pET28a for expression experiments were obtained from Promega (Mannheim, Germany) and Novagen (Darmstadt, Germany), respectively. *Escherichia coli* XL1 Blue MRF' (Stratagene, Amsterdam, the Netherlands) was used as host for cloning and SoluBL21 (Novagen) for expression experiments. They were grown at 37 °C in liquid Luria-Bertani (LB) or Terrific Broth (TB) medium or on solid LB medium with 1.5 % agar (*w/v*). For selection of recombinant *E. coli* strains, 100 µg mL<sup>-1</sup> of ampicillin or 25 µg mL<sup>-1</sup> of kanamycin were used.

In this study, SirD was cloned into pET28a and expressed under the control of a strong T7 promoter. Taking the former expression plasmid in pQE70 (pAK2) (Kremer and Li 2010) as template, the coding region of *sirD* was amplified with Expand High Fidelity PCR Kit (Roche Diagnostic, Mannheim, Germany) by using primers SirD\_F (5-<u>CCATGGCGATGCAGACAGCTCGTCTCTTCC-3</u>) at the 5'-end and SirD\_R (5-<u>GCGGCCGC</u>CTGTCTGTAGCGAT TTGGAT-3) at the 3'-end. The underlined letters represent the restriction enzyme sites *NcoI* and *NotI*, respectively, and italic letters indicate the inserted mutations in comparison to the original gene sequence. PCR amplification was carried out on an iCycler thermal cycler (BioRad, Munich, Germany) with annealing temperature at 56 °C. The PCR fragment of 1360 bp was cloned into pGEM-T easy vector and subsequently sequenced by Eurofins Genomics (Ebersberg, Germany) to confirm the sequence, resulting in the plasmid pHY06. The coding region was then released with *NcoI* and *NotI* and ligated into pET28a vector, which had been digested with the same enzymes previously. The resulted plasmid pHY07 was used for overproduction of SirD. pHC16 described in a previous publication (Fan et al. 2014) was used for production of TyrPT.

For gene expression, E. coli SoluBL21 cells harboring pHY07 or pHC16 were cultivated in a 2000-mL cylindrical flask containing 1000 mL liquid TB medium supplemented with kanamycin (25  $\mu$ g mL<sup>-1</sup>). After growing at 37 °C to an absorption of 0.6 at 600 nm, the gene expression was induced with isopropyl thiogalactoside at a final concentration of 0.8 mM for TyrPT and 0.5 mM for SirD at 30 °C for 16 h. The bacterial cultures were harvested by centrifugation and resuspended in lysis buffer (10 mM imidazole, 50 mM NaH<sub>2</sub>PO<sub>4</sub>, 300 mM NaCl, pH 8.0) with 2–5 mL  $g^{-1}$  wet weight. Lysozyme from the chicken egg white was added at a final concentration of  $1 \text{ mg mL}^{-1}$ . After incubation on ice for 30 min, the cells were sonicated six times for 10 s each at 200 W. To separate the cellular debris from the soluble proteins, the lysate was centrifuged at 13,000 rpm and 4 °C for 30 min. One-step purification of the recombinant His<sub>6</sub>-tagged fusion protein by affinity chromatography with Ni-NTA agarose resin (Macherey-Nagel, Düren, Germany) was carried out according to the manufacturer's instruction. The protein was eluted with 250 mM imidazole in 50 mM NaH<sub>2</sub>PO<sub>4</sub> and 300 mM NaCl, pH 8.0. In order to remove imidazole, the protein fraction was passed through a NAP-5 column (GE Healthcare, Freiburg, Germany), which had been equilibrated with 50 mM Tris-HCl (pH 7.5) containing 15 % (v/v) glycerol. The purified TyrPT and SirD were eluted with the same buffer as for column equilibration and stored at -80 °C for enzyme assays. The protein concentration was determined on Nanodrop C 2000 (Thermo Scientific, Braunschweig, Germany) and then analyzed on 12 % (w/v) SDS-PAGE (Laemmli 1970) and stained with Coomassie Brilliant Blue G-250.

#### Enzyme assays for TyrPT and SirD

For determination of the TyrPT and SirD activity, the reaction mixtures (100  $\mu$ L) contained 50 mM Tris-HCl (pH 7.5), 10 mM CaCl<sub>2</sub>, 1 mM aromatic substrate (Table 1), 1 mM DMAPP or analogs, 1.5–5 % ( $\nu/\nu$ ) glycerol, 0–5 % dimethyl sulfoxide (DMSO), and 20  $\mu$ g of the purified recombinant protein. After incubation at 37 °C for 16 h, the reactions were

terminated by addition of 100  $\mu$ L methanol. Protein was removed by centrifugation at 13,000 rpm for 20 min before injection on HPLC. Two to four independent assays were carried out routinely. For determination of kinetic parameters of DMAPP analogs, 50 mM Tris-HCl (pH 7.5), 10 mM CaCl<sub>2</sub>, 40  $\mu$ g purified recombinant protein, 1 mM L-tyrosine or 4-amino-L-phenylalanine, and DMAPP analogs at final concentration of 0.01, 0.02, 0.05, 0.08, 0.1, 0.2, 0.5, 0.8, 1.0, 2.0, and 5.0 mM were used in enzyme assays. The reaction mixtures were incubated at 37 °C for 2 h.

Preparative synthesis of prenylated products for structural elucidation

The enzyme assays for isolation of enzymatic products contained 50 mM Tris-HCl (pH 7.5), 10 mM CaCl<sub>2</sub>, 1 mM aromatic substrate, 1 mM DMAPP analog, and 2 mg of purified recombinant protein, in a total volume of 10 mL. The reaction mixtures were incubated in glass vials at 37 °C for 16 h, and the reactions were terminated by addition of 1 volume of methanol. After centrifugation at 6000 rpm for 30 min to precipitate protein, the supernatants were concentrated on a rotary evaporator at 35 °C to 1–2 mL and used as samples for separation on HPLC.

HPLC analysis and isolation of enzyme products for structure elucidation

The enzyme assays of TyrPT and SirD were routinely analyzed on an Agilent HPLC series 1200 (Agilent, Böblingen, Germany) by using a Multospher 120 RP-18 column ( $250 \times 4$  mm, 5 µm C + S Chromatographie Service, Langerwehe, Germany) at a flow rate of 1 mL min<sup>-1</sup>. Double-distilled water (solvent A) and methanol (solvent B) were used as solvents. To analyze the enzyme products, a linear gradient of 30–100 % (v/v) solvent B in 20 min was used. The column was then washed with 100 % (v/v) solvent B for 5 min and equilibrated with 30 % (v/v) solvent B for another 5 min. Detection was carried out by a Photo Diode Array detector and illustrated for absorption at 277 nm in this study.

For structure elucidation, the products were isolated on a Multospher 120 RP 18 column  $(250 \times 10 \text{ mm}, 5 \text{ }\mu\text{m})$  with a linear gradient of 60–100 % ( $\nu/\nu$ ) of methanol (solvent B) in water (solvent A) in 60–80 min and a flow rate of 2.5 mL min<sup>-1</sup>. After each run, the column was then washed with 100 % ( $\nu/\nu$ ) solvent B for 10 min and equilibrated with 60 % ( $\nu/\nu$ ) solvent B for 10 min. The collected fractions were evaporated to dryness and subjected to NMR and mass spectrometry (MS) analyses.

Table 1 Product yields of TyrPT and SirD reactions with tyrosine and derivatives in the presence of DMAPP and analogs

Substrate	DMAPP		MAPP		2-pen-PP		benzyl-PP	
	Conversion (%)		Conversion (%)		Conversion (%)		Conversion (%)	
	TyrPT	SirD	TyrPT	SirD	TyrPT	SirD	TyrPT	SirD
L-Tyrosine (1a)	89.1±6.20	99.3±0.06	21.2±0.72	28.0±2.7	56.6±6.21	44.3±2.90	2.2±0.27	1.3±0.24
4-Amino-L-phenylalanine (2a)	78.1±0.36	66.1±1.38	57.7±1.45	$34.8 {\pm} 0.20$	$46.4 {\pm} 0.52$	42.6±2.57	$67.2 \pm 3.84$	54.6±1.54
3-Fluoro-DL-tyrosine (3a)	50.1±0.15	66.5±3.24	13.1±1.15	$8.9 {\pm} 0.66$	43.9±4.69	20.5±1.23	$1.5 \pm 0.40$	$0.4 {\pm} 0.05$
3,4-Dihydroxy-L-phenyl-alanine (4a)	$100 {\pm} 0.0$	88.2±1.28	5.8±0.15	7.3±0.23	$30.2 {\pm} 0.18$	$14.3 {\pm} 0.77$	$0.4{\pm}0.02$	$0.3 {\pm} 0.10$
$\alpha$ -Methyl-L-tyrosine (5a)	$98.3 {\pm} 0.03$	89.4±0.44	$2.9 {\pm} 0.06$	$16.0{\pm}2.11$	$10.3 {\pm} 0.44$	33.5±2.23	$0.1 {\pm} 0.02$	$0.5 {\pm} 0.01$
3-Iodo-L-tyrosine (6a)	$100 {\pm} 0.0$	$100 {\pm} 0.0$	$4.9 {\pm} 0.37$	$1.1 {\pm} 0.21$	$12.0 {\pm} 0.89$	$3.0{\pm}0.08$	$0.2{\pm}0.03$	$0.2 {\pm} 0.04$
3,5-Dibromo-L-tyrosine (7a)	$20.6 {\pm} 0.30$	53.3±4.26	$2.8 {\pm} 0.09$	0.7±0.15	$3.9 {\pm} 0.18$	$1.4{\pm}0.17$	$0.3 {\pm} 0.08$	$0.2 {\pm} 0.05$
D-Tyrosine (8a)	59.5±0.30	57.6±4.10	$0.1 {\pm} 0.04$	$0.2{\pm}0.09$	1.7±0.15	$0.8{\pm}0.08$	$0.1 {\pm} 0.02$	$0.2 {\pm} 0.02$
3-Amino-3-(4-hydroxyphenyl)- propanoic acid (9a)	10.1±0.18	8.7±0.04	$1.7 {\pm} 0.06$	1.6±0.02	1.8±0.14	1.8±0.12	2.0±0.04	2.0±0.23
3-(3,4-Dihydroxyphenyl)-DL-serine (10a)	$16.1 {\pm} 0.54$	$29.9 {\pm} 1.75$	$0.6 {\pm} 0.04$	$0.5 {\pm} 0.03$	$7.1 {\pm} 0.64$	$1.3 {\pm} 0.38$	$0.1 {\pm} 0.03$	< 0.01
DL-m-Tyrosine (11a)	$1.4 {\pm} 0.02$	$0.3 {\pm} 0.02$	$0.7 {\pm} 0.04$	$0.6 {\pm} 0.02$	$0.7 {\pm} 0.06$	$0.6 {\pm} 0.01$	$0.8 {\pm} 0.01$	$0.6 {\pm} 0.02$
3,5-Diiodo-L-tyrosine (12a)	$2.2 \pm 0.14$	$2.2 \pm 0.01$	$0.1 {\pm} 0.03$	$0.1 {\pm} 0.01$	$0.1 {\pm} 0.04$	$0.2 {\pm} 0.07$	$0.1 {\pm} 0.01$	$0.1 {\pm} 0.01$
3-Nitro-L-tyrosine (13a)	6.6±0.03	44.9±1.71	$0.1 {\pm} 0.01$	< 0.01	$0.1 {\pm} 0.02$	< 0.01	< 0.01	< 0.01

DMAPP dimethylallyl diphosphate, MAPP methylallyl diphosphate, 2-pen-PP 2-pentenyl diphosphate, benzyl-PP benzyl diphosphate

#### NMR and MS analyses

The isolated enzyme products were dissolved in  $D_2O$  or  $CD_3OD$ . <sup>1</sup>H NMR spectra were recorded at room temperature on a JEOL ECA-500 spectometer (JEOL, Tokyo, Japan). Two-dimensional spectra HSQC and HMBC were recorded on a Bruker Avance 500 MHz spectrometer (Bruker, Karlsruhe, Germany). All of the spectra were processed with MestReNova 6.0.2 (Metrelab Research, Santiago de Compostella, Spain), and chemical shifts were referenced to the signal of  $D_2O$  at 4.79 ppm and that of  $CD_3OD$  at 3.30 ppm. The NMR data of isolated products are given in Table 2 and spectra in Figs. S1–S12 in electronic supplementary material.

The isolated compounds were also analyzed by highresolution electron impact mass spectrometry (HR-EI-MS) on a Micromass Auto Spec spectrometer (Waters, Milford, MA). The obtained MS data are given in Table 3.

#### Results

#### Overproduction and purification of SirD and TyrPT

Expression of *sirD* was carried out with the newly constructed plasmid pHY07 in pET28a. Purification of the overproduced SirD led to detection of a predominant protein band on SDS-PAGE (Fig. 2a). With the help of the strong T7 promoter and cultivation in nutrient-rich TB media, the protein yield was

improved from 2 to 4 mg L<sup>-1</sup> bacterial culture. By incubation of L-tyrosine with DMAPP and 2-pen-PP, the activity of SirD from the new construct was proven to be nearly the same of that from the previous construct (data not shown). Therefore, SirD for enzyme assays presented in this study was obtained by using pHY07 as expression vector. TyrPT with a protein yield of 4–6 mg L<sup>-1</sup> bacterial culture was overproduced and purified as described previously (Fan et al. 2014) (Fig. 2b).

Acceptance of the unnatural DMAPP analogs by tyrosine prenyltransferases

The purified SirD and TyrPT were firstly assayed with DMAPP in the presence of tyrosine (1a) and 12 derivatives (2a-13a). As shown in Table 1, the behaviors of both enzymes for these substrates were similar to those observed previously (Fan et al. 2014; Zou et al. 2011). In comparison to previous works with 3 (Zou et al. 2011) or 8.6 µg proteins per 100 µL assay (Fan et al. 2014), 20 µg were used in this study. As expected, significantly higher conversion yields were obtained for most substrates. The acceptance of 1a-13a by TyrPT and SirD was then tested in the presence of MAPP, 2-pen-PP, and benzyl-PP as alkyl or benzyl acceptors. After incubation with TyrPT and SirD under the same conditions, the reaction mixtures were analyzed on HPLC (Materials and methods). In comparison to negative controls with heat-inactivated proteins (data not shown), product formation was detected in 73 of 78 incubation mixtures (Table 1). Conversion yields of more than 10 % were calculated for 19 enzyme reactions after incubation

Table 2 10	wire data of the isolated prot	ideis 10 50, 10 50, and 20			
Compound	4 3 1 0 4 5 NH2	3 1 N 4 5 NH2	F 3 2 7 9 F 3 2 7 8 CO <sub>2</sub> H 3 1 6 NH <sub>2</sub>	$\overbrace{\begin{array}{c}3\\4'\\2'\end{array}}^{2}, 0, 4'\\5\\6\end{array} , 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0$	5' 3' 1' N' 4' 5 6' NH2
	1b	2b	3b	1c	2c
Position	$\delta_{H}$ , multi, J	$\delta_{H}$ , multi, J	$\delta_{H}$ , multi, J	$\delta_{H}$ , multi, J	$\delta_{H}$ , multi, J
1	-	-	-	-	-
2	7.19, dd, 8.7, 2.1	7.22, d, 8.5	7.04, dd, 12.5, 2.0	7.19, dd, 8.7, 2.0	7.22, d, 8.4
3	6.88, dd, 8.7, 2.1	6.90, d, 8.5	-	6.88, dd, 8.7, 2.1	6.90, d, 8.4
4	-	-	-	-	-
5	6.88, dd, 8.7, 2.1	6.90, d, 8.5	7.01, t, 8.0	6.88, dd, 8.7, 2.1	6.90, d, 8.4
6	7.19, dd, 8.7, 2.1	7.22, d, 8.5	6.98, dd, 8.5, 1.8	7.19, dd, 8.7, 2.0	7.22, d, 8.4
7	3.23, dd, 14.7, 4.3	3.25, dd, 14.7, 5.1	3.19, dd, 14.7, 4.5	3.22, dd, 14.7, 4.3	3.21, dd, 14.6, 5.1
	2.93, dd, 14.7, 8.8	3.09, dd,14.7, 7.9	2.94, dd, 14.7, 8.4	2.93, dd, 14.7, 8.8	3.05, dd, 14.6, 7.9
8	3.71, dd, 8.8, 4.3	3.99, dd, 7.9, 5.1	3.74, dd, 8.4, 4.5	3.70, dd, 8.8, 4.3	3.93, dd, 7.9, 5.1
1'	4.44, dq, 6.0, 1.2	approx. 3.75*	4.49, d, 6.1	4.46, dd, 6.0, 1.2	3.75, d, 6.1
2'	5.68, dtq, 15.3, 6.0, 1.6	5.66, dtq, 15.4, 6.1, 1.7	5.68, dtq, 15.3, 6.1, 1.7	5.87, dtt, 15.4, 6.4, 1.3	5.89, dbrt, 15.5, 6.2
3'	5.84, dqt, 15.3, 6.5, 1.4	5.83, dqt, 15.4, 6.5, 1.4	5.85, dqt, 15.3, 6.5, 1.3	5.66, dtt, 15.4, 6.0, 1.6	5.64, dbrt, 15.5, 6.2
4'	1.72, dd, 6.5, 1.3	1.73, dd, 6.5, 1.4	1.71, dd, 6.5, 1.2	2.09, dqq, 7.2, 6.9, 1.2	2.10, dq, 7.5, 7.4
5'	-	-	-	1.01, t, 7.5	1.01, t, 7.5
Solvent	CD <sub>3</sub> OD	D <sub>2</sub> O	CD <sub>3</sub> OD	CD <sub>3</sub> OD	D <sub>2</sub> O

 Table 2
 NMR data of the isolated products 1b–3b, 1c–5c, and 2d

00110110	65365	5/0	0230		-2-
Compound	$\frac{F_{3}^{2}}{4} \sum_{Z}^{7} O_{4}^{9} O_{5}^{1} O_{2}H}{3c}$	$\frac{HO_{3}^{2} - \frac{7}{6} + \frac{9}{5} + \frac{9}{5}}{4} + \frac{1}{5} + \frac{1}{$	1	5 C C C C C C C C C C C C C C C C C C C	$\begin{array}{c} \begin{array}{c} & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ $
Position	$\delta_{H}$ , multi, J	$\delta_{H}$ , multi, J	$\delta_{C}$	$\delta_{H}$ , multi, J	$\delta_{H}$ , multi, J
1	-	-	128.9	-	-
2	7.03, dd, 12.4, 2.0	6.86, brs	116.6	7.14, d, 8.6	7.18, d, 8.4
3	-	-	145.8	6.83, d, 8.7	6.90, d, 8.5
4	-	-	145.4	-	-
5	7.00, t, 8.0	7.06, d, 8.3	115.3	6.83, d, 8.7	6.90, d, 8.5
6	6.97, dd,8.4, 1.9	6.82, d, 8.3	121.3	7.14, d, 8.6	7.18, d, 8.4
7	3.13, dd, 14.6, 4.7	3.19, dd, 14.6, 5.0	35.8	3.16, d, 14.2	3.22, dd, 14.7, 5.1
	2.88, dd, 14.6, 7.9	3.01, dd, 14.6, 7.9		2.77, d, 14.2	3.04, dd, 14.7, 8.0
8	3.63, dd, 7.9, 4.7	3.93, dd, 7.6, 5.1	55.9	-	3.95, dd, 8.0, 5.1
9	-	-	174.5	-	-
10	-	-	-	1.42, s	-
1'	4.49, dd, 6.1, 1.1	4.61, d, 6.3	70.3	4.42, d, 5.9	-
2'	5.87, dtt, 15.4, 6.4, 1.3	6.00, d brt, 15.4, 6.2	139.2	5.84, d brt, 15.4, 6.2	7.49, d, 7.4
3'	5.65, dtt, 15.4, 6.1, 1.6	5.73, d brt, 15.4, 6.2	123.1	5.63, d brt, 15,4, 6.0	7.46, t, 7.2
4'	2.07, dq, 7.6, 7.5	2.11, dq, 7.2, 7.0	24.6	2.05, dq, 7.5, 7.4	7.38, t, 7.2
5'	0.99, t, 7.5	1.01, t, 7.5	12.2	0.98, t, 7.5	7.46, t, 7.2
6'	-	-	-	-	7.49, d, 7.4
7'	-	-	-	-	4.43, s
Solvent	CD <sub>3</sub> OD	D <sub>2</sub> O	D <sub>2</sub> O	CD <sub>3</sub> OD	D <sub>2</sub> O

The spectra were taken on a JEOL ECA-500 spectrometer. Chemical shifts ( $\delta$ ) are given in ppm and coupling constants in hertz *brt* broad triplet

\* Signals overlapping with ethanol (impurity)

with 20  $\mu$ g protein at 37 °C for 16 h. Inspection of the HPLC chromatograms of the reaction mixtures revealed the presence of one product peak each. HPLC chromatograms of nine selected enzyme assays are illustrated in Fig. 3.

As given in Table 1, TyrPT and SirD displayed similar preference for tyrosine and derivatives in the presence of all three DMAPP analogs. Higher conversion yields were detected for incubations of TyrPT and SirD in the presence of 2-pen-PP than MAPP, corresponding to those observed with indole prenyltransferases (Liebhold et al. 2012, 2013). 1a and 2a were well accepted by TyrPT and SirD in the presence of MAPP with conversion yields of more than 20 %, while 1a–5a were good acceptors for 2-pen-PP. Conversion yields of more than 20 % were calculated for incubations of 1a–4a with

TyrPT and 1a–3a and 5a with SirD. In comparison to MAPP and 2-pen-PP, benzyl-PP was a poor donor for both enzymes. Conversion yields of 67.2 and 54.6 % were detected for 2a with TyrPT and SirD, respectively. Much lower conversion yields of less than 3 % were found for other substrates. As given in Table 1, 2a was accepted as the best substrate by TyrPT and SirD in the presence of MAPP and benzyl-PP. Comparable acceptance was observed for 1a and 2a by both enzymes in the presence of 2-pen-PP. Overall, 2a was the best or one of the best substrates for both TyrPT and SirD in the presence DMAPP analogs, which differs clearly from their preference toward aromatic substrates in the presence of DMAPP. Using DMAPP as prenyl donor, TyrPT showed higher activities toward 4a–6a than 2a and SirD accepted 6a

Table 3 HR-EI-MS data of the isolated enzyme products

Product	Formula	Calculated (M <sub>r</sub> )	Measured $[M]^+$	Deviation (ppm)
1b	C13H17NO3	235.1208	235.1215	-3.0
2b	$C_{13}H_{18}N_2O_2$	234.1368	234.1379	-4.5
3b	C <sub>13</sub> H <sub>16</sub> FNO <sub>3</sub>	253.1114	253.1109	2.0
1c	C14H19NO3	249.1365	249.1378	-5.2
2c	$C_{14}H_{20}N_2O_2$	248.1525	248.1530	-2.0
3c	C14H18FNO3	267.1271	267.1285	-5.2
4c	C14H19NO4	265.1314	265.1323	-3.4
5c	C15H21NO3	263.1521	263.1533	-4.6
2d	$C_{16}H_{18}N_2O_2$	270.1368	270.1384	-5.9

much better than 2a (Table 1). It seems that the 4-amino group of 2a had a better interaction with the enzymes in the presence of the unnatural donors, so that the cation intermediates (Liebhold et al. 2012) are more stable than in the cases of other aromatic substrates.

In a previous study, TyrPT and SirD were demonstrated to be low stereoselective in the presence of DMAPP as prenyl donor (Fan et al. 2014). D-Tyrosine (8a) was accepted by TyrPT and SirD with relative activities of 50 and 30 % of those of 1a, respectively, which was also confirmed in this study (Table 1). As given in Table 1, 8a was a very poor substrate for both enzymes in the presence of the three DMAPP analogs, and conversion yields of less than 2 % were detected in this study. It can be speculated that in the presence of the unnatural alkyl or benzyl donors, both enzymes had changed




Fig. 2 SDS-PAGE analysis of purified TyrPT-His<sub>6</sub> and SirD-His<sub>6</sub>. The proteins were separated on a 12 % SDS-polyacrylamide gel and stained with Coomassie Brilliant Blue G-250. **a** Purified SirD and **b** purified TyrPT; M molecular mass standard

Fig. 3 HPLC analysis of the incubation mixtures of selected substrates with TyrPT (*left column*) and SirD (*middle column*) as well as the transfer reactions catalyzed by TyrPT and SirD (*right column*). The reaction mixtures contained 20 µg TyrPT or SirD, 1.0 mM of aromatic substrate, 1.0 mM DMAPP analog, 10 mM CaCl<sub>2</sub>, and 50 mM Tris-HCl (pH 7.5) and were incubated at 37 °C for 16 h. The illustrated chromatograms were recorded at 277 nm. Product yields are given in *parentheses* after the product numbers


their conformations, so that 8a was much poorly fixed into the reaction cavities of both enzymes than 1a.

TyrPT and SirD catalyze the same

O-/N-alkylation/benzylation of tyrosine and derivatives

For structure elucidation, nine enzyme products were isolated on preparative HPLC from the incubation mixtures of TyrPT and SirD in different combinations of tyrosine and derivatives with the three DMAPP analogs. 1b–3b were obtained from the incubation mixtures of 1a–3a with MAPP, respectively, 1c–5c from those of 1a–5a with 2-pen-PP, and 2d from that of 2a with benzyl-PP. The obtained products were subjected to MS and NMR analyses. Identical <sup>1</sup>H NMR spectra of the enzyme products were obtained from incubation mixtures of TyrPT and SirD with a given substrate illustrated in Fig. 3 (data not shown), proving the same function of both enzymes in the presence of unnatural DMAPP analogs.

Molecular formula deduced from high-resolution electron impact mass spectrometry (Table 3) proved the nine isolated products to be monoprenylated or benzylated derivatives of the respective substrate. Inspection of the <sup>1</sup>H NMR spectra (Figs. S1-S12 in the Supplementary Material) of 1b-3b, 1c-5c, and 2d revealed the presence of only one product each. The coupling pattern of the signals for the methylallyl and 2pentenyl residues are comparable to those of previously reported compounds with a regular alkyl moiety (Liebhold et al. 2012), proving their attachment in a regular pattern. In comparison to those of the respective substrate, the chemical shifts, number, and coupling pattern of the signals for protons at the aromatic ring and the side chain of the isolated products were nearly unchanged and are similar to those of the prenylated derivatives with DMAPP (Fan et al. 2014; Kremer and Li 2010; Zou et al. 2011). All these observations suggested the alkylation at the hydroxyl or amino group of the aromatic ring. The chemical shifts of H-1' of the alkyl moieties for products 1b, 1c, 3b, 3c, and 5c between 4.44 and 4.49 ppm in CD<sub>3</sub>OD and for 4c at 4.61 ppm in D<sub>2</sub>O proved unequivocally their attachment to O-atoms (Fan et al. 2014; Kremer and Li 2010; Zou et al. 2011). In the case of 3,4dihydroxy-L-phenylalanine (4a), O-alkylation at position C-3 or C-4 would be possible. The correlations found between H-1' and C-4 in the HMBC spectra of 4c (Fig. 4 and Figs. S9 and S10 in the Supplementary Material) revealed that the 2-pentenyl moiety was attached to O-atom at position C-4



\_\_\_\_ Springer




Fig. 4 Selected HMBC correlations observed in 4c

of the aromatic ring. The chemical shifts of H-1' of the alkyl moiety at 3.75 ppm were observed in the spectra of the products 2b and 2c from the incubation mixtures of 2a with MAPP and 2-pen-PP, proving an *N*-alkylation in their structures (Fan et al. 2014; Zou et al. 2011). In the spectrum of 2d from the incubation mixture of 2a with benzyl-PP, the signals for both benzene rings have been nearly unchanged and the signal of the methylene group was detected at 4.43 ppm. These data proved unequivocally the benzylation of the amino group at the aromatic ring. In conclusion, both TyrPT and SirD accepted unnatural alkyl/benzyl donors and catalyzed the *O-/N*-al-kylation/benzylation of tyrosine and derivatives at the same position as in the presence of their natural prenyl donor DMAPP.

# Kinetic parameters of TyrPT and SirD toward the unnatural DMAPP analogs

To compare the catalytic efficiencies of TyrPT and SirD in the presence of unnatural alkyl or benzyl donors with those of their natural prenyl donor DMAPP, kinetic parameters including Michaelis-Menten constant ( $K_{\rm M}$ ) and turnover number ( $k_{\rm cat}$ ) were determined for MAPP and 2-pen-PP by using 1a as substrate (Table 4 and Figs. S13–S16 in the Supplementary Material). Due to the low conversions of benzyl-PP with 1a, its kinetic parameters were obtained from incubation mixtures with 2a (Table 4 and Figs. S17 and S18 in the Supplementary Material). MAPP was accepted by both enzymes with very small  $K_{\rm M}$  values, lower than those of 2pen-PP, benzyl-PP, and DMAPP. All three unnatural donors showed much lower turnover numbers than those of DMAPP.

#### Discussion

As aforementioned, TyrPT and SirD belong to the prenyltransferases of the DMATS superfamily. Similar to other members of this family, TyrPT and SirD showed high substrate flexibility toward tyrosine and derivatives and catalyzed regioselective transfer reactions, i.e., the 4-O- or 4-Nprenylation (Fan et al. 2014; Kremer and Li 2010; Zou et al. 2011). Both enzymes also accepted tryptophan and derivatives as substrates and mainly catalyzed the C7-prenylation at the indole ring (Fan et al. 2014; Kremer and Li 2010; Rudolf and Poulter 2013). In comparison, the tryptophan C4-prenyltransferase FgaPT2 and C7-prenyltransferase 7-DMATS also accepted L-tyrosine and a few number of its derivatives as prenylation substrates, demonstrating the complementary substrate promiscuity of tryptophan and tyrosine prenyltransferases. However, differing from the two tyrosine O-prenyltransferases TyrPT and SirD with the same C7prenylated product from L-tryptophan, FgaPT2 catalyzed a C3- and 7-DMATS an O-prenvlation of tyrosine, respectively (Fan et al. 2015; Fan and Li 2014). Similar to most of the DMATS enzymes, these two enzymes showed strict substrate specificity toward DMAPP and did not accepted geranyl diphosphate as prenyl donor (Kremer and Li 2010) (data for TyrPT not shown). Acceptance of MAPP, 2-pen-PP, and benzyl-PP by TyrPT and SirD presented in this study provided experimental evidence on their substrate promiscuity for prenyl donor and expanded their potential usage for increasing the structural diversity of alkylated compounds in the chemoenzymatic synthesis.

In previous studies, we have demonstrated that several indole prenyltransferases including tryptophan and tryptophancontaining cyclic dipeptide prenyltransferases used MAPP and 2-pen-PP as alkyl donors and the tryptophan *C4*-

 Table 4
 Comparison of kinetic parameters of TyrPT and SirD toward alkyl/benzyl donors

Donor	TyrPT			SirD			
	$K_{\rm M}$ (mM)	$k_{\text{cat}} (\min^{-1})$	$k_{\text{cat}}/K_{\text{M}} (\text{min}^{-1} \text{mM}^{-1})$	$K_{\rm M}$ (mM)	$k_{\rm cat} ({\rm min}^{-1})$	$k_{\text{cat}}/K_{\text{M}} (\min^{-1} \mathrm{mM}^{-1})$	
DMAPP <sup>a</sup>	0.71	41.4	58.3	0.17	60	352.9	
MAPP <sup>b</sup>	$0.029 {\pm} 0.0036$	$0.12 {\pm} 0.013$	4.14	$0.13 {\pm} 0.025$	$0.16{\pm}0.03$	1.23	
2-pen-PP <sup>b</sup>	$0.23 \pm 0.052$	$0.20 {\pm} 0.022$	0.87	$0.22 \pm 0.053$	$0.13 {\pm} 0.004$	0.59	
benzyl-PP <sup>c</sup>	$0.52 {\pm} 0.022$	$0.96 {\pm} 0.003$	1.85	$0.75 {\pm} 0.0021$	$1.68 {\pm} 0.01$	2.24	

DMAPP dimethylallyl diphosphate, MAPP methylallyl diphosphate, 2-pen-PP 2-pentenyl diphosphate, benzyl-PP benzyl diphosphate

<sup>a</sup> Data for DMAPP were adopted from previous studies (Fan et al. 2014; Kremer and Li 2010)

<sup>b</sup> Data were obtained from four independent assays by using 1a as aromatic substrate

<sup>c</sup> Data were obtained from two independent assays by using 2a as aromatic substrate

prenyltransferase FgaPT2 even used benzyl-PP for benzylation (Liebhold et al. 2012, 2013; Liebhold and Li 2013). These enzymes catalyzed regiospecific and stereospecific prenyl transfer reactions from DMAPP onto indole rings (Grundmann and Li 2005; Unsöld and Li 2005; Yin et al. 2009, 2010, 2013; Yu and Li 2012). In the presence of the unnatural DMAPP analogs, the alkylation/benzylation positions were partially or completely shifted to the neighboring position, e.g., from exclusively at C-2 with C2prenyltransferases BrePT and FtmPT1 to both C-2 and C-3 (Liebhold et al. 2013). C2- and C3-alkylations with MAPP and 2-pen-PP were also observed for the three C3prenyltransferases AnaPT, CdpNPT, and CdpC3PT (Liebhold et al. 2013). The alkylation positions of the two tryptophan prenyltransferases FgaPT2 and 5-DMATS were partially (in the presence of MAPP) or completely (in the presence of 2-pen-PP) shifted (Liebhold et al. 2012). The tryptophan C4-prenyltransferase FgaPT2 catalyzed the benzylation at C-5 of the indole ring (Liebhold and Li 2013). As shown in Fig. 3, only one enzyme product each was detected in the incubation mixtures of selected well accepted substrates and identified as 4-O- or 4-N-alkylated or benzylated derivative of the respective substrate. This means that the TyrPT and SirD products with the unnatural DMAPP analogs carry the alkyl/benzyl moieties at the same position as their products with the natural donor DMAPP, although alkylation at other positions of tyrosine and derivatives such as C-3 would be possible. Together with N-acetyl-3-prenyl-L-tyrosine, 3-dimethylallyl-L-tyrosine was isolated from Streptomyces sp. IFM 10937 (Ahmed et al. 2008). Members of the DMATS superfamily are also able to catalyze a C3prenylation of tyrosine or derivatives, as demonstrated very recently with FgaPT2 and especially with its mutant FgaPT2 K174F by using L-tyrosine (1a) and 4-amino-L-phenylalanine (2a) as substrates (Fan et al. 2015). This high regioselectivity of TyrPT and SirD toward tyrosine and derivatives with different alkyl donors would be of essential importance for controlled structure modification.

As mentioned in the "Introduction" section, SirD is involved in the biosynthesis of sirodesmin (Fig. 1) (Gardiner et al. 2004; Kremer and Li 2010) and the genetic context of TyrPT in *A. niger* is unknown (Fig. 1) (Fan et al. 2014). As shown in this and in the previous studies (Fan et al. 2014; Kremer and Li 2010; Zou et al. 2011), both enzymes display similar substrate specificities toward donors and acceptors. It can be speculated that the structures of these two enzymes are highly conserved. Furthermore, both DMAPP and the tested DMAPP analogs are placed in their reaction chambers in similar positions and undergo similar reactions.

Determination of the kinetic parameters revealed that TyrPT and SirD showed high affinity to MAPP and 2-pen-PP (Table 4). However, the turnover numbers of the TyrPT and SirD reactions with the three unnatural DMAPP analogs were found between 0.1 and 1.0 min<sup>-1</sup>, comparable to those of the cyclic dipeptide prenyltransferases (Liebhold et al. 2013) and lower than those of tryptophan prenyltransferases with these DMAPP analogs (Liebhold et al. 2012). The low catalytic efficiency of TyrPT and SirD toward MAPP, 2-pen-PP, and benzyl-PP should be improved in the future by sitedirected mutagenesis experiments after availability of the structures of TyrPT or/and SirD.

Acknowledgments We thank Nina Zitzer and Stefan Newel for taking MS and NMR spectra, respectively. This work was supported in part by grants from the Deutsche Forschungsgemeinschaft (Li844/4-1 to S.-M L.). Huili Yu is a recipient of a scholarship from the China Scholarship Council.

#### References

- Ahmed F, Ohtsuki T, Aida W, Ishibashi M (2008) Tyrosine derivatives isolated from *Streptomyces* sp. IFM 10937 in a screening program for TRAIL-resistance-overcoming activity. J Nat Prod 71:1963– 1966
- Chooi YH, Cacho R, Tang Y (2010) Identification of the viridicatumtoxin and griseofulvin gene clusters from *Penicillium aethiopicum*. Chem Biol 17:483–494
- Chooi YH, Wang P, Fang J, Li Y, Wu K, Wang P, Tang Y (2012) Discovery and characterization of a group of fungal polycyclic polyketide prenyltransferases. J Am Chem Soc 134:9428–9437
- Fan A, Li S-M (2014) Prenylation of tyrosine and derivatives by a tryptophan C7-prenyltransferase. Tetrahedron Lett 55:5199–5202
- Fan A, Chen H, Wu R, Xu H, Li S-M (2014) A new member of the DMATS superfamily from *Aspergillus niger* catalyzes prenylations of both tyrosine and tryptophan derivatives. Appl Microbiol Biotechnol 98:10119–10129
- Fan A, Zocher G, Stec E, Stehle T, Li S-M (2015) Site-directed mutagenesis switching a dimethylallyl tryptophan synthase to a specific tyrosine C3-prenylating enzyme. J Biol Chem 290:1364–1373
- Gardiner DM, Cozijnsen AJ, Wilson LM, Pedras MS, Howlett BJ (2004) The sirodesmin biosynthetic gene cluster of the plant pathogenic fungus *Leptosphaeria maculans*. Mol Microbiol 53:1307–1318
- Grundmann A, Li S-M (2005) Overproduction, purification and characterization of FtmPT1, a brevianamide F prenyltransferase from *Aspergillus fumigatus*. Microbiology 151:2199–2207
- Heide L (2009) Prenyl transfer to aromatic substrates: genetics and enzymology. Curr Opin Chem Biol 13:171–179
- Kremer A, Li S-M (2010) A tyrosine O-prenyltransferase catalyses the first pathway-specific step in the biosynthesis of sirodesmin PL. Microbiology 156:278–286
- Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685
- Li S-M (2010) Prenylated indole derivatives from fungi: structure diversity, biological activities, biosynthesis and chemoenzymatic synthesis. Nat Prod Rep 27:57–78
- Liebhold M, Li S-M (2013) Regiospecific benzylation of tryptophan and derivatives catalyzed by a fungal dimethylallyl transferase. Org Lett 15:5834–5837
- Liebhold M, Xie X, Li S-M (2012) Expansion of enzymatic Friedel-Crafts alkylation on indoles: acceptance of unnatural betaunsaturated allyl diphospates by dimethylallyl-tryptophan synthases. Org Lett 14:4884–4885

- Liebhold M, Xie X, Li S-M (2013) Breaking cyclic dipeptide prenyltransferase regioselectivity by unnatural alkyl donors. Org Lett 15:3062–3065
- Pockrandt D, Li S-M (2013) Geranylation of cyclic dipeptides by the dimethylallyl transferase AnaPT resulting in a shift of prenylation position on the indole ring. Chembiochem 14:2023–2028
- Pockrandt D, Ludwig L, Fan A, König GM, Li S-M (2012) New insights into the biosynthesis of prenylated xanthones: XptB from *Aspergillus nidulans* catalyses an *O*-prenylation of xanthones. Chembiochem 13:2764–2771
- Pockrandt D, Sack C, Kosiol T, Li S-M (2014) A promiscuous prenyltransferase from *Aspergillus oryzae* catalyses C-prenylations of hydroxynaphthalenes in the presence of different prenyl donors. Appl Microbiol Biotechnol 98:4987–4994
- Rudolf JD, Poulter CD (2013) Tyrosine *O*-prenyltransferase SirD catalyzes S-, C-, and N-prenylations on tyrosine and tryptophan derivatives. ACS Chem Biol 8:2707–2714
- Tarcz S, Xie X, Li S-M (2014) Substrate and catalytic promiscuity of secondary metabolite enzymes: O-prenylation of hydroxyxanthones with different prenyl donors by a bisindolyl benzoquinone C- and Nprenyltransferase. RSC Adv 4:17986–17992
- Unsöld IA, Li S-M (2005) Overproduction, purification and characterization of FgaPT2, a dimethylallyltryptophan synthase from *Aspergillus fumigatus*. Microbiology 151:1499–1505
- Wollinsky B, Ludwig L, Hamacher A, Yu X, Kassack MU, Li S-M (2012) Prenylation at the indole ring leads to a significant increase of cytotoxicity of tryptophan-containing cyclic dipeptides. Bioorg Med Chem Lett 22:3866–3869
- Woodside AB, Huang Z, Poulter CD (1988) Trisammonium geranyl diphosphate. Org Synth 66:211–215

- Wunsch C, Zou HX, Linne U, Li S-M (2015) C7-prenylation of tryptophanyl and O-prenylation of tyrosyl residues in dipeptides by an Aspergillus terreus prenyltransferase. Appl Microbiol Biotechnol 99:1719–1730
- Yazaki K, Sasaki K, Tsurumaru Y (2009) Prenylation of aromatic compounds, a key diversification of plant secondary metabolites. Phytochemistry 70:1739–1745
- Yin W-B, Grundmann A, Cheng J, Li S-M (2009) Acetylaszonalenin biosynthesis in *Neosartorya fischeri*: identification of the biosynthetic gene cluster by genomic mining and functional proof of the genes by biochemical investigation. J Biol Chem 284:100–109
- Yin W-B, Yu X, Xie X-L, Li S-M (2010) Preparation of pyrrolo[2,3b]indoles carrying a β-configured reverse C3-dimethylallyl moiety by using a recombinant prenyltransferase CdpC3PT. Org Biomol Chem 8:2430–2438
- Yin S, Yu X, Wang Q, Liu XQ, Li S-M (2013) Identification of a brevianamide F reverse prenyltransferase BrePT from *Aspergillus* versicolor with a broad substrate specificity towards tryptophancontaining cyclic dipeptides. Appl Microbiol Biotechnol 97:1649–1660
- Yu X, Li S-M (2011) Prenylation of flavonoids by using a dimethylallyltryptophan synthase 7-DMATS from Aspergillus fumigatus. Chembiochem 12:2280–2283
- Yu X, Li S-M (2012) Prenyltransferases of the dimethylallyltryptophan synthase superfamily. Methods Enzymol 516:259–278
- Yu X, Xie X, Li S-M (2011) Substrate promiscuity of secondary metabolite enzymes: prenylation of hydroxynaphthalenes by fungal indole prenyltransferases. Appl Microbiol Biotechnol 92:737–748
- Zou H-X, Xie X, Zheng X-D, Li S-M (2011) The tyrosine *O*prenyltransferase SirD catalyzes *O*-, *N*-, and *C*-prenylations. Appl Microbiol Biotechnol 89:1443–1451

### **Electronic supplementary material for:**

## Tyrosine O-prenyltransferases TyrPT and SirD displaying similar behavior towards unnatural alkyl or benzyl diphosphate as their natural prenyl donor dimethylallyl diphosphate

Huili Yu<sup>[a]</sup>, Mike Liebhold<sup>[a]</sup>, Xiulan Xie<sup>[b]</sup>, and Shu-Ming Li<sup>[a]</sup>\*

<sup>[a]</sup>Institut für Pharmazeutische Biologie und Biotechnologie, Philipps-Universität

Marburg, Deutschhausstrasse 17A, 35037 Marburg, Germany

<sup>[b]</sup>Fachbereich Chemie, Philipps-Universität Marburg, Hans-Meerwein-Straße 4, 35032


Marburg, Germany


\*Correspondence to Shu-Ming Li: shuming.li@staff.uni-marburg.de;


Telefon: 49(0) 6421 282-2461; Fax: 49(0)6421 282-5365

### Content

Fig. S1 1H NMR spectrum of 1b in CD3OD
Fig. S2 1H NMR spectrum of 2b in D2O
Fig. S3 H-H COSY spectrum of 2b in D2O4
<b>Fig. S4</b> 1H NMR spectrum of <b>3b</b> in CD3OD
Fig. S5 1H NMR spectrum of 1c in CD3OD5
<b>Fig. S6</b> 1H NMR spectrum of <b>2c</b> in D2O6
Fig. S7 1H NMR spectrum of 3c in CD3OD6
Fig. S8 1H NMR spectrum of 4c in D2O7
Fig. S9 HSQC spectrum of 4c in D2O7
Fig. S10 HMBC spectrum of 4c in D2O
Fig. S11 1H NMR spectrum of 5c in CD3OD8
Fig. S12 1H NMR spectrum of 2d in D2O9
Fig. S13 Determination of kinetic parameters of TyrPT for MAPP10
Fig. S14 Determination of kinetic parameters of TyrPT for 2-pen-PP10
Fig. S15 Determination of kinetic parameters of SirD for MAPP11
Fig. S16 Determination of kinetic parameters of SirD for 2-pen-PP11
Fig. S17 Determination of kinetic parameters of TyrPT for benzyl-PP in the presence of 4-amino-
L-phenylalaine12
Fig. S18 Determination of kinetic parameters of SirD for benzyl-PP in the presence of 4-amino-L-
phenylalaine12







**Fig. S2** <sup>1</sup>H NMR spectrum of **2b** in  $D_2O$ .




Fig. S3 H-H COSY spectrum of 2b in  $D_2O$ .




Fig. S4 <sup>1</sup>H NMR spectrum of 3b in CD<sub>3</sub>OD.





Fig. S5 <sup>1</sup>H NMR spectrum of 1c in CD<sub>3</sub>OD.



**Fig. S6** <sup>1</sup>H NMR spectrum of 2c in  $D_2O$ .







Fig. S7 <sup>1</sup>H NMR spectrum of 3c in CD<sub>3</sub>OD.




**Fig. S8** <sup>1</sup>H NMR spectrum of 4c in  $D_2O$ .






**Fig. S11** <sup>1</sup>H NMR spectrum of **5c** in CD<sub>3</sub>OD.



**Fig. S12** <sup>1</sup>H NMR spectrum of 2d in  $D_2O$ .



**Fig. S13** Determination of kinetic parameters of TyrPT for MAPP in the presence of L-tyrosine (1a).







Fig. S14 Determination of kinetic parameters of TyrPT for 2-pen-PP in the presence of L-tyrosine (1a).




**Fig. S15** Determination of kinetic parameters of SirD for MAPP in the presence of L-tyrosine (1a).



**Fig. S16** Determination of kinetic parameters of SirD for 2-pen-PP in the presence of L-tyrosine (**1a**).



**Fig. S17** Determination of kinetic parameters of TyrPT for benzyl-PP in the presence of 4-amino-L-phenylalaine (**2a**).



**Fig. S18** Determination of kinetic parameters of SirD for benzyl-PP in the presence of 4-amino-L-phenylalaine (**2a**).

### **5** Conclusions and future prospects

In this thesis, the structure diversity of natural/chemoenzymatic products was significantly increased by investigation on the CDP formation and further modification in *Streptomyces* as well as by chemoenzymatic synthesis of prenylated tyrosine analogs.

Initially, thirteen CDPS homologues from eleven *Streptomyces* strains were characterized by heterologous expression in *E. coli*. Two CDPSs WP\_014141671 and WP\_014140974 from *Streptomyces cattleya* DSM 46488 were confirmed to form cWW, integrity with the known results. Nine new members of CDPSs were identified to catalyze the formation of cWX. With high yields of 46 to 211 mg/L *E. coli* culture, it is convenient for future application in synthetic biology. The other two CDPSs WP\_031028810 from *Streptomyces* sp. NRRL F-5639 and BAU83478 from *Streptomyces laurentii* DSM 41684 were proven to catalyze the formation of cFL. Phylogenetic analysis of the CDPSs in this study with the known CDPSs revealed two clades: the relative conserved clade I containing only cWX synthases with the exception for cLL synthase and the promiscuous clade II including cWX synthases and cFX and cYX synthases.

Furthermore, one cWW tailoring P450, P450<sub>NB5737</sub> from *S. purpureus* NRRL-B5737, was characterized by heterologous expression in *S. coelicolor* and by *in vitro* enzyme assays with recombinant proteins. It was demonstrated that the cWW formed by CDPS<sub>NB5737</sub> was further modified by P450<sub>NB5737</sub>, resulting in an adduct of cWW and guanine *via* a C– N bond. However, the activity of P450<sub>NB5737</sub> is very low in the *in vitro* assays, possibly due to the incorrect state of the purified P450 from *E. coli*. The modification of peptides by a nucleobase is not reported prior to this study. P450<sub>NB5737</sub> is one additional example of rare atypical P450s that catalyze the coupling of two substrates with distinct structures. This indicates the presence of novel active site(s) in the identified enzymes differing from those of known P450s, which should be investigated in the future.

The spectra of prenyl donors of *O*-prenyltransferases TyprPT and SirD were also expanded by testing their acceptance toward the unnatural DMAPP analogs, such as MAPP, 2-pen-PP and benzyl-PP. The reactions were performed by incubation of tyrosine and its 12 analogs in the presence of TyrPT and SirD. It was proven that both TyrPT and SirD exhibited similar behavior to the unnatural DMAPP analogs as their natural prenyl donor DMAPP, catalyzing the *O-/N-*alkylation/benzylation of tyrosine and derivatives. This study increased significantly the diversity of prenylated products by chemoenzymatic synthesis.

For future prospects, the following works can be performed:

- Coexpression of the genes of cWX-forming CDPSs with those of CDP PTs such as CdpC2PT, CdpC3PT, CdpNPT or AnaPT or even other tailoring enzymes from different synthetic pathways in engineered heterologous expression system.
- Understanding the catalytic mechanism of P450<sub>NB5737</sub> by solving the crystal structure of P450<sub>NB5737</sub>.
- Identification of the extended clusters containing the CDPS<sub>NB5737</sub> and P450<sub>NB5737</sub> by heterologous expression in *Streptomyces* or gene deletion experiments.

### **6** References

(1) Ventura, M.; Canchaya, C.; Tauch, A.; Chandra, G.; Fitzgerald, G. F.; Chater, K. F.;van, S. D., Genomics of Actinobacteria: tracing the evolutionary history of an ancient phylum, *Microbiol.Mol.Biol.Rev.* **2007**, *71*, 495.

(2) Ghai, R.; McMahon, K. D.;Rodriguez-Valera, F., Breaking a paradigm: cosmopolitan and abundant freshwater actinobacteria are low GC, *Environ.Microbiol.Rep.* **2012**, *4*, 29.

(3) Servin, J. A.; Herbold, C. W.; Skophammer, R. G.;Lake, J. A., Evidence excluding the root of the tree of life from the actinobacteria, *Mol.Biol.Evol.* **2008**, *25*, 1.

(4) Takahashi, Y. and Nakashima, T., Actinomycetes, an inexhaustible source of naturally occurring antibiotics, *Antibiotics (Basel)* **2018**, *7*.

(5) Bentley, S. D.; Chater, K. F.; Cerdeno-Tarraga, A. M.; Challis, G. L.; Thomson, N. R.; James, K. D.; Harris, D. E.; Quail, M. A.; Kieser, H.; Harper, D.; et al., Complete genome sequence of the model actinomycete *Streptomyces coelicolor* A3(2), *Nature* **2002**, *417*, 141.

(6) Mahajan, G. B. and Balachandran, L., Antibacterial agents from Actinomycetes - A Review, *Frontiers in Bioscience* **2012**, *E4*, 240.

(7) Shaw, K. and Singleton, S., "Antimicrobial resistance will kill millions--we must act now", *Nurs.Times* **2016**, *112*, 11.

(8) Baltz, R. H., Renaissance in antibacterial discovery from actinomycetes, *Curr.Opin.Pharmacol.* **2008**, *8*, 557.

(9) Gomez-Escribano, J. P. and Bibb, M. J., Engineering *Streptomyces coelicolor* for heterologous expression of secondary metabolite gene clusters, *Microb.Biotechnol.* **2011**, *4*, 207.

(10) Hug, J. J.; Bader, C. D.; Remskar, M.; Cirnski, K.;Muller, R., Concepts and methods to access novel antibiotics from Actinomycetes, *Antibiotics (Basel)* **2018**, *7*.

(11) Abdelmohsen, U. R.; Grkovic, T.; Balasubramanian, S.; Kamel, M. S.; Quinn, R. J.; Hentschel, U., Elicitation of secondary metabolism in actinomycetes, *Biotechnol.Adv.* **2015**, *33*, 798.

(12) Prasad, C., Bioactive cyclic dipeptides, Peptides 1995, 16, 151.

(13) Mishra, A. K.; Choi, J.; Choi, S. J.;Baek, K. H., Cyclodipeptides: An overview of their biosynthesis and biological activity, *Molecules*. **2017**, *22*, E1796.

(14) McCleland, K.; Milne, P. J.; Lucieto, F. R.; Frost, C.; Brauns, S. C.; van, d., V; Du, P. J.;Dyason, K., An investigation into the biological activity of the selected histidinecontaining diketopiperazines cyclo(His-Phe) and cyclo(His-Tyr), *J.Pharm.Pharmacol.* **2004**, *56*, 1143.

(15) Kanoh, K.; Kohno, S.; Katada, J.; Takahashi, J.;Uno, I., (-)-Phenylahistin arrests cells in mitosis by inhibiting tubulin polymerization, *J.Antibiot.(Tokyo)* **1999**, *52*, 134.

(16) Ström, K.; Sjögren, J.; Broberg, A.;Schnürer, J., *Lactobacillus plantarum* MiLAB 393 produces the antifungal cyclic dipeptides cyclo(L-Phe-L-Pro) and cyclo(L-Phe-trans-4-OH-L-Pro) and 3-phenyllactic acid, *Appl.Environ.Microbiol.* **2002**, *68*, 4322.

(17) Martins, M. B. and Carvalho, I., Diketopiperazines: biological activity and synthesis, *Tetrahedron* **2007**, *63*, 9923.

(18) Kanokmedhakul, S.; Kanokmedhakul, K.; Phonkerd, N.; Soytong, K.; Kongsaeree, P.;Suksamrarn, A., Antimycobacterial anthraquinone-chromanone compound and diketopiperazine alkaloid from the fungus *Chaetomium globosum* KMITL-N0802, *Planta Med.* **2002**, *68*, 834.

(19) Hwang, I. K.; Go, V. L.; Harris, D. M.; Yip, I.; Kang, K. W.;Song, M. K., Effects of cyclo (his-pro) plus zinc on glucose metabolism in genetically diabetic obese mice, *Diabetes Obes.Metab* **2003**, *5*, 317.

(20) Kwon, O. S.; Park, S. H.; Yun, B. S.; Pyun, Y. R.;Kim, C. J., Cyclo(dehydroala-L-Leu), an alpha-glucosidase inhibitor from *Penicillium* sp. F70614, *J.Antibiot.(Tokyo)* **2000**, *53*, 954.

(21) Minelli, A.; Grottelli, S.; Mierla, A.; Pinnen, F.; Cacciatore, I.;Bellezza, I., Cyclo(His-Pro) exerts anti-inflammatory effects by modulating NF-kB and Nrf2 signalling, *Int.J.Biochem.Cell Biol.* **2012**, *44*, 525.

(22) Finking, R. and Marahiel, M. A., Biosynthesis of nonribosomal peptides, *Annu.Rev.Microbiol.* **2004**, *58*, 453.

(23) Winn, M.; Fyans, J. K.; Zhuo, Y.;Micklefield, J., Recent advances in engineering nonribosomal peptide assembly lines, *Nat.Prod.Rep.* **2016**, *33*, 317.

(24) Marahiel, M. A., A structural model for multimodular NRPS assembly lines, *Nat.Prod.Rep.* **2016**, *33*, 136.

(25) Healy, F. G.; Wach, M.; Krasnoff, S. B.; Gibson, D. M.;Loria, R., The txtAB genes of the plant pathogen *Streptomyces acidiscabies* encode a peptide synthetase required for phytotoxin thaxtomin A production and pathogenicity, *Mol.Microbiol.* **2000**, *38*, 794.

(26) Schultz, A. W.; Oh, D. C.; Carney, J. R.; Williamson, R. T.; Udwary, D. W.; Jensen, P. R.; Gould, S. J.; Fenical, W.;Moore, B. S., Biosynthesis and structures of cyclomarins and cyclomarazines, prenylated cyclic peptides of marine actinobacterial origin, *J Am.Chem Soc.* **2008**, *130*, 4507.

(27) Stachelhaus, T.; Mootz, H. D.; Bergendahl, V.;Marahiel, M. A., Peptide bond formation in nonribosomal peptide biosynthesis. Catalytic role of the condensation domain, *J.Biol.Chem.* **1998**, *273*, 22773.

(28) Healy, F. G.; Krasnoff, S. B.; Wach, M.; Gibson, D. M.; Loria, R., Involvement of a cytochrome P450 monooxygenase in thaxtomin A biosynthesis by *Streptomyces acidiscabies*, *J.Bacteriol.* **2002**, *184*, 2019.

(29) Barry, S. M.; Kers, J. A.; Johnson, E. G.; Song, L.; Aston, P. R.; Patel, B.; Krasnoff, S. B.; Crane, B. R.; Gibson, D. M.; Loria, R.; et al., Cytochrome P450-catalyzed L-tryptophan nitration in thaxtomin phytotoxin biosynthesis, *Nat.Chem Biol.* **2012**, *8*, 814.

(30) García-Estrada, C.; Ullán, R. V.; Álbillos, S. M.; Fernández-Bodega, M. A.; Durek, P.; von, D. H.;Martín, J. F., A single cluster of coregulated genes encodes the biosynthesis of the mycotoxins roquefortine C and meleagrin in *Penicillium chrysogenum*, *Chem.Biol.* **2011**, *18*, 1499.

(31) Gardiner, D. M. and Howlett, B. J., Bioinformatic and expression analysis of the putative gliotoxin biosynthetic gene cluster of *Aspergillus fumigatus*, *FEMS Microbiol.Lett.* **2005**, *248*, 241.

(32) Maiya, S.; Grundmann, A.; Li, S.-M.; Turner, G., The fumitremorgin gene cluster of *Aspergillus fumigatus*: identification of a gene encoding brevianamide F synthetase, *Chembiochem.* **2006**, *7*, 1062.

(33) Yin, W.-B.; Grundmann, A.; Cheng, J.;Li, S.-M., Acetylaszonalenin biosynthesis in *Neosartorya fischeri*: Identification of the biosynthetic gene cluster by genomic mining

and functional proof of the genes by biochemical investigation, *J.Biol.Chem.* **2009**, *284*, 100.

(34) Saruwatari, T.; Yagishita, F.; Mino, T.; Noguchi, H.; Hotta, K.;Watanabe, K., Cytochrome P450 as dimerization catalyst in diketopiperazine alkaloid biosynthesis, *Chembiochem.* **2014**, *15*, 656.

(35) Lautru, S.; Gondry, M.; Genet, R.;Pernodet, J. L., The albonoursin gene cluster of *S. noursei*: Biosynthesis of diketopiperazine metabolites independent of nonribosomal peptide synthetases, *Chem Biol.* **2002**, *9*, 1355.

(36) Gondry, M.; Lautru, S.; Fusai, G.; Meunier, G.; Menez, A.;Genet, R., Cyclic dipeptide oxidase from *Streptomyces noursei*. Isolation, purification and partial characterization of a novel, amino acyl a,b-dehydrogenase, *Eur.J.Biochem.* **2001**, *268*, 1712.

(37) Belin, P.; Moutiez, M.; Lautru, S.; Seguin, J.; Pernodet, J. L.;Gondry, M., The nonribosomal synthesis of diketopiperazines in tRNA-dependent cyclodipeptide synthase pathways, *Nat.Prod.Rep.* **2012**, *29*, 961.

(38) Hanson, A. D.; Pribat, A.; Waller, J. C.; de Crecy-Lagard, V., 'Unknown' proteins and 'orphan' enzymes: the missing half of the engineering parts list--and how to find it, *Biochem.J.* **2009**, *425*, 1.

(39) Jacques, I. B.; Moutiez, M.; Witwinowski, J.; Darbon, E.; Martel, C.; Seguin, J.; Favry, E.; Thai, R.; Lecoq, A.; Dubois, S.; et al., Analysis of 51 cyclodipeptide synthases reveals the basis for substrate specificity, *Nat.Chem Biol.* **2015**, *11*, 721.

(40) Liu, J.; Yu, H.;Li, S.-M., Expanding tryptophan-containing cyclodipeptide synthase spectrum by identification of nine members from *Streptomyces* strains, *Appl.Microbiol.Biotechnol* **2018**, *102*, 4435.

(41) Liu, J.; Yu, H.;Li, S.-M., Correction to: Expanding tryptophan-containing cyclodipeptide synthase spectrum by identification of nine members from *Streptomyces s*trains, *Appl.Microbiol.Biotechnol* **2018**, *102*, 5787.

(42) Gondry, M.; Jacques, I. B.; Thai, R.; Babin, M.; Canu, N.; Seguin, J.; Belin, P.; Pernodet, J. L.;Moutiez, M., A comprehensive overview of the cyclodipeptide synthase family enriched with the characterization of 32 new enzymes, *Front Microbiol.* **2018**, *9*, 46.

(43) Seguin, J.; Moutiez, M.; Li, Y.; Belin, P.; Lecoq, A.; Fonvielle, M.; Charbonnier, J. B.; Pernodet, J. L.;Gondry, M., Nonribosomal peptide synthesis in animals: the cyclodipeptide synthase of *Nematostella*, *Chem.Biol.* **2011**, *18*, 1362.

(44) Sauguet, L.; Moutiez, M.; Li, Y.; Belin, P.; Seguin, J.; Le Du, M. H.; Thai, R.; Masson, C.; Fonvielle, M.; Pernodet, J. L.; et al., Cyclodipeptide synthases, a family of class-I aminoacyl-tRNA synthetase-like enzymes involved in non-ribosomal peptide synthesis, *Nucleic Acids Res.* **2011**, *39*, 4475.

(45) Bonnefond, L.; Arai, T.; Sakaguchi, Y.; Suzuki, T.; Ishitani, R.;Nureki, O., Structural basis for nonribosomal peptide synthesis by an aminoacyl-tRNA synthetase paralog, *Proc.Natl.Acad.Sci.U.S.A* **2011**, *108*, 3912.

(46) Vetting, M. W.; Hegde, S. S.;Blanchard, J. S., The structure and mechanism of the *Mycobacterium tuberculosis* cyclodityrosine synthetase, *Nat.Chem.Biol.* **2010**, *6*, 797.

(47) Moutiez, M.; Schmitt, E.; Seguin, J.; Thai, R.; Favry, E.; Belin, P.; Mechulam, Y.;Gondry, M., Unravelling the mechanism of non-ribosomal peptide synthesis by cyclodipeptide synthases, *Nat.Commun.* **2014**, *5*, 5141.

(48) Canu, N.; Belin, P.; Thai, R.; Correia, I.; Lequin, O.; Seguin, J.; Moutiez, M.;Gondry, M., Incorporation of non-canonical amino acids into 2,5-diketopiperazines by cyclodipeptide synthases, *Angew.Chem.Int.Ed Engl.* **2018**, *57*, 3118.

(49) Giessen, T. W.; von Tesmar, A. M.;Marahiel, M. A., A tRNA-dependent twoenzyme pathway for the generation of singly and doubly methylated ditryptophan 2,5diketopiperazines, *Biochemistry* **2013**, *52*, 4274.

(50) Cryle, M. J.; Bell, S. G.; Schlichting, I., Structural and biochemical characterization of the cytochrome P450 CypX (CYP134A1) from *Bacillus subtilis*: a cyclo-L-leucyl-L-leucyl dipeptide oxidase, *Biochemistry* **2010**, *49*, 7282.

(51) Gondry, M.; Sauguet, L.; Belin, P.; Thai, R.; Amouroux, R.; Tellier, C.; Tuphile, K.; Jacquet, M.; Braud, S.; Courcon, M.; et al., Cyclodipeptide synthases are a family of tRNA-dependent peptide bond-forming enzymes, *Nat.Chem.Biol.* **2009**, *5*, 414.

(52) Belin, P.; Le Du, M. H.; Fielding, A.; Lequin, O.; Jacquet, M.; Charbonnier, J. B.; Lecoq, A.; Thai, R.; Courcon, M.; Masson, C.; et al., Identification and structural basis of the reaction catalyzed by CYP121, an essential cytochrome P450 in *Mycobacterium tuberculosis*, *Proc.Natl.Acad.Sci.U.S.A* **2009**, *106*, 7426.

(53) Giessen, T. W.; von Tesmar, A. M.;Marahiel, M. A., Insights into the generation of structural diversity in a tRNA-dependent pathway for highly modified bioactive cyclic dipeptides, *Chem.Biol.* **2013**, *20*, 828.

(54) Patteson, J. B.; Cai, W.; Johnson, R. A.; Santa Maria, K. C.;Li, B., Identification of the biosynthetic pathway for the antibiotic bicyclomycin, *Biochemistry* **2018**, *57*, 61.

(55) Meng, S.; Han, W.; Zhao, J.; Jian, X. H.; Pan, H. X.; Tang, G. L., A six-oxidase cascade for tandem C-H bond activation revealed by reconstitution of bicyclomycin biosynthesis, *Angew.Chem Int.Ed Engl.* **2018**, *57*, 719.

(56) Kanzaki, H.; Yanagisawa, S.;Nitoda, T., Enzymatic synthesis of dehydro cyclo(His-Phe)s, analogs of the potent cell cycle inhibitor, dehydrophenylahistin, and their inhibitory activities toward cell division, *Biosci.Biotechnol.Biochem.* **2004**, *68*, 2341.

(57) Giessen, T. W. and Marahiel, M. A., Rational and combinatorial tailoring of bioactive cyclic dipeptides, *Front Microbiol.* **2015**, *6*, 785.

(58) Li, S.-M., Prenylated indole derivatives from fungi: structure diversity, biological activities, biosynthesis and chemoenzymatic synthesis, *Nat.Prod.Rep.* **2010**, *27*, 57.

(59) Yu, X.; Liu, Y.; Xie, X.; Zheng, X.-D.;Li, S.-M., Biochemical characterization of indole prenyltransferases: Filling the last gap of prenylation positions by a 5dimethylallyltryptophan synthase from *Aspergillus clavatus*, *J.Biol.Chem.* **2012**, *287*, 1371.

(60) Cook, D. J.; Finnigan, J. D.; Cook, K.; Black, G. W.; Charnock, S. J., Cytochromes P450: History, classes, catalytic mechanism, and industrial application, *Adv.Protein Chem.Struct.Biol.* **2016**, *105*, 105.

(61) Omura, T. and Sato, R., The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties, *J.Biol.Chem.* **1964**, *239*, 2379.

(62) Hannemann, F.; Bichet, A.; Ewen, K. M.;Bernhardt, R., Cytochrome P450 systems--biological variations of electron transport chains, *Biochim.Biophys.Acta* **2007**, *1770*, 330.

(63) Podust, L. M. and Sherman, D. H., Diversity of P450 enzymes in the biosynthesis of natural products, *Nat.Prod.Rep.* **2012**, *29*, 1251.

(64) Rudolf, J. D.; Chang, C. Y.; Ma, M.;Shen, B., Cytochromes P450 for natural product biosynthesis in *Streptomyces*: sequence, structure, and function, *Nat.Prod.Rep.* **2017**, *34*, 1141.

(65) Poulos, T. L.; Perez, M.;Wagner, G. C., Preliminary crystallographic data on cytochrome P-450CAM, *J.Biol.Chem.* **1982**, *257*, 10427.

(66) Poulos, T. L.; Finzel, B. C.; Gunsalus, I. C.; Wagner, G. C.; Kraut, J., The 2.6-A crystal structure of *Pseudomonas putida* cytochrome P-450, *J.Biol.Chem.* **1985**, *260*, 16122.

(67) Guengerich, F. P.; Waterman, M. R.; Egli, M., Recent structural insights into cytochrome P450 function, *Trends Pharmacol.Sci.* **2016**, *37*, 625.

(68) Zhang, X. and Li, S., Expansion of chemical space for natural products by uncommon P450 reactions, *Nat.Prod.Rep.* **2017**, *34*, 1061.

(69) Anzai, Y.; Li, S.; Chaulagain, M. R.; Kinoshita, K.; Kato, F.; Montgomery, J.;Sherman, D. H., Functional analysis of MycCI and MycG, cytochrome P450 enzymes involved in biosynthesis of mycinamicin macrolide antibiotics, *Chem.Biol.* **2008**, *15*, 950.

(70) Li, S.; Tietz, D. R.; Rutaganira, F. U.; Kells, P. M.; Anzai, Y.; Kato, F.; Pochapsky, T. C.; Sherman, D. H.; Podust, L. M., Substrate recognition by the multifunctional cytochrome P450 MycG in mycinamicin hydroxylation and epoxidation reactions, *J.Biol.Chem.* **2012**, *287*, 37880.

(71) Carlson, J. C.; Li, S.; Gunatilleke, S. S.; Anzai, Y.; Burr, D. A.; Podust, L. M.; Sherman, D. H., Tirandamycin biosynthesis is mediated by co-dependent oxidative enzymes, *Nat.Chem.* **2011**, *3*, 628.

(72) Mo, X.; Wang, Z.; Wang, B.; Ma, J.; Huang, H.; Tian, X.; Zhang, S.; Zhang, C.;Ju, J., Cloning and characterization of the biosynthetic gene cluster of the bacterial RNA polymerase inhibitor tirandamycin from marine-derived *Streptomyces* sp. SCSIO1666, *Biochem.Biophys.Res.Commun.* **2011**, *406*, 341.

(73) Makino, M.; Sugimoto, H.; Shiro, Y.; Asamizu, S.; Onaka, H.;Nagano, S., Crystal structures and catalytic mechanism of cytochrome P450 StaP that produces the indolocarbazole skeleton, *Proc.Natl.Acad.Sci.U.S.A* **2007**, *104*, 11591.

(74) Onaka, H.; Asamizu, S.; Igarashi, Y.; Yoshida, R.;Furumai, T., Cytochrome P450 homolog is responsible for C-N bond formation between aglycone and deoxysugar in

the staurosporine biosynthesis of *Streptomyces* sp. TP-A0274, *Biosci.Biotechnol Biochem.* **2005**, *69*, 1753.

(75) Ikezawa, N.; Iwasa, K.;Sato, F., Molecular cloning and characterization of CYP80G2, a cytochrome P450 that catalyzes an intramolecular *C*-*C* phenol coupling of (S)-reticuline in magnoflorine biosynthesis, from cultured *Coptis japonica* cells, *J.Biol.Chem.* **2008**, *283*, 8810.

(76) Zhao, B.; Guengerich, F. P.; Bellamine, A.; Lamb, D. C.; Izumikawa, M.; Lei, L.; Podust, L. M.; Sundaramoorthy, M.; Kalaitzis, J. A.; Reddy, L. M.; et al., Binding of two flaviolin substrate molecules, oxidative coupling, and crystal structure of *Streptomyces coelicolor* A3(2) cytochrome P450 158A2, *J.Biol.Chem.* **2005**, *280*, 11599.

(77) Zhao, B.; Lamb, D. C.; Lei, L.; Kelly, S. L.; Yuan, H.; Hachey, D. L.; Waterman, M.
R., Different binding modes of two flaviolin substrate molecules in cytochrome P450
158A1 (CYP158A1) compared to CYP158A2, *Biochemistry* **2007**, *46*, 8725.

(78) Funa, N.; Funabashi, M.; Ohnishi, Y.;Horinouchi, S., Biosynthesis of hexahydroxyperylenequinone melanin via oxidative aryl coupling by cytochrome P-450 in *Streptomyces griseus*, *J.Bacteriol.* **2005**, *187*, 8149.

(79) Agarwal, V.; El Gamal, A. A.; Yamanaka, K.; Poth, D.; Kersten, R. D.; Schorn, M.; Allen, E. E.; Moore, B. S., Biosynthesis of polybrominated aromatic organic compounds by marine bacteria, *Nat.Chem.Biol.* **2014**, *10*, 640.

(80) Mazzaferro, L. S.; Huttel, W.; Fries, A.;Muller, M., Cytochrome P450-catalyzed regio- and stereoselective phenol coupling of fungal natural products, *J.Am.Chem.Soc.* **2015**, *137*, 12289.

(81) Lin, H.-C.; McMahon, T. C.; Patel, A.; Corsello, M.; Simon, A.; Xu, W.; Zhao, M.; Houk, K. N.; Garg, N. K.; Tang, Y., P450-Mediated coupling of indole fragments to forge communesin and unnatural isomers, *J.Am.Chem Soc.* **2016**, *138*, 4002.

(82) Sanchez, J. F.; Somoza, A. D.; Keller, N. P.; Wang, C. C., Advances in *Aspergillus* secondary metabolite research in the post-genomic era, *Nat.Prod.Rep.* **2012**, *29*, 351.

(83) Sunassee, S. N. and Davies-Coleman, M. T., Cytotoxic and antioxidant marine prenylated quinones and hydroquinones, *Nat.Prod.Rep.* **2012**, *29*, 513.

(84) Jo, Y. H.; Shin, B.; Liu, Q.; Lee, K. Y.; Oh, D. C.; Hwang, B. Y.;Lee, M. K., Antiproliferative prenylated xanthones and benzophenones from the roots of *Cudrania tricuspidata* in HSC-T6 cells, *J.Nat.Prod.* **2014**, *77*, 2361.

(85) Wu, S.-B.; Long, C.;Kennelly, E. J., Structural diversity and bioactivities of natural benzophenones, *Nat.Prod.Rep.* **2014**, *31*, 1158.

(86) Heide, L., Prenyl transfer to aromatic substrates: genetics and enzymology, *Curr.Opin.Chem.Biol.* **2009**, *13*, 171.

(87) Yazaki, K.; Sasaki, K.; Tsurumaru, Y., Prenylation of aromatic compounds, a key diversification of plant secondary metabolites, *Phytochemistry* **2009**, *70*, 1739.

(88) Yu, X. and Li, S.-M., Prenyltransferases of the dimethylallyltryptophan synthase superfamily, *Methods Enzymol.* **2012**, *516*, 259.

(89) Wollinsky, B.; Ludwig, L.; Hamacher, A.; Yu, X.; Kassack, M. U.;Li, S. M., Prenylation at the indole ring leads to a significant increase of cytotoxicity of tryptophancontaining cyclic dipeptides, *Bioorg.Med.Chem.Lett.* **2012**, *22*, 3866.

(90) Jones, L. H.; Narayanan, A.;Hett, E. C., Understanding and applying tyrosine biochemical diversity, *Mol.Biosyst.* **2014**, *10*, 952.

(91) Stierle, A. A.; Stierle, D. B.; Goldstein, E.; Parker, K.; Bugni, T.; Baarson, C.; Gress, J.;Blake, D., A novel 5-HT receptor ligand and related cytotoxic compounds from an acid mine waste extremophile, *J.Nat.Prod.* **2003**, *66*, 1097.

(92) Almeida, C.; Part, N.; Bouhired, S.; Kehraus, S.;Konig, G. M., Stachylines A-D from the sponge-derived fungus *Stachylidium* sp, *J.Nat.Prod.* **2011**, *74*, 21.

(93) Ahmed, F.; Ohtsuki, T.; Aida, W.;Ishibashi, M., Tyrosine derivatives isolated from *Streptomyces* sp. IFM 10937 in a screening program for TRAIL-resistance-overcoming activity, *J.Nat.Prod.* **2008**, *71*, 1963.

(94) Gardiner, D. M.; Cozijnsen, A. J.; Wilson, L. M.; Pedras, M. S.; Howlett, B. J., The sirodesmin biosynthetic gene cluster of the plant pathogenic fungus *Leptosphaeria maculans*, *Mol.Microbiol.* **2004**, *53*, 1307.

(95) Kremer, A. and Li, S.-M., A tyrosine O-prenyltransferase catalyses the first pathway-specific step in the biosynthesis of sirodesmin PL, *Microbiology* **2010**, *156*, 278.

(96) Fan, A.; Chen, H.; Wu, R.; Xu, H.;Li, S.-M., A new member of the DMATS superfamily from *Aspergillus niger* catalyzes prenylations of both tyrosine and tryptophan derivatives, *Appl.Microbiol.Biotechnol.* **2014**, *98*, 10119.

(97) Botta, B.; Vitali, A.; Menendez, P.; Misiti, D.;Delle, M. G., Prenylated flavonoids: pharmacology and biotechnology, *Curr.Med.Chem.* **2005**, *12*, 717.

(98) Steffan, N.; Unsöld, I. A.;Li, S.-M., Chemoenzymatic synthesis of prenylated indole derivatives by using a 4-dimethylallyltryptophan synthase from *Aspergillus fumigatus*, *Chembiochem* **2007**, *8*, 1298.

(99) Kremer, A. and Li, S.-M., Potential of a 7-dimethylallyltryptophan synthase as a tool for production of prenylated indole derivatives, *Appl.Microbiol.Biotechnol.* **2008**, *79*, 951.

(100) Yu, X.; Xie, X.;Li, S.-M., Substrate promiscuity of secondary metabolite enzymes: prenylation of hydroxynaphthalenes by fungal indole prenyltransferases, *Appl.Microbiol.Biotechnol.* **2011**, *92*, 737.

(101) Yu, X. and Li, S.-M., Prenylation of flavonoids by using a dimethylallyltryptophan synthase 7-DMATS from *Aspergillus fumigatus*, *Chembiochem* **2011**, *12*, 2280.

(102) Tarcz, S.; Xie, X.;Li, S.-M., Substrate and catalytic promiscuity of secondary metabolite enzymes: *O*-prenylation of hydroxyxanthones with different prenyl donors by a bisindolyl benzoquinone *C*- and *N*-prenyltransferase, *RSC Adv.* **2014**, *4*, 17986.

(103) Fan, A.; Zocher, G.; Stec, E.; Stehle, T.;Li, S.-M., Site-directed mutagenesis switching a dimethylallyl tryptophan synthase to a specific tyrosine C3-prenylating enzyme, *J.Biol.Chem.* **2015**, *290*, 1364.

(104) Zou, H.-X.; Xie, X.; Zheng, X.-D.;Li, S.-M., The tyrosine *O*-prenyltransferase SirD catalyzes *O*-, *N*-, and *C*-prenylations, *Appl.Microbiol.Biotechnol.* **2011**, *89*, 1443.

(105) Rudolf, J. D. and Poulter, C. D., Tyrosine *O*-prenyltransferase SirD catalyzes *S*-, *C*-, and *N*-prenylations on tyrosine and tryptophan derivatives, *ACS Chem.Biol.* **2013**, *8*, 2707.

(106) Chooi, Y. H.; Cacho, R.; Tang, Y., Identification of the viridicatumtoxin and griseofulvin gene clusters from *Penicillium aethiopicum*, *Chem.Biol.* **2010**, *17*, 483.

(107) Pockrandt, D.; Sack, C.; Kosiol, T.;Li, S.-M., A promiscuous prenyltransferase from *Aspergillus oryzae* catalyses *C*-prenylations of hydroxynaphthalenes in the presence of different prenyl donors, *Appl.Microbiol.Biotechnol.* **2014**, *98*, 4987.

(108) Pockrandt, D. and Li, S.-M., Geranylation of cyclic dipeptides by the dimethylallyl transferase AnaPT resulting in a shift of prenylation position on the indole ring, *Chembiochem.* **2013**, *14*, 2023.

(109) Liebhold, M.; Xie, X.;Li, S.-M., Expansion of enzymatic Friedel-Crafts alkylation on indoles: Acceptance of unnatural beta-unsaturated allyl diphospates by dimethylallyl-tryptophan synthases, *Org.Lett.* **2012**, *14*, 4884.

(110) Liebhold, M.; Xie, X.;Li, S.-M., Breaking cyclic dipeptide prenyltransferase regioselectivity by unnatural alkyl donors, *Org.Lett.* **2013**, *15*, 3062.

(111) Liebhold, M. and Li, S.-M., Regiospecific benzylation of tryptophan and derivatives catalyzed by a fungal dimethylallyl transferase, *Org.Lett.* **2013**, *15*, 5834.

(112) James, E. D.; Knuckley, B.; Alqahtani, N.; Porwal, S.; Ban, J.; Karty, J. A.; Viswanathan, R.;Lane, A. L., Two distinct cyclodipeptide synthases from a marine actinomycete catalyze biosynthesis of the same diketopiperazine natural product, *ACS Synth.Biol.* **2016**, *5*, 547.

(113) Yu, H.; Xie, X.;Li, S. M., Coupling of guanine with cyclo-I-Trp-I-Trp mediated by a cytochrome P450 homologue from *Streptomyces purpureus*, *Org.Lett.* **2018**, *20*, 4921-4925.

## **Statutory Declaration**

Ich, Huili Yu, versichere, dass ich meine Dissertation

"Investigation on Cyclodipeptide Formation and Metabolism in Actinomycetes and Application of Fungal Prenyltransferases in the Chemoenzymatic Synthesis "

selbständig ohne unerlaubte Hilfe angefertigt und mich dabei keiner anderen als der von mir ausdrücklich bezeichneten Quellen bedient habe. Alle vollständig oder sinngemäß übernommenen Zitate sind als solche gekennzeichnet.

Die Dissertation wurde in der jetzigen oder einer ähnlichen Form noch bei keiner anderen Hochschule eingereicht und hat noch keinen sonstigen Prüfungszwecken gedient.

Marburg, den.....

.....

Huili Yu

### Acknowledgements

Firstly, I would like to express my sincere gratitude to my supervisor Prof. Dr. Shu-Ming Li for accepting me as his PhD student and his excellent supervision during my PhD study. He is always willing to help to solve the problems in both research and life. And my personal development has greatly benefited from his rigorous approach, ambitious motivation, hard working as well as high efficiency in scientific research.

I am grateful to Prof. Dr. Michael Keusgen for acting as my second referee and examiner.

I would like to thank Dr. Xiulan Xie, Dr. Regina Ortmann and Stefan Newel for taking NMR spectra, Rixa Kraut and Nina Zitzer for taking mass spectra as well as Prof. Dr. Wenhan Lin from Peking University for his help in structure elucidation of my compounds. I also express the deep appreciation to Dr. Dieter Kreusch and Sabine Burgers for ordering chemicals and lab supplies as well as maintenance of laboratory equipment and to Nadja Braun, Buvac Drázen for preparing media and distilled water.

I would like to thank Jing Liu for her idea communication and help in the cooperation of the first project in this dissertation. I thank Lena Ludwig for her synthesis of DMAPP and its unnatural analogs in the third project. Sincere thanks to Theodor Peez and Maximilian Jung for their assistance in measurement of the UV-Vis spectra of P450 enzyme. My special gratitude goes to Lindsay Coby and Florian Kindinger for translating and proof reading the summary part of this dissertation, and Ge Liao for proof reading this dissertation.

Many thanks go to Dr. Aili Fan, Viola Wohlgemuth, Peter Mai, Kang Zhou, Linus Naumann, Jie Fan, Jinglin Wang and Sandra Ditzler for sharing the old and new offices and nice talks in the office. Also special thanks go to my "Mensa partner" Jie Fan, Huomiao Ran for their company to Mensa and excellent cooking in the kitchen.

I want to thank all my current and former colleagues in the institute including Kristin Öqvist, Elisabeth Hühner, Liujuan Zheng, Pan Xiang, Bastian Kemmerich, Jonas Nies, Dr. Katija Backhaus, Johanna Schäfer, Lena Mikulski, Alexander Frehse, Kirsten Brockmeyer, Thang Son Ta, Victoria Werner, Dr. Nina Gerhards, Dr. Julia Winkelblech, Dr. Mike Liebhold, Dr. Kathrin Mundt, Dr. Carsten Wunsch, Dr. Daniel Pockrandt, Dr. Sylwia Tarcz, Dr. Beate Wollinsky, Dr. Jennifer Robinson, Dr. Lennart Poppe, Dr. Agus Chahyadi, Dr. Soheil Pezeshki for the great and wonderful time. I also thank the short-term communication professors and students in our institute for the great experience together.

I further express my thanks to my friends outside of the laboratory for their wonderful friendship.

I thank the China Scholarship Council (CSC) and the MArburg University Research Academy (MARA) for financial supports.

At last but not the least, I deeply thank my family for their encouragement, unconditional love and support over the past years. Special and heartful thanks to my husband Xiaowei Han for his company during this time. We always support with each other and I will remember this valuable experience forever.

## **Curriculum Vitae**

Pages 135-136 (Curriculum vitae) contain personal data. It is therefore not part of the online-publication of this thesis.